



Systematic Review The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies

Ana Carolina Silveira Rabelo^{1,2,*}, Amanda Kelly de Lima Andrade³ and Daniela Caldeira Costa^{1,*}

- ¹ Postgraduate Program in Biological Sciences, Federal University of Ouro Preto, Ouro Preto 35402-163, Brazil
- ² Department of Biochemistry, Federal University of Alfenas, Alfenas 37130-001, Brazil
- ³ Nutrition School, Federal University of Ouro Preto, Ouro Preto 35400-000, Brazil; amanda.kla@aluno.ufop.edu.br
- * Correspondence: ana.rabelo@unifal-mg.edu.br (A.C.S.R.); daniela.costa@ufop.edu.br (D.C.C.); Tel.: +55-(35)-3701-9000 (A.C.S.R.); +55-(31)-3559-1761 (D.C.C.)

Abstract: Alcoholic Fatty Liver Disease (AFLD) is characterized by the accumulation of lipids in liver cells owing to the metabolism of ethanol. This process leads to a decrease in the NAD+/NADH ratio and the generation of reactive oxygen species. A systematic review and meta-analysis were conducted to investigate the role of oxidative stress in AFLD. A total of 201 eligible manuscripts were included, which revealed that animals with AFLD exhibited elevated expression of CYP2E1, decreased enzymatic activity of antioxidant enzymes, and reduced levels of the transcription factor Nrf2, which plays a pivotal role in the synthesis of antioxidant enzymes. Furthermore, animals with AFLD exhibited increased levels of lipid peroxidation markers and carbonylated proteins, collectively contributing to a weakened antioxidant defense and increased oxidative damage. The liver damage in AFLD was supported by significantly higher activity of alanine and aspartate aminotransferase enzymes. Moreover, animals with AFLD had increased levels of triacylglycerol in the serum and liver, likely due to reduced fatty acid metabolism caused by decreased PPAR- α expression, which is responsible for fatty acid oxidation, and increased expression of SREBP-1c, which is involved in fatty acid synthesis. With regard to inflammation, animals with AFLD exhibited elevated levels of pro-inflammatory cytokines, including TNF-a, IL-1β, and IL-6. The heightened oxidative stress, along with inflammation, led to an upregulation of cell death markers, such as caspase-3, and an increased Bax/Bcl-2 ratio. Overall, the findings of the review and meta-analysis indicate that ethanol metabolism reduces important markers of antioxidant defense while increasing inflammatory and apoptotic markers, thereby contributing to the development of AFLD.

Keywords: alcoholic steatosis; antioxidant enzymes; lipid peroxidation; apoptosis; inflammation

1. Introduction

Alcohol is a prevalent chemical compound found in numerous beverages that are regularly consumed by populations worldwide. According to the latest 2023 report from the World Health Organization (WHO) [1], alcohol is a major factor in the development of around 200 diseases, and no amount of alcohol consumption is considered safe. One of the significant consequences of alcohol consumption is Alcoholic Fatty Liver Disease (AFLD), which is characterized by the excessive accumulation of triglycerides (TAG) and cholesterol in liver cells [2].

Ethanol can be metabolized through both oxidative and non-oxidative pathways, with the oxidative pathway being the predominant route. The key liver enzymes involved in ethanol detoxification are alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), and Cytochrome P450 2E1 (CYP2E1). ADH and ALDH are activated by acute alcohol consumption, whereas chronic alcohol intake enhances the activity of CYP2E1 [2–4]. During these metabolic processes, three major factors contribute to toxicity: (1) acetaldehyde accumulation; (2) an alteration in the nicotinamide adenine dinucleotide (NAD)H/NAD+ ratio;



Citation: Rabelo, A.C.S.; Andrade, A.K.d.L.; Costa, D.C. The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies. *Nutrients* **2024**, *16*, 1174. https://doi.org/10.3390/nu16081174

Academic Editor: Naoki Tanaka

Received: 14 March 2024 Revised: 5 April 2024 Accepted: 11 April 2024 Published: 15 April 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). and/or (3) generation of reactive oxygen species (ROS). These factors collectively result in a decrease in Peroxisomal Proliferator-Activated Receptor alpha (PPAR-alpha) and an increase in sterol regulatory element-binding protein 1 (SREBP-1). As a result, mechanisms for fatty acid export and oxidation decrease, while hepatic lipogenesis increases, leading to the accumulation of lipids in hepatic micro- and/or macrovesicles [2,4,5].

CYP2E1 activation exacerbates ROS production through the accumulation of reduced NADH in the mitochondria, triggering electron leakage. These ROS can attach to cellular proteins, creating pathways for the accumulation of fat droplets, and they can also trigger lipid peroxidation and protein carbonyl, worsening liver dysfunction and amplifying oxidative stress [6]. Compounding this scenario, the inhibition of antioxidant mechanisms further heightens intracellular oxidative stress. A pivotal player, the erythroid-derived nuclear factor 2 (NRF2), which is responsible for orchestrating the production of antioxidant enzymes like Superoxide Dismutase (SOD) and Catalase (CAT), becomes suppressed. This disturbance, coupled with compromised antioxidant defenses, fuels the production of pro-inflammatory cytokines by Kupffer cells. This, in turn, triggers local inflammation and leads to an increased presence of ROS within the liver tissue [2,7].

Although narrative reviews in the literature have mentioned the importance of oxidative stress in AFLD, a comprehensive systematic review and meta-analysis that consolidates primary studies investigating the relationship between ethanol metabolism and oxidative stress in AFLD is lacking. Our goal was to thoroughly examine the biochemical pathways involved in ethanol-related oxidative processes through a systematic review and meta-analysis, which is a widely recognized approach known for its high scientific rigor.

2. Materials and Methods

The protocol of this systematic review and meta-analysis was registered at the International Prospective Register of Systematic Reviews—PROSPERO [CRD42022350708] and was written based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [8]. The guiding question of this research was: "What is the role of oxidative stress in the pathogenesis of alcoholic fatty liver disease?" The elaboration of this guiding question was structured in the PICOT search strategy; i.e., the population (P) to be studied, intervention (I), comparison (C), outcomes (O), and time point (T). In this project, (P) was rats/mice with AFLD, (I) was alcohol induction of AFLD, (C) was control rats/mice (healthy), (O) represented measurements of liver and lipid profiles, oxidative stress, inflammation, and apoptosis, and (T) was any point in time. Inclusion and exclusion criteria were defined to facilitate the selection of appropriate studies to answer the research question.

2.1. Inclusion Criteria

(1) The study design should be performed in rats and/or mice (all species, all sexes, all ages, and all weights); (2) the experimental design had to include AFLD (induced by alcohol/ethanol at any dose and time); (3) had to contain dosages of antioxidant enzymes (e.g.,: SOD, catalase, glutathione peroxidase, glutathione reductase) concomitantly with dosages of oxidative damage markers (e.g., thiobarbituric acid reactive species (TBARS), malondialdehyde (MDA), or protein carbonyl); and (4) had a control group for comparison with the AFLD group.

2.2. Exclusion Criteria

(1) Animals with co-morbidities; (2) animals with non-alcoholic fatty liver disease; (3) ex vivo; (4) in vitro; (5) in silico; (6) animals from the control group that have been exposed to a substance other than water, Phosphate Buffer Saline (PBS), methylcellulose, or inert substances; (7) studies without a separate control group; (8) case studies, cross-over studies, abstracts, case reports, letters to the editor, editorials, comments, or reviews; and (9) missing data necessary for extraction.

2.3. Search Strategy

A literature search was conducted up to 2 September 2022, using the Pubmed, Scopus, and LILACS electronic databases. The following keywords were used in the search strategy: ((((((((((((Alcoholic Fatty Liver Disease"[Title/Abstract]) OR ("Fatty liver alcoholic"[Title/Abstract])) OR ("Fatty liver alcoholic disease"[Title/Abstract])) OR ("Fatty liver ethanol disease"[Title/Abstract])) OR ("Alcohol-induced fatty liver disease"[Title/Abstract])) OR ("Ethanol induces fatty liver disease"[Title/Abstract])) OR ("Alcoholic Steatohepatitis"[Title/Abstract])) OR ("Ethanol induced hepatotoxicity"[Title/Abstract])) OR ("Alcohol induced hepatotoxicity"[Title/Abstract])) OR ("Steatohepatitis"[Title/Abstract])) OR ("Alcoholassociated liver disease"[Title/Abstract])) OR ("Alcoholic liver disease"[Title/Abstract])) OR ("Alcohol-induced liver disease" [Title/Abstract])) AND ((((((("Oxidative Stresses" [Title/ Abstract]) OR ("Oxidative Stress"[Title/Abstract])) OR ("Oxidative Damage"[Title/Abstract])) OR ("Oxidative Stress Injury" [Title/Abstract])) OR ("Oxidative Injuries" [Title/Abstract])) OR ("Oxidative Cleavages" [Title/Abstract])) OR ("Oxidative DNA Damage" [Title/Abstract])) OR ("Oxidative Nitrative Stress" [Title/Abstract])) OR ("Redox Status" [Title/Abstract])) OR ("Redox Processes" [Title/Abstract]))) NOT ((((("Non-Alcoholic Fatty Liver Disease" [Title/ Abstract]) OR ("Nonalcoholic fatty liver disease" [Title/Abstract])) OR ("Non-Alcoholic Steatohepatitis"[Title/Abstract])) OR ("Nonalcoholic Steatohepatitis"[Title/Abstract])) OR ("Nonalcoholic liver disease"[Title/Abstract])) OR ("Nonalcoholic liver disease"[Title/Abstract])). The search was not restricted by date or language.

2.4. Study Selection

The primary literature search was carried out by two independent reviewers (ACSR and AKLA), where the title, author, year of publication, and DOI of each identified article were exported to Excel. The titles and abstracts of the retrieved records were then independently screened by two reviewers (ACSR and AKLA) to identify studies that potentially met the inclusion criteria. Those who met the eligibility criteria had their full texts scanned. Discrepancies that arose during any phases were resolved through consensus or the involvement of a third author (DCC). For manuscripts that met the inclusion criteria but had missing data, the authors were contacted once by email. If there was no response, the files were excluded.

2.5. Data Extraction

Data were independently extracted (ACSR and AKLA) based on the characteristics of the study (name of the author, year of publication, place where the study was conducted, funding, and conflict of interest), the characteristics of the animals (breeding, sex, size, and age), the characteristics of the study design to induce AFLD (alcohol concentration, time, and frequency of exposure), the sample number of each group (n) (control and AFLD), and the primary and secondary outcomes of interest (primary outcomes: dosage of antioxidant enzyme and oxidative damage; secondary outcomes: markers of liver damage, lipid profile, inflammation, apoptosis, lipid and glycemic metabolism, and liver histology). Through online meetings, both tables were compared between the two authors (ACSR and AKLA), and discrepancies were resolved through consensus or the involvement of a third author (DCC).

Then, the quantitative data of mean and standard deviation related to the primary and secondary outcomes of each included article were extracted independently (ACSR and AKLA). For data that were not expressed as a table, means and standard deviations were extracted from graphs using WebPlotDigitizer https://automeris.io/WebPlotDigitizer/ (accessed on 10 April 2024). As this tool has a high level of sensitivity (approximately 8–10 decimal places), small discrepancies can often occur in the last decimal places. Therefore, we opted to obtain an average for the extracted data, performed by ACSR and AKLA.

For each outcome, the most frequent measurement unit was selected, and all other units were converted to that unit for consistency. For those measurement units that were unique or could not be grouped with the others, the outcome was removed. In cases of doubt about measurements, typing errors, or any other problems, the authors were contacted once by email. If there was no response, that specific outcome was removed. Likewise, the tables were compared, and discrepancies were resolved between the two authors (ACSR and AKLA) or with the involvement of a third author (DCC).

2.6. Risk of Bias in Individual Studies

All included reports were critically analyzed using SYRCLE's risk of bias tool for animal studies [9]. This tool assesses the methodological quality of preclinical studies and has ten entries related to six biases. For each group, there are specific questions:

- (1) Selection bias: Was the allocation sequence properly generated and applied? Were the groups similar at baseline or were they adjusted for confounders in the analysis? Was the allocation to the different groups properly concealed?
- (2) Performance bias: Were the animals randomly housed during the experiment? Were the caregivers and/or investigators blinded from knowledge of which intervention each animal received during the experiment?
- (3) Detection bias: Were animals selected at random for outcome assessment? Was the outcome advisor blinded?
- (4) Attrition bias: Were incomplete outcome data adequately addressed?
- (5) Reporting bias: Are reports of the study free of selective outcome reporting?
- (6) Other biases: Was the study apparently free of other problems that could result in a high risk of bias?

Both the reviewers (ACSR and AKLA) assessed each report for the risk of bias, answering the questions with yes (Y), no (N), or unclear (U). The results were compared, and disagreements were resolved through discussion or by consulting a third investigator (DCC).

2.7. Statistical Analysis

The sample size and mean \pm standard deviation data extracted from the primary studies were plotted using the Review Manager (RevMan 5.3) software to generate the effective size. The random model was applied to estimate the pooled effects, the 95% confidence interval (95% CI) was used, and a *p*-value of <0.05 was considered statistically significant. The statistical heterogeneity among the studies was assessed using I^2 statistics, and values of 25%, 50%, and 75% indicate low, moderate, and high heterogeneity, respectively. Assuming that there was some heterogeneity, subgroup analyses were carried out in categories (e.g.: liver × serum; mg/dL × mg/g). The standard mean difference (SMD) and in some cases, the mean difference (MD) were adopted. For analyses where there were more than 10 studies, funnel plots were produced.

3. Results

3.1. Literature Search

Initially, our search found 1348 articles in Scopus, 829 in Pubmed, and none in LILACS. Of these files, 777 were duplicates and were excluded. Therefore, 1400 records were filtered based on title and abstract. Files were excluded when they were reviews, book chapters, or event abstracts (n = 491); were not an AFLD model (n = 148); did not contain an in vivo study with rats and/or mice (n = 187); or did not contain antioxidant dosing concomitant with oxidative damage (n = 218). The full texts of 356 of these records were retrieved for further assessment. After the full texts were read, 133 articles were excluded because the animals had some type of comorbidity (n = 100); the control group received a substance that was not inert (n = 7); AFLD was induced by techniques other than orally or intragastrically (e.g., received ethanol intraperitoneally) (n = 23); and articles that were removed or portrayed in a newspaper (n = 3). After this analysis, 223 articles were potentially eligible for the review; however, 17 were excluded owing to missing data. Therefore, 206 files [10–215] entered the systematic review, but 5 did not present outcomes that could be grouped with the others and were excluded from the meta-analysis. Figure 1




Figure 1. Flow diagram of the study selection process for this systematic review and meta-analysis.

3.2. Characteristics of the Included Studies

A total of 206 [10–215] eligible studies are illustrated in detail in Table 1, which includes studies published between 2000 and 2022. The animal species included mice [C57BL/6 (n = 69), Kunming (n = 19), ICR (n = 16), BALB/c (n = 9), Swiss (n = 2)] and rats [Wistar (n = 60), Sprague Dawley (n = 25), Albino (n = 3), did not declare the lineage (n = 2), Fisher (n = 1)]. Most studies used male animals (n = 169), followed by female (n = 16), both sexes (n = 8), or did not state the sex (n = 8). The weights of the mice ranged from 12 to 30 g, those of the rats were in the range of 100 to 350 g, and 46 studies did not state the weight. The youngest animals were 4 weeks old, the oldest were 17 weeks old, and 101 studies did not state the age.

	Study Characteri	istics			Animal Cha	racteristics			Total (n)		_
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Contro	I AFLD	Outcomes
Abdelhamid et al., 2020 [10]	Egypt	Any specific grant from funding agencies in the public, commercial, or not-for-profit sectors	No conflicts declared	BALB/c mice	Male	$25\pm3g$	10 weeks old	Ethanol-containing liquid diet. Ethanol increased from 1% to 4% (v/v) from day 2 to day 5, and 5% (v/v) on day 6 and for 10 days. After that, mice were gavaged with a single dose of ethanol (5 g/kg)	12	12	ALT, AST, MDA, SOD, GSH, IL-6, IL-1B, and TNF-a
Abdelhamid et al., 2021 [11]	Egypt	No information	No conflicts declared	BALB/c mice	Male	25 ± 3 g	10 weeks old	Lieber-DeCarli liquid diet for 10 days. Ethanol increased from 1% to 4% (v/v) from day 2 to day 5, respectively. Then, from day 6 and for 10 days 5% (v/v). After that, mice were gavaged with a single dose of ethanol (5 g/kg)]	6	6	ALT, AST, SOD, GSH, MDA, TNF-a, IL-6, and IL-1B
Al-Rejaie, 2012 [12]	Saudi Arabia	Deanship of Scientific Research at King Saud University and Global Research Network for Medicinal Plantas and King Saud University	No information	Wistar rats	Male	180–200 g	8 weeks old	25% ethanol (5 g/kg/bw) for 5 weeks	6	6	ALT, AST, TAG, GSH, MDA, SOD, andCAT
Atef et al., 2018 [13]	Egypt	No information	No conflicts declared	Albino rats	Male	120–150 g	90 days old	20% ethanol (7.9 g kg/day) once a day orally for 8 weeks	6	6	ALT, AST, TAG, MDA, GSH, and SOD
Bae et al., 2015 [14]	Korea	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture Forestry, and Fisheries	No conflicts declared	Sprague Dawley rats	Male	220–240 g	Not declared	Ethanol 2.5 g/kg every 12 h for a total of 42 doses	8	8	ALT, AST, CAT, GST, GPx, GR, GSH, MDA, CYP2E1 and Histopathologi- cal score
Balasubramaniyan et al., 2003 [15]	India	No information	No information	Swiss mice	Male	25–30 g	Not declared	16% ethanol (6.32 g/kg/bw) as an aqueous solution using an intragastric tube daily for 45 days	6	6	TBARS, CAT, GSH, and GST
Baranisrinivasan et al., 2009 [16]	India	No information	No information	Wistar rats	Male	160–180 g	Not declared	20% ethanol (7.9 g/kg/bw) for 45 days	6	6	TBARS, SOD, and CAT
Bardag-Gorce et al., 2011 [17]	United States	NIH/NIAAA, USC Research Center for Alcoholic Liver and Pancreatic Disease, Cirrhosis Pilot Project Funding, and Morphologic Core	No information	Wistar rats	Male	250–300 g	Not declared	Liquid diet containing ethanol (13 g/kg/bw/day) for 4 weeks	3	3	/
Bedi et al., 2017 [18]	India	Mr. Parveen Garg, Chairman, ISF College of Pharmacy	No information	Wistar rats	Either sex	200–250 g	Not declared	40% alcohol (2 mL/100 g/day) for 21 days	6	6	ALT, AST, LPO, TNF-a, IL-1B, and IL-6

Table 1. Data from primary articles used in the construction of the systematic review.

Table	1	Cont
Table	1.	Com.

	Study Character	istics			Animal Cha	racteristics			Total	(n)	_
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	 Study Design 	Control	AFLD	Outcomes
Bharrhan et al., 2011 [19]	India	Indian Council of Medical Research	No conflicts declared	Wistar rats	Female	200–250 g	Not declared	35% ethanol (10 g/kg/bw) by oral gavage for 2 weeks. Thereafter, the dose was increased to 14 g/kg/bw and was continued for 10 weeks	6 or 8	6 or 8	ALT, AST, TNF-a, MDA, GSH, SOD, GR, and GPx
Bisht et al., 2018 [20]	India	No information	Declare no conflict	Wistar rats	Either sex	150–200 g	Not declared	Ethanol (3.76 g/kg) for 26 days	6	6	ALT, AST, TAG, SOD, CAT, and LPO
Bispo et al., 2017 [21]	Brazil	Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq); Instituto Nacional de Ciência e Tecnologia de Processos Redox em Biomedicina	No information	Wistar rats	Male	$250\pm50~g$	Not declared	2.5 mL/kg of ethanol 35% (w/v) twice a day for 4 days	5	5	ALT, AST, CAT, TBARS, LPO, TAG, GSH, and GSSG/GSH ratio
Buko et al., 2019 [22]	Belarus	State Program of Belarus "Fundamental and Applied Sciences for Medicine," Subprogram 11.1, "Fundamental and Applied Medicine"	No conflicts declared	Wistar rats	Male	200–230 g	Not declared	30% Ethanol(4 g/kg/bw) for 8 weeks	8	8	ALT, AST, TAG, TNFα, IL-1β, TBARS, GSH, and Inflammatory foci
Bulle et al., 2015 [23]	India	No information	No information	Wistar rats	Male	120–140 g	2 month old	Alcohol 20% (5 g/kg/bw) for 60 days	8	8	/
Cao et al., 2015 [24]	China	Research Committee of the University of Macau and Macao Science and Technology Development Fund	No information	C57BL/6 mice	Female	25–30 g	16–17 weeks old	Lieber-DeCarli liquid alcohol diet for 4 weeks	4	4	ALT, AST, TAG, TNF-a, IL-6, MDA, GSH, SOD, GPx, CYP2E1, and Nrf2
Chandra et al., 2000 [25]	India	No information	No information	Wistar rats	Male	150–180 g	Not declared	2 mL of 50% ethanol (v/v) per day for a period of 7 days	8	8	GSH and GST
Chang et al., 2017 [26]	Taiwan	Ministry of Science and Technology	No conflicts declared	C57BL/6J mice	Male	20–22 g	8 weeks old	Lieber-DeCarli ethanol liquid diet for 4 weeks	8	8	ALT, AST, TAG, TBARS, GSH, SOD, CAT, GPx, TNF-a, IL-1B, CYP2E1, and inflammation score
Chang et al., 2021 [27]	Korea	Technology Development Program funded by the Ministry of SMEs and Startups	No conflicts declared	Sprague Dawley rats	Male	160–170 g	6–7 weeks old	Alcohol was administered intragastrically at a dose of 5 g/kg every 12 h for a total of 3 doses	10	10	ALT, AST, TAG, MDA, and GSH

Table	1.	Cont.

	Study Character	istics			Animal Cha	racteristics			Total (n)		
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Contro	1 AFLD	Outcomes
Chaturvedi et al., 2007 [28]	Africa	University of Botswana	No information	Wistar rats	Male	200–250 g	Not declared	Ethanol (5 g/kg/bw) for 30 days	5	5	ALT and AST
Chavan et al., 2017 [29]	India	Bharati Vidyapeeth Deemed University	No conflicts declared	Wistar rats	Male	150–200 g	Not declared	1 mL of 30% alcohol per 100 g/bw/day for 15 days	6	6	ALT, AST, TAG, SOD, and CAT
Chen et al., 2013 [30]	Taiwan	Gold Nanotech, Inc., Taiwan, Republic of China	No conflicts declared	Wistar rats	Male	Not declared	6 weeks old	Liber-DeCarli liquid diet for 10 weeks. Ethanol contributed 35% of the total calories, $8/125$, (v/v)	6	6	ALT, AST, TAG, GPx, GR, SOD, CAT, GSH/GSSG ratio, TBARS, CYP2E1, and TNF-a
Chen et al., 2016 [31]	United States	NIH and NIAAA	No conflicts declared	C57BL/6J mice	Male	Not declared	10–12 weeks old	Modified Lieber-DeCarli for 6 weeks. Ethanol was increased 1% weekly until it reached 5% (v/v)]	4, 5 or 6	4, 5 or 6	ALT, AST, TAG, CYP2E1, GSH, andNrf2
Cheng and Khong, 2011 [32]	China	Department of Education, Liaoning Province	No information	Rats (lineage not specified)	Male	200–220 g	12 weeks old	56% (v/v) ethanol administered by gastric infusion (7 g/kg/bw) three times a day for 30 consecutive days	12	12	ALT, AST, TAG, MDA, SOD, CAT, GPx, and GSH
Chiu et al., 2011 [33]	China	Lee Kum Kee Health Products Group Ltd.	No conflicts declared	Sprague Dawley rats	Female	250–300 g	Not declared	Ethanol intragastrically at 7.9 g/kg/day (20% v/v) for 45 days	6	6	ALT, MDA, SOD< GSH, GR, GPx, and GST
Chu et al., 2021 [34]	China	Chinese National Natural Science Foundation and the Natural Science Foundation from the Department of Science and Technology of Liaoning Province	No information	C57BL/6 mice	Male	Not declared	8 weeks old	Lieber-DeCarli liquid diet containing 5% ethanol (v/v) (EtOH) for 8 weeks	3, 6 or 8	3, 6 or 8	ALT, AST, TAG, Nrf2, GSH, and MDA
Colontoni et al., 2000 [35]	United States	National Institute on Alcohol Abuse and Alcoholism	No information	Sprague Dawley rats	Either sex	218 ± 3.3 g (female) 126 ± 1.7 g (male)	30–35 days old	Lieber-DeCarli liquid diet for 8 weeks	12 or 16	12 or 16	MDA, GSH, and GSH/GSSG ratio

Tabl	е 1.	Cont.

	Study Character	istics			Animal Cha	aracteristics			Tota	l (n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Contro	1 AFLD	Outcomes
Cui et al., 2014 [36]	China	No information	No information	Kunming mice	Male	18–22 g	Not declared	Alcohol (50 %, v/v) administered intragastrically by gavage twice daily as in previous studies. The amount of the 50% alcohol was initially 10 mL/kg/bw/day (4.0 g/kg/bw/day) and gradually increased as tolerance developed during the first 3 weeks to a maintenance dose of 16 mL/kg/bw/day (6.3 g/kg/bw/day) that was continued for 8 more weeks.	12	12	ALT, AST, TAG, MDA, GSH, SOD, TNF-a, IL-1B, and IL-10
Cui et al., 2014 [37]	China	National Science and Technology Support Program, the Priority Academic Program Development of Jiangsu Higher Education Institution, and the Fundamental Research Funds for the Central Universities of China	No information	Kunming mice	Male	18–22 g	Not declared	Alcohol (50% <i>v/v</i>) twice a day for 11 weeks. The 50% alcohol administered was gradually increased every week from 10 to 16 mL/kg/day according to animal tolerance	10	10	ALT, AST, TAG, MDA, GSH, SOD, TNF-α, IL-1β, and IL-10
Das et al., 2006 [38]	India	No information	No information	BALB/c mice	Male	20–30 g	8–10 weeks old	1.6 g ethanol/kg/bw/day for 12 weeks	6	6	ALT, AST, and IL-10
Das et al., 2012 [39]	India	Kerala State Council for Science, Technology, and Environment, Government of Kerala, India, and the Van Slyke Foundation of the American Association for Clinical Chemistry	No conflicts declared	Wistar rats	Male	200–220 g	16–18 weeks old	1.6 g ethanol/kg/bw/day administered intragastrically for 4, 12, or 36 weeks	3 or 6	3 or 6	TBARS, GSH, GSH/GSSG ratio, GPx, GR, GST, CAT, SOD, IL-10, IL-1B, and TNF-a
De Souza et al., 2015 [40]	Brazil	Fundação Araucária and CAPES	No information	Wistar rats	Male	$200\pm20~g$	Not declared	10% ethanol for 4 weeks	10	10	ALT, AST, TAG, SOD, GST, GSH, and LPO
Develi et al., 2014 [41]	Turkey	Research Fund of Istanbul University	No conflicts declared	Sprague Dawley rats	Female	250–300 g	16 weeks old	Ethanol 40% (5 g/kg) every 12 h for three doses in total	8	8	ALT, AST, MDA, GSH, SOD, GPx, and GST
Dou et al., 2013 [42]	China	National Institutes of Health NIAAA	No conflicts declared	C57BL/6 mice	Male	$25\pm0.5~g$	Not declared	Animals were fed ad libitum with ethanol for 4 weeks Ethanol-derived calories were increased from 30% to 36% during the first 4 weeks, with a 2% increase each week	6	6	ALT, TBARS, GSH, and GSH/GSSG ratio

	Study Character	istics			Animal Cha	aracteristics			Total	l (n)	- Outcomes
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Du et al., 2015 [43]	China	China–Japan Friendship Hospital Youth Science and Technology Excellence Project and the Research Fund of the China–Japan Friendship Hospital	No conflicts declared	Wistar rats	Not declared	150–200 g	Not declared	Ethanol [5 g/kg/bw] by gavage every 12 h for a total of 3 doses	6	6	ALT, AST, Protein carbonyl, Lipid peroxidation, SOD, CAT, GPx, GST, Nrf-2, TNF-α, IL-6, and IL-1β
Duryee et al., 2018 [44]	United States	U.S. Department of Veterans Affairs Rehabilitation Research and Development Service VA Merritt Application	No information	Wistar rats	Male	Not declared	270 days old	Ethanol liquid diet daily for 7 weeks	4 or 6	4 or 6	ALT, AST, TNF-a, and IL-6
Feng et al., 2019 [45]	China	Research Committee of the University of Macau and Health Nutrition Research	No conflicts declared	C57BL/6 mice	Male	Not declared	8–10 weeks old	Lieber-DeCarli liquid diet for 10 days. On day 11, the mice orally received a single dose of 31.5% (v/v) ethanol (5 g/kg/bw)	8	8	ALT, AST, TBARS, GSH, GSH/GSSG ratio, SOD, CAT, GR, GPx, TAG, TNF-a, IL-6, and Il-1B
Galligan et al., 2012 [46]	United States	National Institutes of Health/National Institutes of Alcoholism and Alcohol Abuse	No information	C57/BL6J mice	Male	Not declared	Not declared	Modified Lieber-DeCarli liquid diet for 6 weeks [2% (v/v) ethanol in the first week, increased on a weekly basis; week 6 consisted of 6% ethanol (v/v)]	6 or 12	6 or 12	ALT, TAG, TBARS, GSH, GSH/GSSG ratio, GR, and GST
Gao et al., 2021 [47]	China	Natural Science Foundation of Jiangsu Province	No conflicts declared	ICR mice	Male	Not declared	4 weeks old	Ethanol (30%, v/v) by gavage (10 mL/kg/bw/day) for 8 weeks	9	9	ALT, AST, TAG, GPx, CAT, GSH, and MDA
George and Chaturvedi, 2009 [48]	Africa	Office of Research and Development, University of Botswana	No conflicts declared	Wistar rats	Male	200–250 g	Not declared	Alcohol (5 g/kg/bw) for 30 days	6	6	ALT and AST
Gustot et al., 2006 [49]	Belgium	No information	No information	C57Bl6/J mice	Female	Not declared	8 weeks old	Lieber-DeCarli ethanol liquid diet for 10 days	13	13	/
Han et al., 2021 [50]	China	National Natural Science Foundation of China	No conflicts declared	C57BL/6J mice	Male	$18\pm0.5~g$	4 weeks old	Mice were oral gavaged with 30% ethanol for 15 days. On the 16th day, 50% ethanol (10 mL/kg) was administrated	10	10	ALT, AST, SOD, MDA, CAT, GSH, TNF-a, IL-1B, IL-6, and number of inflammatory cells

Tabl	e	1.	Cont.

	Study Characteri	istics			Animal Cha	aracteristics			Total (n)		
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Hao et al., 2018 [51]	United States	National Institutes of Health	No conflicts declared	C57BL/6J mice	Male	Not declared	10 weeks old	Lieber-DeCarli liquid alcohol diet for 8 weeks [the ethanol content (%, w/v) in the diet was 3.6 for the first 2 weeks and increased by 0.3% every 2 weeks, reaching 4.5% for the last 2 weeks]	8	8	ALT, AST, GSH, CYP2E1, PPAR-a, TAG, and Caspase 3
Hao et al., 2021 [52]	United States	National Institutes of Health	No information	C57BL/6 mice	Male	Not declared	12 weeks old	Lieber-DeCarli liquid diet for 8 weeks and 4 h before tissue collection, the mice were gavaged with one dose of ethanol (4 g/kg)	5	5	ALT, AST, TAG, caspase 3, and CYP2E1
Hasanein et al., 2018 [53]	Iran	Not declared	No conflicts declared	Wistar rats	Male	220–250 g	8 weeks old	Ethanol (4 g/bw) via gavage for 30 days	7	7	ALT, AST, TNF-a, IL-6, MDA, GSH, SOD, and CAT
He et al., 2021 [54]	China	National Natural Science Foundation of China and Jilin Province Administration of Traditional Chinese Medicine Projects	No information	Sprague Dawley rats	Male	180–220 g	Not declared	10 mL/kg of 60% ethanol solution orally every day for 30 days	12	12	ALT, AST, MDA, GSH, TAG, Bax/Bcl-2 ratio, Caspase-3, CYP2E1, and Nrf2
Hsu et al., 2018 [55]	Taiwan	No external funding	No conflicts declared	C57BL/6J mice	Male	Not declared	5 weeks old	Lieber–DeCarli alcohol-containing liquid diet for 5 weeks (alcohol was gradually increased to 10% of total energy on days 1 and 2, 20% on days 3 and 4, 30% on days 5 and 6, and 36% on day 7 and thereafter)	10	10	ALT, AST, TAG, PPAR-a, SREBP-1, CYP2E1, SOD, CAT, GPx, GSH, and MDA
Hu et al., 2021 [56]	China	National Key Research and Development Program of China	No conflicts declared	Kunming mice	Male	$20\pm 2g$	Not declared	56% (v/v) alcohol for 21 consecutive days	6	6	ALT, AST, TAG, SOD, MDA, GSH, GPx, IL-6, TNF-a, IL-1B, and Nrf-2

Tabl	e 1.	Cont.
Iuv	IC I.	COm

	Study Character	istics			Animal Cha	racteristics			Total	(n)	_
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Huang et al., 2017 [57]	China	Hong Kong, Macao, and Taiwan Science and Technology Cooperation Program of China, Science and Technology Major Project of Guangdong Province, Science and Technology Planning Project of Guangdong Province, China, Guangdong International Cooperation Project, Guangdong Provincial Department of Education Feature Innovation Project, and Key Disciplines Construction Projects of High-level University of Guangdong Province	No conflicts declared	Wistar rats	Male	$210\pm10\text{g}$	Not declared	Ethanol (7 mL/kg) intragastrically every 12 h at 5 different time points for 9 days	12	12	ALT, AST, TAG, CAT, SOD, GPx, MDA, CYP2E1, Nrf2, TNF- α , IL-1 β , and IL-6
Ilaiyaraja and Khanum, 2011 [58]	India	No information	No conflicts declared	Wistar rats	Male	250–280 g	Not declared	Rats received 20% ethanol (7.9 g/kg/bw) orally for 6 weeks	6	6	ALT, AST, MDA, GR, GSH, and Protein carbonyl
Jayaraman et al., 2009 [59]	India	No significant financial support for this work	No conflicts declared	Wistar rats	Male	150–170 g	Not declared	20% ethanol (6 g/kg/bw) as an aqueous solution by intragastric intubation for 60 days	8	8	ALT, AST, TBARS, LOOH, Protein carbonyl, CAT, GR, GST, and GSH
Jiang et al., 2016 [60]	China	High-end Foreign Experts Recruitment Program of State Administration of Foreign Expert Affairs, the Ministry of Education and State Administration, the Key Construction Program of International Cooperation Base in S&T, Shanxi Provincial Science and Technology Coordinating Innovative Engineering Project	No conflicts declared	Kunming mice	Either sex	16–18 g	3 weeks old	Increasing dose of alcohol 25% v/v per week (5, 8, 10, 12, and 15 mL/kg of body weight) for a total of 5 weeks	8	8	ALT, AST, GSH, SOD, MDA, TAG, and CYP2E1

	Study Characteri	istics			Animal Cha	racteristics			Total (r	n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	 Study Design 	Control A	AFLD	Outcomes
Jiang et al., 2019 [61]	China	National Natural Science Foundation of China, Science and Technology Innovation as a Whole Plan Project of Yulin City, International Scientific and Technological Cooperation and Exchange Program, the Postdoctoral Program of China, the Excellent Doctoral Dissertation Funded Projects of Shaanxi Normal University, and the Development Program for Innovative Research Team of Shaanxi Normal University	No conflicts declared	Kunming mice	Male	18–22 g	Not declared	28% (v/v) ethanol (10 mL/kg/bw) by intragastricgavage for 10 weeks	10	10	ALT, AST, TAG, MDA, SOD, GPx TNF-a, and IL-6
Jin et al., 2010 [62]	Korea	No information	No information	Sprague Dawley rats	Male	$250\pm20~g$	Not declared	Acute experiment: single dose of 4 mL of 30% ethanolChronic experiment: 4 mL of 30% ethanol 10 times every 2 days for 20 days	5	5	ALT, AST, TNF-a GSH, SOD, CAT GPx, and TBARS
Jose et al., 2018 [63]	India	M/s Akay Flavours and Aromatics Pvt Ltd, Cochin, India	One conflict declared	Wistar rats	Male	$150\pm10~{\rm g}$	Not declared	Ethanol 90% (12.5 g/kg/bw) by oral gavage for 30 days	8	8	ALT, AST, TBARS, TNF-a, IL-6, SOD, CAT, and GPx
Kanbak et al., 2001 [64]	Turkey	Osmangazi University	No information	Wistar rats	Male	150–250 g	Not declared	Animals consumed an approximately 60 mL diet (containing 2.5–4% ethanol) per day over 60 days (corresponding to 8 g/kg/day)	8	8	ALT, GSH, and MDA
Kanchana and Jayapriya, 2013 [65]	India	No information	No information	Wistar rats	Female	140–150 g	Not declared	Ethanol (3 g/kg/bw) for 35 days	6	6	TBARS, GSH, SOD, CAT, and GPx
Kang et al., 2009 [66]	United States	National Institutes of Health, Office of Dietary Supplements grants, and the Veterans Administration	No information	129S mice	Male	Not declared	Not declared	Lieber-DeCarli liquid alcohol diet for 4 weeks	4	4	ALT, TAG, SOD, GPx, CAT, and MDA
Kang et al., 2022 [67]	United States	USDA Multi-State Hatch	No conflicts declared	C57BL/6J mice	Male	25–30 g	12 weeks old	5% ethanol (v/v) Lieber-DeCarli diet for 10 days	4	4	ALT, TAG, CYP2E1, and Nrf-2
Kaviarasan et al., 2008 [68]	India	Indian Council of Medical Research	No conflicts declared	Wistar rats	Male	150–170 g	Not declared	Ethanol (6 g/kg) as an aqueous solution for 60 days	6	6	TBARS, Protein carbonyl, SOD, CAT, GR, and GSH

Lee et al., 2020 [77]

Korea

Basic Science Research

Program through the National

Research Foundation of Korea

and the Chung-Ang University Graduate Research Scholarship

	Study Character	istics			Animal Cha	racteristics			Tota	al (n)
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Contro	l AFLD
Khanal et al., 2009 [69]	Republic of Korea	Jangsaeng Doraji Co. Ltd., Jinju, South Korea, provided the Changkil	No conflicts declared	C57BL/6 mice	Male	23–25 g	Not declared	Ethanol (50%) was administered orally to mice at a dose of 5 g/kg every 12 h for a total of 3 doses	4	4
Kim et al., 2012 [70]	Korea	Basic Science Research Program through the National Research Foundation of Korea	No conflicts declared	Sprague Dawley rats	Male	150–170 g	Not declared	Lieber-DeCarli ethanol liquid diet. Ethanol was introduced progressively, with 30 g/L for 2 days, 40 g/L for the subsequent 2 days, followed by the final formula containing 50 g/L	8	8
Kim et al., 2016 [71]	United States	No information	No conflicts declared	Wister rats	Male	$80 \pm 5g$	4 weeks old	Ethanol 20% (3.95 g/kg/bw) daily for 42 days	5	5
Kumar et al., 2019 [72]	India	No significant financial support	No conflicts declared	Wistar rats	Male	175 ± 25 g	Not declared	Ethanol 3% to 15% (in water) gradually increased weekly for 12 weeks	3 or 6	3 or 6
Lai et al., 2019 [73]	Taiwan	No information	No conflicts declared	C57BL/6J mice	Male	Not declared	6 weeks old	Lieber-DeCarli ethanol liquid diet for 6 weeks	8	8
Lee et al., 2015 [74]	Korea	Ministry of Agriculture, Food, and Rural Affairs of Korea	No information	C57BL/6 mice	Male	$22\pm1\mathrm{g}$	8 weeks old	Ethanol (5 g/kg/bw) for 3 days	8	8
Lee et al., 2016 [75]	Korea	No information	No information	C57BL/6J mice	Male	Not declared	7 weeks old	Lieber-DeCarli ethanol liquid diet for 6 weeks	10	10
Lee et al., 2016 [76]	Taiwan	Ministry of Science and Technology	No conflicts declared	C57BL/6 mice	Male	12–16 g	4–5 weeks old	Lieber-DeCarli formulation 5% (v/v) ethanol for 6 weeks	10	10

No conflicts declared

Male

Sprague Dawley

rats

Not

declared

7 weeks old

Ethanol 70% was administered

orally (7 g/kg) for 42 days

Table 1. Cont.

Outcomes

ALT, TNF-a, Steatosis score, Inflammation score, TBARS, GSH, TAG, and CYP2E1 MDA, GSH, and Nrf2

ALT, AST, TAG, TBARS, SOD, and CAT

ALT, AST, TAG,

GSH, IL-1B, and Nrf2

ALT, AST, TAG, CAT, SOD, GPx, GR, Nrf2, PPAR-a, and SREBP

ALT, AST, SOD, CAT, GR, GSH, MDA, and CYP2E1

ALT, AST, MDA, CAT, GST, GPx, GR, and CYP2E1

ALT, AST, TAG, TBARS, and SOD

ALT, AST, TAG,

TNF- α , and

IL-1β

7

7

	Study Character	istics			Animal Cha	racteristics		Churcher Descione	Total	(n)	<u> </u>
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Lee et al., 2020 [78]	Republic of Korea	National Research Foundationof Korea	No conflicts declared	C57BL/6 mice	Male	Not declared	9 weeks old	Lieber-DeCarli liquid ethanol diet for 10 days	20	20	ALT, AST, TAG, GSH/GSSG ratio, and MDA
Lee et al., 2021 [79]	Taiwan	Ministry of Science and Technology and the Chung Shan Medical University Hospital	No conflicts declared	C57BL/6J mice	Male	22 ± 2 g	Not declared	Lieber-DeCarli liquid ethanol diet for 8 weeks	8	8	ALT, AST, TAG, CAT, GPx, SOD, TBARS, Leukocyte infiltration, Accumulation of hepatic lipids, TAG, and SREBP1
Li et al., 2013 [80]	China	National Natural Science Foundation of China, the Program for New Century Excellent Talents in the University of China, and the Wuhan Planning Project of Science and Technology	No conflicts declared	Balb/c mice	Male	18–22 g	Not declared	Ethanol 50% (v/v) (5 g/kg/bw) three times with 12 h of interval	12	12	ALT, AST, GSH, SOD, MDA, TNF-a, and IL-6
Li et al., 2015 [81]	China	No information	No information	Sprague Dawley rats	Male	Not declared	8 weeks old	Different alcohol doses [10%, <i>v</i> / <i>v</i> , 0.8 g/kg/bw; or 20%, 1.6 g/kg/bw; or 30%, 2.4 g/kg/bw] for 90 days	10	10	ALT, AST, GSH, MDA, SOD, and CYP2E1
Li et al., 2016 [82]	China	National Natural Science Foundation of China	No conflicts declared	C57BL/6J mice	Male	18–20 g	Not declared	Lieber-DeCarli ethanol liquid diet for 15 weeks	12	12	MDA and GSH/GSSG ratio
Li et al., 2017 [83]	China	National Natural Science Foundation of China	No conflicts declared	ICR mice	Male	18–22 g	6–7 weeks old	Ethanol (50%, <i>v/v</i> , 12 mL/kg) for 1 or 7 days	8	8	ALT, AST, TAG, TBARS, GSH, SOD, CAT, GR, and GPx
Li et al., 2018 [84]	China	China Agriculture Research System	Declare no conflict	C57 mice	Not declared	20–32 g	Not declared	10 mL/kg alcohol (55%, v/v) by gavage for 4 weeks	8	8	ALT, AST, TAG, MDA, GPx, SOD, TNF-a, IL-1B, and IL-6
Li et al., 2021 [85]	China	National Key R&D Program of China and the Key Project of Guangdong Provincial Science and Technology Program	No conflicts declared	C57BL/6J mice	Male	Not declared	8 weeks old	Lieber-DeCarli diet for 11 days and then Lieber-DeCarli ethanol liquid diet containing 4% (w/v) ethanol for 4 weeks	9	9	ALT, AST, TAG, CYP2E1, MDA, SOD, CAT, GPx, GSH, IL-6, and TNF-a
Li et al., 2021 [86]	China	National Key R&D Program of China and the Key Project of Guangdong Provincial Science and Technology Program	No conflicts declared	C57BL/6 J mice	Male	Not declared	8 weeks old	Lieber–DeCarli liquid diet (4% ethanol w/v) for 11 days, and distilled water (10 mL/kg) for 4 weeks	9	9	ALT, AST, TAG, MDA, GSH, GPx, SOD, CAT, TNF-a, IL-6, and CYP2E1

	Study Character	istics			Animal Cha	racteristics			Total	(n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Li et al., 2021 [87]	China	National Key Research and Development Program of China, Natural Science Foundation of Heilongjiang Province, National Natural Science Foundation of China, and Academic Backbone Plan of Northeast Agricultural University	No conflicts declared	C57BL/6J mice	Male	Not declared	6 weeks old	Lieber-DeCarli liquid diet. Alcohol was gradually increased to $4\% (w/v)$ by the end of the week and was maintained at 4% for 6 weeks	12	12	ALT, AST, and TAG
Li et al., 2021 [88]	China	National Key R&D Program of China, China Central Public-Interest Scientific Institution Basal Research Fund, Chinese Academy of Agricultural Sciences, and the Key Project of Guangdong Provincial Science and Technology Program	No conflicts declared	C57BL/6J mice	Male	20 g	Not declared	Lieber-DeCarli ethanol liquid for 6 days and 4% ethanol liquid diet plus distilled water (10 mL/kg) for 4 weeks	9	9	ALT, AST, TAG, CYP2E1, SOD, CAT, GPx, GSH, and MDA
Lian et al., 2010 [89]	China	No information	No information	C57BL/6mice	Male	Not declared	Not declared	Ethanol (5 g/kg/bw) every 12 h for a total of three doses	10	10	ALT, AST, TAG, MDA, GSH, GPx, SOD, CAT, CYP2E1, and SREBP-1
Lin et al., 2017 [90]	Taiwan	Chung Shan Medical University	Declare no conflict	C57BL/6 mice	Female	Not declared	5 weeks old	Ethanol content in the diet was graded from 7.2% to 36% of energy composition for 10 weeks. After that, mice were gavaged with a single dose of ethanol (5 g/kg)	8	8	ALT, AST, TAG, TNF-a, IL-6, IL-10, SOD, GPx, GSH, and MDA
Lin et al., 2021 [91]	Taiwan	No significant financial support for this work	No conflicts declared	C57BL/6J mice	Male	Not declared	7 weeks old	Lieber-DeCarli liquid ethanol diet for 6 weeks	8	8	ALT, AST, TAG, MDA, CAT, SOD, GPx, GSH, and PPPAR-a
Liu et al., 2014 [92]	China	Program for Changjiang Scholars, Innovative Research Team in University and National Nature Scientific Foundation	No conflicts declared	Sprague Dawley rats	Not declared	180–200 g	Not declared	Ethanol 51.3% (4 g/kg/day) via an intragastric administration tube for 30 days	7	7	AL, AST, TAG, MDA, CSH, GSH/GSSG ratio, SOD, CAT, GR, Nrf-2, and CYP2E1

	Study Character	istics			Animal Cha	racteristics			Tota	l (n)	0
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Liu et al., 2015 [93]	China	Program for Changjiang Scholars, National Nature Scientific Foundation and Natural Science Foundation of Shanxi Province	No conflicts declared	C57BL/6 mice	Male	33–34 g	12–14 weeks old	Ethanol (5 g/kg) intragastrically for 7 days	3 or 8	3 or 8	ALT, AST, Caspase-3, Bax/Blc-2 ratio, MDA, GSH, GSH/GSSG, Nrf-2, CAT, SOD, GR, CYP2E1, TAG, and SREBP-1c
Liu et al., 2020 [94]	China	National Natural Science Foundation of China	No conflicts declared	C57BL/6J mice	Male	18–20 g	Not declared	Ethanol-containing Lieber-DeCarli liquid diet (30% of total calories from ethanol) for 15 weeks	9	9	GSH
Liu et al., 2022 [95]	China	National Natural Science Foundation of China	No conflicts declared	C57BL/6 mice	Male	Not declared	Not declared	Ethanol liquid diet for 17 days. Ethanol was gradually increased from 0 to 5% (v/v) during one week; after that, mice were fed with ethanol (5%) for 10 consecutive days. On the 11th day, mice were gavaged with 5 g/kg ethanol	9	9	AL, AST, TAG, MDA, GSH, GSH/GSSG ratio, Nrf2, TNF-a, PPAR-a, and SREBP-1c
Liu et al., 2022 [96]	China	Program for Changjiang Scholars, Innovative Research Team in University and National Nature Scientific Foundation	No conflicts declared	C57BL/6 mice	Male	20–21 g	6–8 weeks old	Ethanol 51.3% (5 g/kg, intragastrically) twice a day for 7 days	3 or 8	3 or 8	ALT, AST, TAG, caspase 3, Bax/Bcl2 ratio, MDA, GSH, GSH/GSSG ratio, SOD, GR, Nrf-2, and CYP2E1
Lu et al., 2014 [97]	Taiwan	National Science Council and National Taiwan University	No information	C57BL/6 mice	Male	23–25 g	6 weeks old	Lieber-DeCarli ethanol liquid diet (alcohol-containing liquid in the mixture increased gradually from 20% to 100%) for 4 weeks	3 or 12	3 or 12	ALT, AST, TAG, GSH, TBARS, TNF-a, IL-1B, IL-6, GPx, GR, CAT, SOD, CYP2E1, and SREBP-1c

	Study Characteristics				Animal Cha	racteristics		Chu des Danie in	Total (n)		
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Lu et al., 2015 [98]	China	National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions, Youth Natural Science Foundation of Jiangsu Province, 2013 Program for Excellent Scientific, Technological Innovation Team of Jiangsu Higher Education, Youth Natural Science Foundation of Nanjing University of Chinese Medicine, and the Natural Science Research General Program of Jiangsu Higher Education Institutions	No conflicts declared	Sprague Dawley rats	Male	200 ± 20 g	Not declared	Alcohol (56%, <i>v/v</i> , 10 mL/kg) by gavage every day for 9 weeks	10	10	ALT, AST, TAG, SREBP-1c, PPAR-a, MDA, GSH, GR, SOD, CAT, Nrf2, Bax/Bcl-2 ratio, and Caspase-3
Lu et al., 2020 [99]	Taiwan	Ministry of Science and Technology	No conflicts declared	Wistar rats	Male	Not declared	8 weeks old	Lieber-DeCarli ethanol liquid diet for 8 weeks	5	5	ALT, AST, Steatosis score, Inflammation score, TAG, GSH/GSSG ratio, TNF-a, IL-1β, IL-6, IL-10, and CYP2E1
Ma et al., 2007 [100]	Korea	Ministry of Commerce, Industry, and Energy and Korea Institute of Industrial Technology Evaluation and Planning through the Biohealth Products Research Center of Inje University	No information	C57BL/6 mice	Male	20–25 g	9 weeks old	Single dose of 50% ethanol (5 g/kg/bw)	6	6	ALT, AST, TAG, MDA, CAT, GPx, and GR
Madushani Herath et al., 2018 [101]	Republic of Korea	Ministry of Trade, Industry, and Energy and Korea Institute for Advancement of Technology through the Promoting Regional Specialized Industry	Declare no conflict	C57BL/6 mice	Not declared	20–25 g	8–9 weeks old	30% ethanol (5 g/kg/bw) by gavage every 12 h for a total of 3 doses	3	3	CYP2E1

	Study Character	istics			Animal Cha	aracteristics			Total	(n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Mai et al., 2022 [102]	China	Guangdong Province Rural Science and Technology Commissioner Project, Guangdong Modern Agricultural Industrial Technology System Innovation Team Construction Project with Agricultural Products as the Unit, Guangdong Province Lingnan Chinese Herbal Medicine Protection Fund Talents Training Special Project, and Project of Traditional Chinese Medicine Bureau of Guangdong Province	Declared some conflicts	BALB/c mice	Male	18–20 g	Not declared	Ethanol (6 mL/kg) for the first week and then increased by 1 mL every week (up to 10 mL/kg) for 7 weeks	6	6	ALT, AST, MDA, GSH, SOD, TNF-a, IL-6, IL-1B, and CYP2E1
Maimaitimin et al., 2018 [103]	China	National Natural Science Foundation, SCO Regional Collaborative Innovation Project, Xinjiang, Urumqi Science Project; the High-End Foreign Experts Recruitment Program of State Administration of Foreign Expert Affairs	No information	Kunming mice	Female	28 ± 2 g	6 weeks old	Single dose of 50% alcohol (10 mL/kg)	7	7	ALT, AST, MDA, SOD, GSH, and CYP2E1
Mallikarjuna et al., 2008 [104]	India	No information	No information	Wistar rats	Male	$170\pm10~{ m g}$	Not declared	Absolute ethanol (2.0 g/kg/bw) via orogastric tube for 4 weeks	6	6	SOD, CAT, GPx, GR, GSH, and MDA
Mandal et al., 2013 [105]	India	Council of Scientific and Industrial Research and CSIR fellowships	No conflicts declared	Sprague Dawley rats	Female	110–130 g	Not declared	Lieber-DeCarli diet for 8 weeks	5	5	ALT, AST, Protein carbonyl, TBARS, and GSH
Mehanna et al., 2021 [106]	Egypt	No external funding	No conflicts declared	Albino rats	Male	180–200 g	Not declared	Ethanol (70% w/v) daily at a dose of 3 or 5 g/kg through intra-gastric gavage for 28 days	8	8	ALT, AST, MDA, GSH, CAT, SOD, TNF-a, IL-6, and Inflammation score
Meng et al., 2020 [107]	China	No information	No conflicts declared	Kunming mice	Male	18–22 g	Not declared	Single dose of alcohol (10 mL/kg, 52%, v/v) intragastrically	8	8	ALT, AST, TAG, SOD, CAT, GSH, and MDA
Miñana et al., 2002 [108]	Spain	No information	No information	Wistar rats	Male	Not declared	4–6 months	Liquid ethanol diet (12 g/k/ bw) for 8 or 18 weeks	8	8	MDA

	Study Character	stics			Animal Ch	aracteristics			Total (r	ı)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control A	FLD	Outcomes
Ming et al., 2021 [109]	China	National Key Research and Development Project, and the High-level Talents Introduction to Scientific Research Start-up Project	No conflicts declared	C57BL/6NCr mice	Male	$20 \pm 2 \mathrm{g}$	8–10 weeks old	Lieber-DeCarli ethanol liquid diet for 8 weeks, then animals received 31.5% (v/v) ethanol by oral gavage at a dose of 7.3 g/kg	8	8	ALT, AST, TNF-a, IL-6, IL-1B, IL-10, TAG, MDA, SOD, and GSH
Mohan et al., 2019 [110]	India	M/s Akay Flavours and Aromatics Pvt Ltd., Cochin	One conflict declared	Wistar rats	Male	$250\pm10~g$	Not declared	38% ethanol (12.5 g/kg/bw) for 30 days	8	8	ALT, AST, SOD, CAT, GPx, GSH, and TBARS
Nagappan et al., 2018 [111]	Korea	National Research Foundation of Korea	No conflicts declared	C57BL/6N mice	Male	20–22 g	8-week-old	Ethanol Lieber-DeCarli diet (gradually increasing ethanol concentrations of 0–5%) for the first 5 days. Then, mice were allowed free access to the ethanol Lieber-DeCarli diet containing 5% (v/v) ethanol for 10 days	6	6	ALT, AST, TAG, SREBP-1c, PPAR-a, TBARS, CYP2E1, and GSH
Nie et al., 2021 [112]	China	R&D and Demonstration of Key Technologies and Equipment for Green Manufacturing of Chinese Traditional Meat Products, and Anhui Qiangwang Flavouring Food CO	No conflicts declared	C57BL/6 mice	Male	$20\pm 2g$	8 weeks old	Lieber-DeCarli 3–5 % (v/v) liquid alcohol diet by daily oral gavage for 21 days. Then, a 31.5 % (v/v) alcohol solution (5 g/kg/bw) was given twice by oral gavage for 1 week	8	8	ALT, AST, TNF-a, IL-1B, IL-6, GPx, SOD, Nrf-2, TAG, SREBP-1, and CYP2E1
Nie et al., 2022 [113]	China	Anhui province, and Anhui Qiangwang Flavouring Food Co., Ltd.	No conflicts declared	C57BL/6 mice	Male	$20\pm 2\mathrm{g}$	8 weeks old	Daily oral gavage of 3.0 g/kg/bw alcohol for 15 days and 5.0 g/kg/bw alcohol for 20 days	8	8	ALT, AST, TNF-a, IL-6, IL-1B, SOD, GPx, and TAG
Oh et al., 2002 [114]	Korea	Korea Research Foundation for Health Science and Seoul National University Hospital	No information	Sprague Dawley rats	Male	120–180 g	Not declared	Liber-DeCarli liquid diet for 41 days. Ethanol was increased from 0 to 5% over a 1-week period)	6	6	ALT and AST
Osaki et al., 2016 [115]	Korea	Bigenhwaseong Co., Ltd	No information	Wistar rats	Male	Not declared	4 weeks old	40% ethanol 5 g/kg/bw for 6 weeks	12	12	ALT, AST, Numbers of fatty changed hepatocytes, SOD, GPx, GSH, MDA, andCYP2E1

	Study Characteri	istics			Animal Cha	racteristics			Total (n)		
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Panda et al., 2012 [116]	India	No information	No information	Wistar rats	Either sex	150–200 g	Not declared	Ethanol (5 g/kg, 20% w/v) once daily for 21 days	6	6	ALT, AST, TAG, TBARS, GSH, SOD, CAT, GPx, and GR
Panda et al., 2015 [117]	India	No information	No information	Wistar rats	Either sex	150–200 g	Not declared	20% Ethanol (4 g/kg) once daily for 21 days	6	6	ALT, AST, TBARS, GSH, SOD, CAT, GPx, and GR
Pari and Suresh, 2008 [118]	India	No information	No conflicts declared	Wistar rats	Male	150–170 g	Not declared	20% ethanol (3.95 g/kg/bw) twice daily for 45 days	6	6	ALT, AST, TBARS, GSH, SOD, CAT, GPx, and GST
Park et al., 2013 [119]	Korea	No information	No conflicts declared	ICR mice	Male	27–28 g	8 weeks old	40% ethanol (6.5 g/kg/bw) for 8 weeks	10	10	ALT, AST, TAG, GSH, MDA, TNF-a, and IL-1B
Park et al., 2017 [120]	Republic of Korea	National Institute of Fisheries Science	No conflicts declared	Balb/c mice	Either sex	19–21 g	6 weeks old	Ethanol 4 g/kg for 20 days	6	6	ALT, AST, TAG, SOD, CAT, GPx, and TBARS
Park et al., 2019 [121]	Korea	Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology	No conflicts declared	Balb/c mice	Male	23–26 g	6 weeks old	Ethanol 3 g/kg/day for 10 days	6	6	ALT, AST, MDA, Bax/Bcl-2 ratio, Caspase-3, SOD, CAT, GPx, and Nrf-2
Patere et al., 2011 [122]	India	University of Mumbai	No information	Wistar rats	Male	120–150 g	Not declared	Animals received 10%, 15%, and 20% (v/v) ethanol for 30 days (8–10 g/kg/day during the first week, gradually increasing to 14–16 g/kg/day). The group that maintained the alcohol level between 150–350 mg/dL was selected for the next steps [received increasing concentrations of alcohol through drinking water (10–30%)]	6	6	ALT, MDA, SOD, and CAT

		-
Table	1.	Cont.

	Study Character	istics			Animal Cha	racteristics			Total (1	n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control A	AFLD	Outcomes
Peng et al., 2011 [123]	Taiwan	National Science Council of Taiwan	No information	Wistar rats	Male	160 g	Not declared	Lieber-DeCarli ethanol liquid diet for 7 weeks	10	10	ALT, AST, Fatty change, Inflammation, TAG, GSH/GSSG ratio, TNF-α, IL-1β, IL-6, TNF-α, IL-1β, IL-6, and CYP2E1
Peng et al., 2013 [124]	Taiwan	Cathay General Hospital	No conflicts declared	Wistar rats	Male	Not declared	6 weeks old	Modified Lieber-DeCarli liquid diet for 12 weeks	10	10	ALT, AST, Fatty change, Inflammation, TNF-α, TBARS, GSH/GSSG ratio, CYP2E1, and Caspase-3
Pi et al., 2021 [125]	China	Natural Science Foundation of China, Zhejiang Natural Science Foundation for Distinguished Young Scholars, Special Support Program for High Level Talents in Zhejiang Province, and Research Project of Zhejiang Chinese Medical University	No conflicts declared	C57BL/6J mice	Male	${}^{18.51\pm}_{1.21\rm g}$	Not declared	Lieber-DeCarli ethanol diet for 4 weeks	8	8	ALT, TAG, MDA, SOD, GPx, Caspase-3, Bax/Bd2 ratio, PPAR-a, and SREBP-1c
Prathibha et al., 2013 [126]	India	District Development Office for Scheduled Castes, Trivandrum Kerala	No information	Sprague Dawley rats	Male	100–140 g	Not declared	Ethanol diluted with distilled water (1:1) (4 g/kg/bw/day) was given orally by gastric intubation for 90 days	6	6	MDA, Protein carbonyls, CAT, SOD, GPx, GR, GSH, and CYP2E1
Qi et al., 2017 [127]	China	National Natural Science Foundation of China, Provincial Natural Science Research Project of Anhui, and National Undergraduate Training Programs for Innovation and Entrepreneurship of China	No conflicts declared	Kunming mice	Male	18–22 g	Not declared	10 mL (5.14 mol/L alcohol)/kg body weight in the first 4 weeks, 11 mL (6.85 mol/L alcohol)/kg body weight in the second 4 weeks, and 12 mL (8.56 mol/L alcohol)/kg body weight in the final 4 weeks	10	10	ALT, AST, TAG, MDA, SOD, GPx, and Caspase-3

Table	1	Cont
Table	1.	Cont.

	Study Characteri	stics			Animal Cha	aracteristics			Tota	l (n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	 Study Design 	Contro	I AFLD	Outcomes
Qu et al., 2019 [128]	China	National Natural Science Foundation of China	No information	ICR mice	Male	18–22 g	6 weeks old	Ethanol 50% (10 mL/kg/bw) for 6 weeks	8	8	ALT, AST, TNF-a, IL-6, IL-1B, SOD, MDA, GSH, CYP2E1, Bax/Bcl2 ratio, and Caspase-3
Rabelo et al., 2018 [129]	Brazil	Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Universidade Federal de Ouro Preto (UFOP	No conflicts declared	Fisher rats	Male	220–250 g	Not declared	Acute experiment: 5 mL/kg of absolute ethanol by gavage for 2 days Chronic experiment: 5 mL/kg of diluted ethanol (in the first week they received 20% ethanol (v/v), in the second 40% and third and fourth 60%) for 28 days	7	5	ALT, AST, TAG, SOD, CAT, GSH/GSSG ratio, GPx, GR, TBARS, Carbonylated protein
Rejitha et al., 2012 [130]	India	Council of Scientific and Industrial Research	No conflicts declared	Sprague Dawley rats	Male	100–140 g	Not declared	Alcohol (4 g/kg/bw) for 90 days	6	6	SOD, CAT, GPx, GR, MDA, andProtein carbonyls
Roede et al., 2008 [131]	United States	NIH/NIAAA RO1AA09300, NIH/NIDDK 074407, and NIH/NIAAA F31AA016710	No information	C57/Bl6 mice	Male	Not declared	Not declared	Modified Lieber-DeCarli diet for 9 weeks. Animals began the study on a diet containing 2% ethanol (v/v) , and the amount of ethanol was increased each week until the diet contained 5% ethanol (v/v)	3 or 8	3 or 8	ALT, TAG, CYP2E1, and GSH
Roede et al., 2009 [132]	United States	National Institutes of Health National Institute of Alcohol Abuse and Alcoholism, and National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases	No information	C57/BL6 mice	Male	Not declared	Not declared	Lieber-DeCarli diet for 9 weeks. Animals began the study on a diet containing 2% ethanol (v/v) , and the amount of ethanol was increased each week until the diet contained 5% ethanol (v/v)	4 or 8	4 or 8	ALT, CYP2E1, GSH, SOD, GPx, and GST
Rong et al., 2012 [133]	China	Graduates' Innovation Fund of HUST, National Natural Science Foundation of China, and Program for New Century Excellent Talents in the University of China	No information	Balb/c mice	Male	18–22 g	6 weeks old	2.4 g/kg/day ethanol for the initial 4 weeks and 4 g/kg/day for another 2 weeks	12	12	ALT, AST, TAG, GSH, GPx, and GST

Table	1.	Cont.

	Study Characteri	stics			Animal Cha	racteristics			Total ((n)	_
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Ronis et al., 2005 [134]	United States	Supported in part by R01 AA088645	No information	Sprague Dawley rats	Male	250–300 g	Not declared	Ethanol beginning at 10 g/kg and increased by 0.5 g/kg a week to attain a final concentration of 12.5 g/kg (39% of total energy) for 70 days	8	8	Steatosis score, Inflammation score, CYP2E1, GSH, GSH/GSSG ratio, TBARS, and TAG
Ronis et al., 2010 [135]	United States	Supported in part by the National Institute on Alcohol Abuse and Alcoholism	No information	Sprague Dawley rats	Male	300–350 g	Not declared	Ethanol (10–12 g/kg/day) by total enteral nutrition for 45 days	15	18	ALT, TAG, CYP2E1, Steatosis score, Inflammation score, TBARS, and GSH
Samuhasaneeto et al., 2009 [136]	Thailand	90th Anniversary of Chulalongkorn University Fund (Ratchada phiseksomphot Endowment Fund) and Grant of Ratchada Phiseksomphot, Faculty of Medicine, Chulalongkorn University	No information	Sprague Dawley rats	Female	180–220 g	Not declared	50% ethanol (7.5 g/kg/bw a day) orally via an intragastric tube twice a day for 4 weeks	8	8	MDA and SOD
Saravanan, 2007 [137]	India	No information	No information	Wistar rats	Male	130–180 g	90 days	20% ethanol (5.0 g/kg daily) using an intragastric tube daily for 60 days	10	10	ALT, AST, TBARS, LOOH, SOD, CAT, GPx, and GSH
Saravanan and Nalini, 2007 [138]	India	No information	No information	Wistar rats	Male	130–180 g	Not declared	Ethanol 20% (5.0 g/kg/bw/day) for 60 days	10	10	AL, AST, TBARS, LOOH, SOD, CAT, GPx, and GSH
Sathiavelu et al., 2009 [139]	India	No specific grant from any funding agency in the public, commercial, or not-for-profit sectors	No conflicts declared	Wistar rats	Female	160–180 g	Not declared	20% ethanol (5 g/kg/bw) by intragastric intubation for 60 days	8	8	TBARS, Lipid hydroperoxides, CAT, GSH, GR, and GST
Senthilkumar et al., 2004 [140]	India	No information	No information	Wistar rats	Male	150–170 g	90 days	20% ethanol, 5 mL each (7.9 g/kg/bw) for 60 days	10	10	TBARS, GSH, GR, SOD, and CAT
Shankari et al., 2010 [141]	India	No information	No information	Wistar rats	Male	180–220 g	Not declared	20% ethanol (2.5 mL twice daily), equivalent to 7.9 g/kg/bw for 60 days	6	6	ALT and AST

	Study Character	stics			Animal Cha	aracteristics			Total (n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Shearn et al., 2014 [142]	United States	University of Colorado Anschutz Medical Campus, University of Colorado Denver Cancer Center Research Histology Core, and Colorado Clinical Translational Science Institute	No information	C57BL/6J mice	Male	Not declared	6–8 weeks old	Modified Lieber-DeCarli diet. The ethanol-derived caloric content was ramped from week 1 of 10.8%, with incremental increases weekly to 16.2, 21.5, 26.9, 29.2, 31.8, and 34.7% for the last 1.5 weeks of feeding	6	6	ALT, TAG, GSH, and GSH/GSSG ratio
Shenbagam and Nalini, 2010 [143]	India	No information	No information	Wistar rats	Male	150–180 g	Not declared	20% ethanol twice a day (7.9 g/kg/bw) for 60 days	6	6	ALT, AST, TBARS, LOOH, CAT, GPx, GST, and GSH
Shi et al., 2018 [144]	China	Chinese National Natural Science Foundation and the Natural Science Foundation of Liaoning Province	No conflicts declared	Sprague Dawley rats	Male	180–220 g	Not declared	Lieber-DeCarli diet for 8 weeks	3 or 8	3 or 8	ALT, AST, TAG, and CYP2E1
Smathers et al., 2013 [145]	United States	National Institutes of Health	No information	C57BL/6 mice	Male	Not declared	10 weeks old	Single dose of modified 45% fat-containing Lieber-DeCarli liquid diet	6	6	ALT, TAG, CYP2E1, TBARS, GSH, GSH/GSSG ratio, GPx, and PPAR-a
Sönmez et al., 2012 [146]	Turkey	No information	No conflicts declared	Wistar rats	Male	200–250 g	Not declared	Alcohol-containing liquid diet for 28 days (2.4% ethanol was administered for 3 days, then the ethanol was increased to 4.8% and 7.2% for the following 4 and 21 days on a liquid diet, respectively)	6	6	1
Song et al., 2006 [147]	United States	No information	No information	C57BL/6 mice	Male	Not declared	9 weeks old	Ethanol (5 g/kg/bw) by gavage every 12 h for a total of 3 doses	6	6	ALT, TAG, TBARS, GSH, TNF-a, and CYP2E1
Song et al., 2018 [148]	China	The Central Hospital of Taian and Mushroom Technology System ofShandong Province	No conflicts declared	Kunming mice	Male	$20\pm 2g$	8 weeks old	Alcohol intragastric (50%, v/v, 12 mL/kg/bw) three times at 8-h intervals	10	10	ALT, AST, TAG, TNF-a, IL-6, IL-1B, SOD, GPx, CAT, MDA, LPO
Song et al., 2020 [149]	China	National Natural Science Foundation of China and Jilin Province Health Science and Technology Capacity Improvement Project.	No conflicts declared	C57BL/6J mice	Male	16–20 g	8 weeks old	Alcohol solution 52% [v/v], 7.5 mL/kg/bw, oral gavage	10	10	ALT, AST, MDA, and SOD

Tabl	e	1.	Cont.
Idvi	le.	1.	Com.

	Study Characteri	stics			Animal Cha	aracteristics			Tota	(n)	_
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Song et al., 2021 [150]	China	Mushroom Technology System of Shandong Province and Shandong Key Research and Development Program	No conflicts declared	Kunming mice	Male	18–22 g	8–10 weeks old	Intragastrically injected daily with ethanol (50%, <i>v</i> / <i>v</i> , 10 mL/kg) for 6 weeks	10	10	ALT, AST, SOD, GPx, CAT, MDA, Nrf2, TNF-a, IL-1B, and IL-6
Sudha et al., 2012 [151]	India	No information	No information	Wistar rats	Male	150–180 g	Not declared	20% ethanol (5 g/kg/bw) for 3 weeks	6	6	ALT, AST, MDA, GSH, GR, GSH, and SOD
Sun et al., 2016 [152]	United States	National Institutes of Health	No conflicts declared	Wistar rats	Male	Not declared	8 weeks old	Lieber-DeCarli liquid alcohol diet for 5 months. the ethanol content (%, w/v) in the diet started at 1.6 and increased by 1 every 2 days to reach 3.6 at the end of prefeeding. On the day of feeding, the ethanol content in the diet was 5.0 (36% of total calories) and gradually increased to 6.3 (44% of total calories)	6	6	TAG
Tahir et al., 2013 [153]	India	No information	No information	Wistar rats	Female	150–200 g	6–8 weeks old	Increased dose of ethanol 25% v/v (5, 8, 10, and 12 g/kg/bw per week) for 28 days	6	6	ALT, AST, CYP2E1, LPO, GSH, GPx, GR, CAT, and TNF-a
Tan et al., 2017 [154]	China	National Natural Science Foundation of China, the Scientific Research Foundation for the Returned Overseas Chinese Scholars of Heilongjiang Province, and the Graduate Innovation Foundation of Harbin Medical University. Dr. Ying Liu was supported by the Scientific Research Foundation of Heilongjiang Province	One conflict declared	C57BL/6 mice	Male	Not declared	8–10 weeks old	5% alcohol solution during the first week. Then, alcohol was increased every two weeks by 5% until the alcohol concentration reached 15% (v/v). The final concentration was continued for up to 9 or 12 months	5 or 6	5 or 6	TAG and SOD
Tang et al., 2012 [155]	China	National Natural Science Foundation of China and Program for New Century Excellent Talents in University of China	No conflicts declared	Sprague Dawley rats	Male	140–160 g	Not declared	Ethanol 4.0 g/kg (50%, 10 mL/kg/bw) intragastrically for 90 days	8	8	ALT, AST, TAG, GSH, GPx, SOD, and GST

		-
Table	1.	Cont.

	Study Characteri	istics			Animal Cha	aracteristics			Total (n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Tang et al., 2014 [156]	Taiwan	National Science Council	No information	C57BL/6J mice	Male	20 g	8 weeks old	Lieber-DeCarli ethanol diet (36% ethanol-derived calories) for 6 weeks	3 or 8	3 or 8	ALT, AST, TAG, TBARS, GSH, GPx, CAT, SREBP1, and PPAR-a
Tang et al., 2014 [157]	China	National Natural Science Foundation of China, Program for New Century Excellent Talents in the University of China, and Wuhan Planning Project of Science and Technology	No conflicts declared	C57BL/6J mice	Male	18–20 g	Not declared	Lieber-Decarli liquid diet (the ethanol content was gradually increased over a 12-day period, reaching 30% of total calories as ethanol)	12 or 15	12 or 15	ALT, AST, MDA, and GSH
Tang et al., 2017 [158]	China	Xiamen Science and Technology Program, Education Department of Hunan Province, Joint Funds of Hunan Provincial Natural Science Foundation of China, and the Fujian Province Young and Middle-aged Teacher Education Research Project	No conflicts declared	ICR mice	Male	25 ± 2 g	7 weeks old	Gavage with 12 mL/kg/bw alcohol for 10 consecutive days	7 or 10	7 or 10	ALT, AST, TAG, Steatosis score, Inflammation score, and SOD
Tao et al., 2021 [159]	China	National Key Research and Development Program of China, Jiangsu "333" Project of Cultivation of High-level Talents, and 11th Six Talents Peak Project of Jiangsu Province	No conflicts declared	C57BL/6 mice	Male	20–25 g	Not declared	Lieber-DeCarli ethanol liquid diet for 10 days. On the 11th day, the animals were administered 31.6% ethanol	3 or 8	3 or 8	ALT, AST, CYP2E1, MDA, PPARa, and SREBP-1c
Valansa et al., 2020 [160]	Cameroon	No significant financial support for this work	No conflicts declared	Albino mice	Both sexes	20–25 g	Not declared	Acute experiment: ethanol 40% for 3 daysChronic experiment: 40% ethanol (10 mL/kg) for 28 days	4 or 5	4 or 5	MDA and TNF-a
Varghese et al., 2016 [161]	India	Department of Biotechnology, Government of India and a Fluid Research Grant	No conflicts declared	Swiss albino mice	Male	28–30 g	Not declared	Lieber-DeCarli liquid alcohol diet for 2, 4, 8, or 12 weeks	3	3	CYP2E1 and GSH/GSSG ratio
Velvizhi et al., 2002 [162]	India	No information	No information	Wistar rats	Male	180–220 g	Not declared	20% ethanol (5 mL/day) with an intragastric tube for 60 days	6	6	ALT and AST
Wang et al., 2014 [163]	China	Beijing Natural Science Foundation	No conflicts declared	Wistar rats	Male	$250\pm20~g$	8 weeks old	Lieber-Decarli liquid alcohol diet (4.8, wt/v) for 1 week, and ethanol content increased up to 5.4 in the next 7 weeks	8	8	ALT, AST, IL-1 β , IL-6, and TNF- α

Tabl	e	1.	Cont.
Idvi	le.	1.	Com.

	Study Character	istics			Animal Cha	racteristics			Tota	(n)	_
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Wang et al., 2015 [164]	China	No information	No conflicts declared	C57BL/6 mice	Female	20–24 g	6 weeks old	Lieber-DeCarli diet, where in the first 3 days, the concentration of alcohol was 1% (v/v), followed by $5% (v/v)for the remaining 9 days$	9	9	ALT, AST, TAG, MDA, and SOD
Wang et al., 2016 [165]	China	China–Japan Friendship Hospital Youth Science, Technology Excellence Project, and the Research Fund of the China–Japan Friendship Hospital	No conflicts declared	Wistar rats	Male	180–220 g	Not declared	Alcohol 65 % for 4 or 8 weeks [(5 mL/kg/day) in the first 3 days, and then 10 mL/kg/day in the following days]	6	6	ALT, AST, TAG, MDA, SOD, GPx, TNF-a, IL-1B, IL-6, Caspase-3, and Bax/Bcl-2 ratio
Wang et al., 2018 [166]	China	Mushroom Technology System of Shandong Province	No conflicts declared	Kunming mice	Male	$20\pm 2g$	Not declared	50% alcohol solution (8 mL/kg) four times at 6-h intervals	10	10	ALT, AST, SOD, GPx, CAT, LPO, MDA, TAG, and CYP2E1
Wang et al., 2021 [167]	China	Natural Science Research Project of Colleges and Universities of the Department of Education, Anhui Province	No conflicts declared	ICR mice	Female	Not declared	8 weeks old	Free access to a liquid diet containing 5% (v/v) ethanol for 10 days. Then, mice were gavaged with a megadose of ethanol (5 g/kg)	6, 7 or 8	6, 7 or 8	ALT, AST, TAG, MDA, GSH, CAT, SOD, GPx, and Nrf2
Wang et al., 2020 [168]	China	Talent Innovation and Entrepreneurship Project and the Science and Technology Bureau	No conflicts declared	Wistar rats	Male	190–230 g	Not declared	Ethanol was administered by gavage twice daily with an initial dose of 2 g/kg/d for 3 days, and the dose was gradually increased to 4 g/kg/d for 5 days, 6 g/kg/d for 6 days, and 8 g/kg/d for 28 days (1 mL per 100 g bw)	5 or 10	5 or 10	SOD, GPx, LPO, and Nrf2
Wang et al., 2020 [169]	Japan	No significantfinancial support for this work	No conflicts declared	C57BL/6J mice	Male	Not declared	8–10 weeks old	Modified Lieber-DeCarli liquid alcohol diet for 4 weeks	7 or 16	7 or 16	ALT, AST, TAG, MDA, and SOD
Wang et al., 2021 [170]	China	No information	No conflicts declared	Wistar rats	Male	200–240 g	Not declared	Lieber-DeCarli liquid ethanol diet for 5 weeks	12	12	ALT, AST, IL-1 β , IL-6, and TNF- α
Wang et al., 2022 [171]	China	Key Projects for Major Projects on the Transformation of Old and Novel Kinetic Energy of Shandong Province, STS Project of the Chinese Academy of Sciences	No conflicts declared	C57BL/6 mice	Not declared	18–22 g	4 weeks old	Orally administered daily dose of 50% (v/v) ethanol (10 mL/kg/bw) for 6 weeks	10	10	ALT, AST, TAG, SOD, GSH, MDA, IL-1β, IL-6, and TNF-α

Tabl	e	1.	Cont.

	Study Character	istics			Animal Cha	racteristics		City des Designs	Tota	l (n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Wang et al., 2022 [172]	China	National Key R&D Program of China	No conflicts declared	C57BL/6N mice	Male	Not declared	6 weeks old	Ethanol liquid diet (for the first week, 2 g ethanol/kg/bw/day; for the second week, 4 g ethanol/kg/bw/day; and for 3–5 weeks, 6 g ethanol/kg/bw/day)	10	10	ALT, AST, TAG, SOD, and MDA
Wang and Mu, 2021 [173]	China	No information	No conflicts declared	Wistar rats	Not declared	180–210 g	Not declared	3 g/kg/day (40% v/v) ethanol challenge for 4 weeks	6	6	ALT, SOD, GPx, LPO, TNF-a, and IL-6
Wei et al., 2013 [174]	China	National Natural Science Foundation of China, the Guangxi Natural Science Foundation, and the Foundation for the Guangxi Key Laboratory for Prevention and Treatment of Regional High-Incidence Diseases	No conflicts declared	Wistar rats	Male	180–200 g	Not declared	Ethanol 5.0 g/kg/day from 1 to 4 weeks, 7.0 g/kg/day from 5 to 8 weeks, and 9.0 g/kg/day from 9 to 12 weeks, for a total of 24 weeks	15	15	ALT, AST, TNF-a, IL-1B, SOD, GPx, GR, CAT, MDA, and CYP2E1
Wu et al., 2019 [175]	China	National Natural Science Foundation of China	No conflicts declared	C57BL/6J mice	Male	$\begin{array}{c} 18.0\pm2.0\\ g\end{array}$	8 weeks old	Alcohol solution (52%, 7.5 mL/kg/bw) for 12 weeks	10	10	ALT, AST, MDA, and SOD
Wu et al., 2019 [176]	China	The National Key Research and Development Program of China and National Natural Science Foundation of China	No conflicts declared	Kunming mice	Female	21–25 g	4 weeks old	50% ethanol (14 mL/kg) for 4 weeks	3 or 10	3 or 10	ALT, AST, SOD, CAT, GPx, MDA, TAG, TNF-a, IL-6, IL-1B, CYP2E1, and Bax/Blc-2 ratio
Xia et al., 2018 [177]	China	National Natural Science Foundation of China, Tianjin Municipal Science and Technology Commission, Rural Affairs Committee of Tianjin, and the Innovative Research Team of Tianjin Municipral Education Commission	No conflicts declared	ICR mice	Male	Not declared	8 weeks old	Single dose of ethanol 50% (w/v) , 4.8 g/kg bw	6	6	ALT, AST, MDA, SOD, CYP2E1, Caspase 3, TNF-a, and IL-6
Xiao et al., 2014 [178]	China	Zhejiang Provincial Natural Science Foundation of China; Small Project Funding, University Research Committee, HKU; General Research Fund, University Grant Council, Hong Kong SAR; and the Azalea Endowment Fund to KFS	No conflicts declared	Sprague Dawley rats	Female	180–200 g	Not declared	Ethanol 4.0 g/kg for 10 weeks	6	6	ALT, AST, TAG, and CYP2E1

	Study Character	istics			Animal Cha	racteristics			Total	l (n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	Study Design	Control	AFLD	Outcomes
Xiao et al., 2017 [179]	China	Joint Fund from the NSFC and Guangdong Provincial Government, the National Nature Science Foundation of China, the PhD Start-up Fund of the Natural Science Foundation of Guangdong, the China Postdoctoral Science Foundation, and the Guangdong	No conflicts declared	C57BL/6 mice	Male	$26 \pm 2 \text{ g}$	10 weeks old	Lieber-DeCarli 4% (w/v) ethanol-containing liquid diet for 8 weeks	4 or 10	4 or 10	ALT, AST, TAG, TBARS, SOD, GPx, CAT, GSH, GSH/GSSH ratio, Caspase-3, and Bax/bcl2 ratio
Xiao et al., 2020 [180]	China	Key Research and Development Program of Guangdong Province, the National Natural Science Foundation of China, the Scientific Research Startup Fund of Hainan University, the Guangdong Special Support Program, the Group Program of Natural Science Foundation of Guangdong Province, the Special Fund for Scientific Innovation Strategy-Construction of the High-level Academy of Agriculture Science, the Discipline Team Building Projects of Guangdong Academy of Agricultural Sciences in the 13th Five-Year Period, and the Open Fund of the Key Laboratory of Food Nutrition and Functional Food of Hainan Province	No conflicts declared	C57BL/6 mice	Male	18 ± 2 g	6 weeks old	Lieber-DeCarli ethanol liquid diet (4%, w/v) for 8 weeks	4 or 8	4 or 8	ALT, AST, TAG, TBARS, SOD, GPx, CAT, Caspase 3, Bax/Bcl2 ratio, GSH, and GSH/GSSG ratio
Xu et al., 2021 [181]	China	National Natural Science Foundation of China, Anhui Medical University of Science and Technology, and the University Synergy Innovation Program of Anhui Province	No conflicts declared	C57BL/6J mice	Male	18–22 g	6–8 weeks old	5% ethanol liquid diet for 16 days, and a single alcohol plus binge (5 g/kg, 33% ethanol) on the last day	6	6	Steatosis score, ALT, AST, IL-1 β , IL-6, and TNF- α
Yalçinkaya et al., 2007 [182]	Turkey	Research Fund of the University of İstanbul	No information	Wistar rats	Male	180–200 g	Not declared	Ethanol was added to drinking water 20% (v/v) for 75 days (approximately 8.5 g/kg/bw/day)	6	8	ALT, AST, MDA, Protein carbonyl, GSH, SOD, GPx, and GST

Table 1. Co	nt

	Study Characteri	stics			Animal Cha	racteristics			Tota	ıl (n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	Study Design	Contro	AFLD	Outcomes
Yan and Yin, 2007 [183]	Taiwan	No information	No information	Balb/cA mice	Male	Not declared	5–6 weeks old	Three doses of 25% (w/v) ethanol were administered at 5 g/kg/bw by gavage every 12 h	15	15	ALT, AST, GSH, GSH/GSSG ratio, GPx, and CAT
Yang et al., 2013 [184]	China	973 Program	No conflicts declared	C57BL/6 mice	Male	Not declared	8–10 weeks old	A single dose of ethanol (5 g/kg)	5	5	ALT, AST, TAG, MDA, GSH, and SOD
Yang et al., 2021 [185]	China	Zhongyuan Scholars, Strategic Consulting Research Project of Henan Institute of Chinese Engineering Development Strategies, Major Science and Technology Projects for Public Welfare of Henan Province, Youth Talent Support Program, Key Project Foundation of Natural Science Research, Key Scientific and Technological Research Projects of Henan Province, Fundamental Research Funds for the Henan Provincial Colleges and Universities in Henan University of Technology, High-Level Talents Research Fund of HAUT, and Open Research Subject of the National Engineering Laboratory for Wheat and Corn Further Processing	No conflicts declared	Kunming mice	Male	20 ± 2 g	6 weeks old	52% ethanol (5 mL/kg/bw) thrice every 12 h	10	10	TAG, GSH, MDA, and SOD
Yang et al., 2022 [186]	China	National Natural Science Foundation of China	No conflicts declared	C57BL/6J mice	Male	$22\pm 2g$	8 weeks old	Lieber-DeCarli liquid alcohol diet for 5 weeks [alcohol was gradually increased from 1% to 4% (w/v)]	10	10 or 12	ALT, AST, TAG, GSH, GPx, SOD, MDA, TNF-a, IL-6, IL-1B, and CAT
Yao et al., 2007 [187]	China	National Natural Science Foundation of China, and Program for New Century Excellent Talents in the University of China	No information	Sprague Dawley rats	Male	140–160 g	Not declared	Ethanol 2.4 g/kg (30% v/v, 10 mL/kg) for 90 days	3 or 8	3 or 8	ALT, AST, GPx, CAT, GSH, and MDA

Table 1. Cont.	Cont.	I. (le	Tab	
----------------	-------	------	----	-----	--

	Study Character	istics			Animal Cha	racteristics			Total	(n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Yeh et al., 2020 [188]	Taiwan	Ministry of Science and Technology and National Taiwan Normal University	No conflicts declared	C57BL/6 mice	Male	Not declared	7 weeks old	Modified Lieber-DeCarli ethanol liquid diet (500 mg/kg/bw) for 11 weeks	10	10	ALT, AST, TAG, TNF-α, IL-1β, Histology (liver steatosis score and liver inflammation score), PPAR-a, SREBP-1, MDA, GSH, CYP2E1, and Nrf2
Yoon et al., 2012 [189]	South Korea	Technology Development Program for Food, Ministry for Food, Agriculture, Forestry, and Fisheries	No conflicts declared	Sprague Dawley rats	Male	150–170 g	Not declared	Lieber-DeCarli ethanol liquid diet for 8 weeks, Ethanol was introduced progressively at 3% (w/v) of the liquid diet for 2 days, 4% for the subsequent 2 days, and 5% thereafter	8	8	ALT, AST, Steatosis score, Inflammation score, TNF-a, IL-6, MDA, and GSH
You et al., 2010 [190]	Republic of Korea	Jeollanam-Do	No conflicts declared	ICR mice	Male	$30\pm 2g$	8 weeks old	5 g/kg/bw/day of ethanol by gastric intubation for 8 days	8	8	ALT, AST, CAT, GST, GPx, GR, GSH, and MDA
You et al., 2020 [191]	China	National Key R&D Program of China	No conflicts declared	C57BL/6 mice	Male	Not declared	Not declared	Lieber-DeCarli liquid diet for 8 weeks	3 or 10	3 or 10	ALT, AST, TAG, IL-6, TNF-a, MDA, Protein Carbonyl, and GPx
Yu et al., 2019 [192]	China	National Natural Science Foundation of China, Special Funds for National Key Sci-Tech Special Project of China, Shanghai Science and Technology Committee, Science Fund for Creative Research Groups	No conflicts declared	C57BL/6J mice	Male	20–22 g	6–8 weeks old	Single dose of ethanol 50% (v/v) (5 g/bw) by gavage	10	10	ALT, AST, Histology, TAG, and MDA
Yu et al., 2022 [193]	China	No information	No information	Sprague Dawley rats	Male	185–200 g	6–7 weeks old	8 mL/kg/day ethanol twice daily, changing weekly, for 4 weeks (10%, 15%, 30%, and 56% alcohol v/v)	5 or 10	5 or 10	ALT, AST, SOD, GPx, MDA, and Nrf-2
Yuan et al., 2018 [194]	China	Jilin Pharmaceutical Industry Promotion Plan	No conflicts declared	ICR mice	Male	19–21 g	Not declared	Single dose of 50% ethanol solution (12 mL/bw) intragastrically	10	10	ALT, AST, TAG, MDA, SOD, and CYP2E1

	Study Characteri	istics			Animal Cha	racteristics			Total	(n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Yuan et al., 2020 [195]	China	Guangdong Province Key Laboratory for New Drugs Research and Development of Chinese Medicine, China, Project of Guangzhou University of Chinese Medicine, Science and Technology Project Scheme of Guangdong Province, China, and Natural Science Foundation of Guangdong Province, China	No conflicts declared	Kunming mice	Male	18–22 g	Not declared	30% ethanol (10 mL/kg) intragastrically for one week, after that, the ethanol concentration iwas ncreased gradually (the next 3 weeks were 40%, 50%, and 55%)	3, 5 or 6	3, 5, or 6	ALT, AST, TAG, Bax/Bcl-2 ratio, Caspase3, and TNF-a
Zahid et al., 2018 [196]	India	No significantfinancial support for this work	No conflicts declared	Sprague Dawley rats	Not declared	150–210 g	Not declared	50% ethanol (12 mL/kg/bw) administered once a day for 8 days	5	5	ALT, AST, SOD, CAT, GSH, and TBARS
Zeng et al., 2013 [197]	China	Shandong Province Science Foundation and Postdoctoral Science Foundation Funded Project of Shandong Province	No conflicts declared	Kunming mice	Male	18–22 g	Not declared	Ethanol (5 g/kg/bw) at 12-h intervals for a total of three doses	10	10	ALT, AST, MDA, and GSH
Zhang et al., 2011 [198]	China	Science and Technology Funds of Suzhou City and Jiangsu Province	No conflicts declared	Kunming mice	Male	$22\pm 2g$	Not declared	52% alcohol for 4 weeks (the amount of alcohol was gradually increased from 0.2 mL (10 g/day) to 0.4 mL (10 g/day) over 1 week)	6 or 10	6 or 10	TAG, SOD, MDA, and GPx
Zhang et al., 2014 [199]	China	National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions and College Students Innovation Project for the R&D of Novel Drugs	No conflicts declared	ICR mice	Male	24–16 g	8 weeks old	Acute experiment: Three doses of ethanol (6 g/kg) at 12-h intervalsChronic experiment: Lieber-DeCarli liquid diets containing 36% ethanol for 5 weeks	7 or 8	7 or 8	ALT, TBARS, GSH, Steatosis score, TAG, TBARS, and CYP2E1
Zhang et al., 2015 [200]	China	No information	No information	ICR mice	Male	24–26 g	8 weeks old	Acute experiment: ethanol (6 g/kg orally gavage) three times at 12-h intervalsChronic experiment: Lieber-DeCarli liquid diet containing ethanol at 36% of the caloric content for 5 weeks	3,4 or 6	3,4 or 6	ALT, AST, GSH, GPx, TBARS, TAG, and CYP2E1

	Study Character	istics			Animal Cha	aracteristics			Total	(n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control	AFLD	Outcomes
Zhang et al., 2020 [201]	China	Science and Technology Develop Project in Jilin Province of China, the Special Projects of Cooperation between Jilin University and Jilin Province in China, Innovation Training Program of Zhuhai College of Jilin University, and "Three levels" Talent Construction Projects in Zhuhai College of Jilin University	No conflicts declared	C57BL/6 mice	Male	18–22 g	8–10 weeks old	Mice were intragastrically administrated with 13 g/kg of 56% ethanol for 14 days	6 or 10	6 or 10	ALT, AST, MDA, SOD, GPx, and CAT
Zhang et al., 2020 [202]	China	National Natural Science Foundation of China and Changsha Science and Technology Bureau	No conflicts declared	C57BL/6 mice	Male	Over 20 g	8 weeks old	Lieber-DeCarli ethanol liquid diet for 10 days	6	6	/
Zhang et al., 2021 [203]	China	National Natural Science Foundation of China and the Science and Technology Research of Shanxi Province	No conflicts declared	C57/B6 mice	Male	Not declared	6 weeks old	Daily oral gavage of 50% (v/v) ethanol (4 g/kg) for 8 weeks	7	7	ALT, AST, TAG, TNF- α , IL-1 β , IL-10, SOD, and GPx
Zhao et al., 2008 [204]	China	National Grand Fundamental Research 973 Program of China	No information	ICR mice	Male	22–24 g	Not declared	Single dose of alcohol 6 g/kg	8	8	ALT, TAG, TBARS, CSH, SOD, CAT, GR, GPx, TNF-a, and IL-1B
Zhao et al., 2018 [205]	China	National Natural Science Foundation of China and the Study and Demonstration of Introduction and Deep Processing Technology of Quinoa in Mountainous Regions	No conflicts declared	ICR mice	Male	20–22 g	Not declared	50% alcohol (10 mL/kg/bw) by oral gavage for 5 weeks	10	10	ALT, AST, TAG, MDA, SOD, CAT, GSH, GPx, TNF-a, and IL-6
Zhao et al., 2021 [206]	China	China Postdoctoral Science Foundation, Beijing Postdoctoral Research Foundation, Technological Innovation Service Capacity Building-Basic Scientific Research Expenses, and Taif University Researchers Supporting Project	No conflicts declared	ICR mice	Male	22–24 g	7–9 weeks old	50% (v/v) alcohol (10 mL/kg/bw daily) by oral route for 4 weeks	6	6	ALT, AST, TAG, MDA, SOD, GPx, GSH, CAT, IL-6, IL-1 β , and TNF- α

	Tabl	le 1	1.	Cont.
--	------	------	----	-------

	Study Characteri	stics			Animal Cha	racteristics			Total	(n)	
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	 Study Design 	Control	AFLD	Outcomes
Zhao et al., 2021 [207]	China	National Natural science Foundation of China, the Major Science, Technology Innovation Project of Shandong Province, and the Shandong Provincial Natural Science Foundation	No conflicts declared	Rats (lineage not specified)	Male	200 ± 20 g	8 weeks old	Oral gavage of 7 mL per kg/bw ethanol 56% (v/v) for the first 4 weeks, and then gavage of 9 mL per kg/bw alcohol for the remaining 16 weeks	5 or 10	5 or 10	ALT, AST, TAG, SOD, GPx, CAT, MDA, Bax/Bcl2 ratio, and Caspase-3
Zheng et al., 2019 [208]	China	National Natural Science Foundation of China; the Priority Academic Program Development of Jiangsu Higher Education Institutions, the Universities Natural Science Research Project of Jiangsu Province; the Primary Research and Development Plan of Jiangsu Province; the Northern Jiangsu Project of Science and Technology Development	No conflicts declared	Kunming mice	Male	$20\pm 2g$	Not declared	12 mL/kg of 50% alcohol every 12 h for a total of three times	10	10	ALT, AST, TNF-a, IL-1B, SOD, CAT, GPx, and MDA
Zheng et al., 2022 [209]	China	Basal Research Fund of the National Health Commission Key Laboratory of Birth Defect Prevention, the Medical Science and Technology Research Project of Henan Province, the Project of Basal Research Fund of Henan Institute of Medical and Pharmacological Sciences, the Basal Research Fund of Henan Academy of Sciences	No conflicts declared	Kunming mice	Male	20–22 g	8 weeks old	Single dose of 70% ethanol (12 mL/kg/bw)	8	8	ALT, AST, TAG, CAT, GPx, Nrf2, and Caspase 3
Zhou et al., 2002 [210]	United States	No information	No information	C57BL/6 mice	Male	Not declared	9 weeks old	Three doses of 25% (w/v) ethanol were administered at 5 g/kg body weight by gavage every 12 h	5	5	ALT, GSH, GSH/GSSG ratio, TBARS, Protein carbonyl, and CYP2E1
Zhou et al., 2018 [211]	China	No information	No information	Wistar rats	Not declared	220–240 g	7 weeks old	In the first week, rats were treated with alcohol (56%; 0.8 mL/100 g) daily by oral gavage. The amount of alcohol was increased by 0.1 mL every other week until the 8th week (1.5 mL/100 g in the 8th week)	6 or 10	6 or 10	ALT, AST, TAG, GSH, SOD, MDA, amd TNF-a

Tabl	e	1.	Cont.
Idvi	le.	1.	Com.

	Study Characteri	Animal Characteristics						Total (n)		
Author and Year	Study Location	Funding	Conflict of Interest	Lineage	Gender	Size	Age	- Study Design	Control AFL	Outcomes
Zhou et al., 2021 [212]	China	Deep Process and Functional Food Development of Daylily and Astragalus	No conflicts declared	ICR mice	Male	18–21 g	Not declared	10 mL/kg of 50% alcohol, by oral gavage for 4 weeks	12 12	ALT, AST, TAG, SOD, CAT, GSH, GPx, MDA, TNF-a, IL-6, and IL-1B
Zhou et al., 2022 [213]	China	Deep Process and Functional Food Development of Daylily and Astragalus, Taif University Researchers Supporting Project, and the National Dairy Industry and Technology System of China	No conflicts declared	ICR mice	Male	$20\pm1g$	5 weeks old	50% alcohol (10 mL/kg/bw) for 4 weeks	12 12	ALT, AST, TAG, CAT, SOD, GSH, GPx, MDA, IL-1B, IL-6, and TNF-a
Zhu et al., 2014 [214]	China	Heilongjiang Development and Reform Commission, Heilongjiang Education Department, the Heilongjiang Education Department of Science and Technology Research Project; the Harbin Special Funds for Technological Innovation Research Projects, the Heilongjiang Postdoctoral Scientific Research Foundation, and the National Natural Science Foundation of China	No information	Kunming mice	Male	Not declared	8–10 weeks old	40% ethanol (5 g/kg/bw) for 6 weeks	8 8	ALT, AST, TAG, SOD, and GPx
Zhu et al., 2021 [215]	China	National Natural Science Foundation of China	No conflicts declared	C57BL/6 mice	Male	22–25 g	Not declared	Lieber-DeCarli ethanol diet for 10 days. On day 11, mice were gavaged with a single dose of 31.5% (v/v) ethanol (20 µL/gbw)	8 8	ALT, AST, TAG, MDA, SREBP-1, and PPAR-a

With regard to the induction of AFLD, there was significant variation in the concentration of ethanol used (ranging from absolute to 1% diluted in water), the methods of administering ethanol (including gavage, intragastric tube, in drinking water, and in the form of a Lieber-DeCarli diet), the doses administered (ranging from 1 mL/kg/bw to 15 mL/kg/bw or 1 g/kg/bw to 12 g/kg/bw), and the treatment durations (ranging from single doses to 24-week treatments).

In terms of the primary outcomes, the studies measured the activity of antioxidant enzymes, including SOD (n = 120), CAT (n = 84), GPx (n = 88), GR (n = 34), and GST (n = 20). The non-enzymatic antioxidant GSH (n = 118) and the GSH/GSSG ratio (n = 24) were also measured. Oxidative damage was assessed by measuring lipoperoxidation (n =158) and carbonylated protein (n = 11). For secondary outcomes, the studies evaluated liver damage by measuring ALT (n = 175) and AST (n = 156), and the lipid profile was assessed by measuring TAG (n = 112). Inflammation was assessed by measuring TNF-a (n = 66), IL-1 β (n = 41), IL-6 (n = 43), and IL-10 (n = 7). Apoptosis was evaluated by measuring the Bax/Bcl-2 ratio (n = 13) and caspase 3 (n = 18). Enzymes that metabolize ethanol, such as CYP2E1, were also measured (n = 55). Histological analysis was performed to assess steatosis (n = 15) and inflammation (n = 14). Finally, transcription factors related to lipid and carbohydrate metabolism, including SREBP-1 (n = 16) and PPAR-a (n = 14), as well as antioxidant enzyme regulation, such as Nrf2 (n = 24), were also evaluated.

Table 1 shows the data extracted from the primary articles, including author name and year, study location, funding source, animal characteristics (lineage, sex, weight, age), the AFLD induction model, the number of animals in each group, and the outcomes of interest.

3.3. Parameters Analyzed in the Systematic Review and Meta-Analysis

The parameters chosen for extraction from the primary articles were based on those that validate the model of alcoholic steatosis, such as liver damage and lipid profile, but also on those that analyzed the markers of oxidative stress (the focus of the present work), inflammation, and cell death. Combining these parameters offers compelling evidence regarding the liver's condition in response to ethanol metabolism. Each of these factors is elaborated upon below.

3.3.1. Liver Damage

Typically, ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are present in the liver and are involved in protein metabolism, so there are low levels in the bloodstream. However, when there is liver damage, these enzymes commonly leak into the bloodstream and lead to an increase in their quantification in serum/plasma. Thus, measuring this activity is a good tool for understanding liver damage. Accordingly, we extracted data on ALT and AST activity from primary studies eligible for systematic review and meta-analysis in order to understand the state of liver damage in animals from the AFLD and control groups.

A total of 175 manuscripts evaluated the activity of ALT in serum/plasma (U/L). It is possible to observe through the SMD that there is an increase in the activity of this enzyme in AFLD groups compared with control groups (SMD: 3.51, 95% CI 3.21, 3.81, p < 0.00001). There was also high heterogeneity among the studies ($I^2 = 84\%$) (Supplementary Figure S1). With regard to AST, a total of 156 articles were included in the analysis, and these articles were heterogeneous among themselves ($I^2 = 85\%$). Similarly, an increase in AST activity was observed in AFLD groups compared with control groups (SMD: 3.56, 95% CI 3.24, 3.89, p < 0.00001) (Supplementary Figure S2).

3.3.2. Lipid Profile

Triacylglycerol (TAG)

The body of literature shows that ethanol metabolism leads to dysregulation of the lipid profile, especially of TAG; therefore, this systematic review and meta-analysis aimed to analyze TAG levels in animals with or without AFLD. A total of 112 articles eligible for our

study quantified TAG in serum/plasma (50 measured in mmol/L and 27 in mg/dL) and liver (36 measured in mmol/g and 39 in mg/g). Subgroup analysis was adopted, namely liver and serum/plasma, but there was high heterogeneity among the studies ($I^2 = 82\%$). It was evident that there was an increase in TAG levels in AFLD groups compared with control groups, both in the liver and in the plasma. This effect was noted for both the subgroup analysis and the overall analysis (SMD: 2.91, 95% CI 2.63, 3.19, *p* < 0.00001) (Supplementary Figure S3).

Sterol Regulatory Element-Binding Transcription Factor 1c (SREBP-1c)

SREBP-1c triggers the activation of a group of genes that play a significant role in glucose metabolism and the production of fatty acids. Thus, its activation can contribute to AFLD. In order to prove whether there is evidence of this contribution to AFLD, this systematic review included the extraction of data on SREBP-1c protein expression from primary articles. Through analysis of 16 studies (all measuring protein expression), it was evident that there is an increase in the expression of this transcription factor in AFLD groups compared with control groups (MD: 1.40, 95% CI 0.76, 2.03, p < 0.00001) (Supplementary Figure S4).

Peroxisome Proliferator-Activated Receptor Alpha (PPAR- α)

The activation of PPAR- α triggers a cascade of biological actions, including the uptake, utilization, and breakdown of fatty acids. Upregulating genes that are involved in fatty acid transport, binding, activation, and peroxisomal and mitochondrial fatty acid β -oxidation facilitate this process. Given the importance of PPAR- α in lipid metabolism, this systematic review included analysis of 14 manuscripts that quantified the expression of this transcription factor. There was a reduction of PPAR- α in AFLD groups compared with control groups (MD: -0.53, 95% CI -0.72, -0.35, p < 0.00001) (Supplementary Figure S5).

Histological Analysis of the Liver

A total of 15 articles analyzed the presence of hepatic steatosis, 5 of them through fatty accumulation and 10 through measurement of the steatosis score. There was an increase in the histological grade in AFLD groups compared with control groups (SMD: 4.33, 95% CI 2.92, 5.73, p < 0.00001) (Supplementary Figure S6).

3.3.3. Ethanol Metabolism through Cytochrome P450 2E (CYP2E1)

It is well established that CYP2E1 is one of the pathways involved in ethanol metabolism, and this pathway has a direct association with oxidative stress. Therefore, this meta-analysis included examination of 55 primary studies that investigated CYP2E1 expression (n = 48) and activity (11 measured in nmol/min/mg and 3 in ng/mg) in the livers of animals with or without AFLD. According to a forest plot, it was clear that there was an increase in the expression and activity of CYP2E1 in the animals of AFLD groups compared with control groups. This profile was maintained for individual subgroups and the overall analysis (SMD: 3.73, 95% CI 3.22, 4.24, p < 0.00001) (Supplementary Figure S7).

3.3.4. Oxidative Stress Biomarkers

In order to verify if there is increased oxidative stress in animals with AFLD, this meta-analysis included an evaluation of primary articles that analyzed antioxidant defense (SOD, CAT, GPx, GR, GST, GSH, and GSH/GSSG ratio) and oxidative damage (lipid peroxidation and carbonyl protein). The effect of ethanol metabolism for each parameter is described below.

Antioxidant Profile in AFLD

• Superoxide Dismutase (SOD)

Liver SOD activity (U/mg) in animals was measured in 120 studies, which demonstrated a significant decrease in AFLD groups compared with control groups (MD of -1.77;

udv or Subaroup		AFLD SD	Tetal		ontrol SD	Tetal	Moinht	Mean Difference	Mean Difference
delhamid et al., 2020 [10]	Mean 358.696	114.13	Total 12	Mean 2,274.457	97.826	12	Weight 0.0%	V, Random, 95% CI -1915.76 [-2000.81, -1830.71]	IV, Random, 95% Cl
delhamid et al., 2021 [11] Rejaie, 2012 [12]	0.357 9.5	0.11 1.47	6 6	2.288 12.9	0.093 1.715	6 6	4.4% 0.1%	-1.93 [-2.05, -1.82] -3.40 [-5.21, -1.59]	
ef et al., 2018 (13) iranisrinivasan et al., 2009 (16)	90.423 2.54	10.378 0.24	6 6	226.747 6.32	23.602 0.7	6 6	0.0% 0.9%	-136.32 [-156.95, -115.69] -3.78 [-4.37, -3.19]	
amhan et al., 2011 (19) sht et al., 2018 (20)	1.996 26.2	0.17 0.196	8 6	4.46 11.01	0.42 2.156	8 6	2.2% 0.1%	-2.46 [-2.78, -2.15] 15.19 [13.46, 16.92]	
ao et al., 2015 [24] nang et al., 2017 [26]	172.87	27.6	4	223.87	17.1	4	0.0%	-51.00 [-82.82, -19.18]	•
navan et al., 2017 [29]	14.56	0.0098 1.225	6	0.0742 66.23	0.0097 1.053	6	0.2%	0.00 [-0.00, 0.01] -51.67 [-52.96, -50.38]	•
nen et al., 2013 [30] neng and Khong, 2011 [32]	9 6.98	1.6 2.85	6 12	6.8 12.53	2.1 4.47	6 12	0.1% 0.0%	2.20 [0.09, 4.31] -5.55 [-8.55, -2.55]	←
niu et al., 2011 (33) vi et al., 2014 (36)	0.0133 2.815	0.0008	6 12	0.0149 3.467	0	6 12	1.4%	Not estimable -0.65 [-1.08, -0.22]	
i et al., 2014 [37]	2.59	0.7	12	2.93	0.72	12	0.9%	-0.34 [-0.91, 0.23]	+
as et al., 2012 [39] e Souza et al., 2015 [40]	8.0133 9.456	1.573 2.239	18 10	6.26 8.04	0.06 0.959	6 10	0.6% 0.2%	1.75 [1.03, 2.48] 1.42 [-0.09, 2.93]	
eveli et al., 2014 [41] i et al., 2015 [43]	29.9 3.873	2.24 9.233	8 6	28.2 5.4	3.34 12.481	8 6	0.0% 0.0%	1.70 [-1.09, 4.49] -1.53 [-13.95, 10.90]	•
ng et al., 2019 [45]	0.132	0.025	8	0.253	0.037	8	5.2%	-0.12 [-0.15, -0.09]	•
an et al., 2021 (50) asanein et al., 2018 (53)	142.688 7.683	7.165 0.614	10 7	193.082 12.198	39.463 0.317	10 7	0.0% 1.1%	-50.39 [-75.25, -25.54] -4.52 [-5.03, -4.00]	:
su et al., 2018 [55] Jang et al., 2017 [57]	0.8 149.115	0.3 14.279	10 12	1.6 190.77	0.3 9.905	10 12	2.6% 0.0%	-0.80 [-1.06, -0.54] -41.66 [-51.49, -31.82]	•
ietal., 2021 (56) ang etal., 2016 (60)	58.748 131.08	8.973 12.74	6 8	87.529 178.44	10.666 2.15	6 8	0.0%	-28.78 [-39.93, -17.63] -47.36 [-56.31, -38.41]	
ang et al., 2019 [61]	220.285	11.164	10	274.746	12.385	10	0.0%	-54.46 [-64.80, -44.13]	
1 et al., 2010 [62] se et al., 2018 [63]	32.51 1.176	11.8558 0.086	15 8	37.14 4.672	10.2566 0.256	15 8	0.0% 3.5%	-4.63 [-12.56, 3.30] -3.50 [-3.68, -3.31]	
inchana and Jayapriya, 2013 [65] ing et al., 2009 [66]	3.75 15.016	0.37 4.758	6 4	7.55 25.872	0.62 1.438	6 4	0.9% 0.0%	-3.80 [-4.38, -3.22] -10.86 [-15.73, -5.98]	
warasan et al., 2008 (68)	5.39	0.46	6	9.92	0.7	6	0.7%	-4.53 [-5.20, -3.86]	
m et al., 2016 [71] i et al., 2019 [73]	1.21 2.51	0.18	5 8	4.7 4.7	0.66 0.64	5	0.9% 1.3%	-3.49 [-4.09, -2.89] -2.19 [-2.66, -1.72]	·
e et al., 2015 [74] e et al., 2016 [76]	16.7 34.887	0.5 7.894	8 10	19.3 113.203	0.6 14.708	8 10	1.0% 0.0%	-2.60 [-3.14, -2.06] -78.32 [-88.66, -67.97]	
e et al., 2021 [79]	35.598	6.852	8	112.854	16.147	8	0.0%	-77.26 [-89.41, -65.10]	:
an et al., 2010 (89) et al., 2013 (80)	34.504 7.92	1.441 4.122	10 12	59.031 10.9	1.972 4.018	10 12	0.2% 0.0%	-24.53 [-26.04, -23.01] -2.98 [-6.24, 0.28]	↓
et al., 2015 [81] et al., 2017 [83]	33.424 0.802	10.5537 0.043	30 8	55.699 1.097	4.386 0.093	10 8	0.0% 4.9%	-22.27 [-26.93, -17.62] -0.29 [-0.37, -0.22]	· _
et al., 2018 [84]	181.1625	26.0193	16	247.385	31.7035	16	0.0%	-66.22 [-86.32, -46.13]	:
et al., 2021 [85] et al., 2021 [86]	867.487 896.821	141.317 162.885	9 9	1,162.265 1,137.622	176.077 82.618	9 9	0.0% 0.0%	-294.78 [-442.28, -147.28] -240.80 [-360.12, -121.48]	2
et al., 2021 (88) n et al., 2017 (90)	752.528 4.366	58.567 1.59	9 8	932.444 6.584	60.253 0.558	9 8	0.0%	-179.92 [-234.81, -125.02] -2.22 [-3.39, -1.05]	
n et al., 2021 [91]	0.591	0.182	8	0.918	0.102	8	4.0%	-0.33 [-0.47, -0.18]	-
uetal., 2014 [92] uetal., 2015 [93]	3.838 4.744	0.806 1.106	7	5.822 8.288	0.75 0.899	7	0.5% 0.4%	-1.98 [-2.80, -1.17] -3.54 [-4.53, -2.56]	←
ı et al., 2022 [96] et al., 2014 [97]	167.077 55.52	13.017 11.62	8 12	243.645 68.5	31.304 8.15	8 12	0.0%	-76.57 [-100.06, -53.08] -12.98 [-21.01, -4.95]	
et al., 2015 (98)	3.48	0.71	10	7.59	1.46	10	0.3%	-4.11 [-5.12, -3.10]	1
ai et al., 2022 (102) aimaitimin et al., 2018 (103)	19.209 10.779	1.114 0.742	6 7	35.459 14.275	2.325 0.495	6 7	0.1% 0.7%	-16.25 [-18.31, -14.19] -3.50 [-4.16, -2.84]	
illikarjuna et al., 2008 (104) shanna et al., 2021 (106)	8.526 14.2485	0.501 1.4468	6 16	12.665 22.047	0.477	6 8	1.0% 0.2%	-4.14 [-4.69, -3.59] -7.80 [-9.32, -6.28]	:
eng et al., 2020 [107]	264.096	40.194	8	311.46	29.66	8	0.0%	-47.36 [-81.98, -12.75]	
ng et al., 2021 (109) bhan et al., 2019 (110)	1,079.49 1.44	165.322 0.213	8 8	1,184.41 4.952	118.257 0.807	8 8	0.0% 0.9%	-104.92 [-245.77, 35.93] -3.51 [-4.09, -2.93]	
e et al., 2021 [112] e et al., 2022 [113]	339.878 109.818	41.694 32.507	8 8	627.938 162.894	50.096 26.315	8	0.0% 0.0%	-288.06 [-333.22, -242.90] -53.08 [-82.06, -24.09]	
aki et al., 2016 (115)	174.48	12.02	12	220.35	9.95	12	0.0%	-45.87 [-54.70, -37.04]	•
inda et al., 2012 [116] inda et al., 2015 [117]	32.6 0.43	3.797 0.318	6 6	43.57 2.3	2.107 0.073	6 6	0.0% 2.7%	-10.97 [-14.44, -7.50] -1.87 [-2.13, -1.61]	•
ri and Suresh, 2008 (118) Irk et al., 2017 (120)	4.07 4.126	0.39 0.044	6 6	8.57 5.273	0.73 0.073	6 6	0.7% 4.9%	-4.50 [-5.16, -3.84] -1.15 [-1.22, -1.08]	• _
irk et al., 2019 [121]	3.075	0.177	6	3.312	0.182	6	3.3%	-0.24 [-0.44, -0.03]	
itere et al., 2011 [122] et al., 2021 [125]	6.23 202.52	0.588 24.19	6 8	7.07 276.27	0.416 31.65	6 8	0.9% 0.0%	-0.84 [-1.42, -0.26] -73.75 [-101.35, -46.15]	•
athibha et al., 2013 [126] et al., 2017 [127]	25.66 4.747	2.449 0.964	6 10	79.14 7.893	7.569 0.628	6 10	0.0% 0.6%	-53.48 [-59.85, -47.11] -3.15 [-3.86, -2.43]	·
i et al., 2019 (128)	25.09	4.285	8	38.519	6.744	8	0.0%	-13.43 [-18.97, -7.89]	•
abelo et al., 2018 [129] githa et al., 2012 [130]	1.1157 29.45	0.1518 2.83	15 6	1.1921 81.17	0.1515 7.52	13 6	4.4% 0.0%	-0.08 [-0.19, 0.04] -51.72 [-58.15, -45.29]	• 1
ede et al., 2009 (132) muhasaneeto et al., 2009 (136)	8,460.6895 1,133.845	7,092.3772 210.138	8		7,634.4366	8	0.0%	-1306.03 [-8526.93, 5914.86] 50.79 [-125.38, 226.96]	
iravanan, 2007 [137]	2.07	0.19	10	5.75	0.15	10	4.0%	-3.68 [-3.83, -3.53]	
rravanan and Nalini, 2007 [[138] Inthilkumar et al., 2004 [140]	2.07 1.99	0.19 0.12	10 10	5.75 5.82	0.15 0.68	10 10	4.0% 1.5%	-3.68 [-3.83, -3.53] -3.83 [-4.26, -3.40]	
ing et al., 2018 [148]	72.759 148.102	11.353 25.287	10 10	174.144 232.033	18.202 31.883	10 10	0.0%	-101.39 [-114.68, -88.09] -83.93 [-109.15, -58.71]	:
ing et al., 2020 [149] ing et al., 2021 [150]	51.499	4.58	10	147.034	4.214	10	0.0%	-95.53 [-99.39, -91.68]	•
idha et al., 2012 [151] n et al., 2017 [154]	0.0461 94.745	0.001 6.4842	6 10	0.0724 99.57	0.001 9.5456	6 10	5.2% 0.0%	0.03 [0.03, 0.03] -4.82 [-11.98, 2.33]	·
ng et al., 2012 [155] ng et al., 2017 [158]	17.41 164.971	2.274 4.704	8 10	25.215 206.492	2.681 12.946	8 10	0.1%	-7.80 [-10.24, -5.37] -41.52 [-50.06, -32.98]	:
ang and Mu, 2021 [173]	1,325.949	25.316	6	1,547.468	22.152	6	0.0%	-221.52 [-248.44, -194.60]	•
ang et al., 2015 [164] ang et al., 2016 [165]	0.205 24.568	0.026 4.7387	9 12	0.329 55.549	0.073 7.628	9 6	5.0% 0.0%	-0.12 [-0.17, -0.07] -30.98 [-37.65, -24.31]	• •
ang et al., 2018 [166]	95.923	5.017	10	160.401	5.473	10	0.0%	-64.48 [-69.08, -59.88]	:
ang et al., 2020 [167] ang et al., 2020 [168]	190.884 1,195.999	31.7 109.889	10	275.287 1,567	19.372 206.001	8 10	0.0%	-84.40 [-110.15, -58.66] -371.00 [-515.71, -226.29]	•
ang et al., 2020 (169) ang et al., 2022 (171)	192.206 77.43	28.509 7.93	7	263.516 136.16	13.154 11.75	7 10	0.0%	-71.31 [-94.57, -48.05] -58.73 [-67.52, -49.94]	
ang et al., 2022 [172]	46.173	2.448	10	68.463	5.892	10	0.0%	-22.29 [-26.24, -18.34]	:
ei et al., 2013 (174) u et al., 2019 (175)	94.792 149.387	62.518 26.7	15 10	259.965 234.408	106.371 26.794	15 10	0.0% 0.0%	-165.17 [-227.61, -102.73] -85.02 [-108.47, -61.58]	
u et al., 2019 [176] a et al., 2018 [177]	154.2 252.117	10.1 8.541	10 6	245.8 371.85	15.5 36.043	10 6	0.0%	-91.60 [-103.07, -80.13] -119.73 [-149.37, -90.09]	
ao et al., 2017 [179]	558.08	31.18	10	616.12	59.88	10	0.0%	-58.04 [-99.88, -16.20]	
ao et al., 2020 (180) Içinkaya et al., 2007 (182)	542.742 13.8	29.273 2.61	8 8	643.681 13.8	52.778 1.7	8 6	0.0% 0.1%	-100.94 [-142.76, -59.12] 0.00 [-2.26, 2.26]	
ng et al., 2013 [184] ng et al., 2021 [185]	219.308 1.581	47.558 0.351	5 10	298.003 2.484	32.365 0.249	5 10	0.0%	-78.69 [-129.12, -28.27] -0.90 [-1.17, -0.64]	·
ng et al., 2022 [186]	27.325	3.771	10	44.447	3.46	10	0.0%	-17.12 [-20.29, -13.95]	
an et al., 2018 [194] et al., 2022 [193]	213.097 0.008869	21.758 0.001725	10 10	273.888 0.031019	22.278 0.002562	10 10	0.0% 5.2%	-60.79 [-80.09, -41.49] -0.02 [-0.02, -0.02]	`
hid et al., 2018 (196) ang et al., 2011 (198)	1.76 32.7	0.47 1.4	5 10	4.94 37.5	0.537 4.7	5 10	0.8%	-3.18 [-3.81, -2.55] -4.80 [-7.84, -1.76]	←
ang et al., 2020 [201]	70.1	7.589	10	91.6	6.641	10	0.0%	-21.50 [-27.75, -15.25]	•
ang et al., 2021 [203] ao et al., 2008 [204]	175.73 143.9	11.906 25.53	7	152.41 223.78	15.478 29.27	7	0.0% 0.0%	23.32 [8.85, 37.79] -79.88 [-106.79, -52.97]	•
ao et al., 2018 [205] ao et al., 2021 [206]	2.896 11.219	0.201	10 6	4.037	0.313	10	3.0% 0.2%	-1.14 [-1.37, -0.91] -7.49 [-8.83, -6.14]	
ao et al., 2021 (207)	396.64	10.59	10	469.56	66.04	10	0.0%	-72.92 [-114.37, -31.47]	•
eng et al., 2019 (208) ou et al., 2018 (211)	196.43 356.611	11 157.258	10 10	289.56 569.67	5.8 116.893	10 10	0.0% 0.0%	-93.13 [-100.84, -85.42] -213.06 [-334.50, -91.61]	
ou et al., 2021 [212] ou et al., 2022 [213]	5.999 5.549	0.642 0.253	12	10.561 10.628	0.556	12	1.2%	-4.56 [-5.04, -4.08] -5.08 [-5.37, -4.79]	•
	5.549 30.17	3.026	12	10.628 37.77	0.438 9.673	12	2.4%	-5.08 [-5.37, -4.79] -7.60 [-14.62, -0.58]	·
u et al., 2014 [214]									

95% CI -1.83, -1.71; p < 0.00001), with statistically significant heterogeneity (p < 0.00001, $l^2 = 88\%$) (Figure 2).

Figure 2. Evidence of decreased superoxide dismutase (SOD) activity in liver tissue. The forest plot indicates lower SOD activity in the livers of animals with alcoholic fatty liver disease (AFLD) compared with healthy controls (p < 0.05 for each). 95% Cl: confidence interval.

• Catalase (CAT)

The CAT activity in the liver was assessed in 84 studies, which mainly used two different units of measurement (70 used U/mg and 14 used nmol/min/mg). The results showed significant reduction in CAT activity in AFLD groups compared with control groups in the subgroups and the overall analysis (SMD of -3.34; 95% CI -3.85, -2.84; $I^2 = 88\%$) (Figure 3).

5.1 CAT in liver Fregiaie, 2012 [12] ae et al., 2015 [14] alasubramaniyan et al., 2009 [16] isint et al., 2018 [20] isint et al., 2017 [21] thang et al., 2017 [25] then et al., 2017 [25] then et al., 2017 [29] ue tal., 2015 [43] eng et al., 2012 [45] ao et al., 2021 [45] an et al., 2021 [45] as et al., 2021 [55] uang et al., 2009 [55] uang et al., 2009 [59]	413,200 2.35 35,630 91,03 37,31 0.0000182 122.52 0.00000056 1.2.7 12.79 30,743.33 11.922 19,554	42,131.22 0.12 3,540 2.98 0.245 0.0000003 9.956 0.00000007 1.3	6 8 6 5 8	519,300 3.12 52,260 170.51 9.21	32,578.21 0.15 4,740 3.58	6 8 6	1.3% 1.2% 1.2% 0.2%	-2.60 [-4.30, -0.90] -5.36 [-7.71, -3.01] -3.67 [-6.79, -1.55] -22.27 [-33.21, -11.34]	
ae et al., 2015 [14] alsuburnamiyam et al., 2003 [15] aranisrinivasan et al., 2003 [16] isint et al., 2017 [20] isint et al., 2017 [21] thang et al., 2017 [23] then et al., 2017 [29] then et al., 2017 [29] then et al., 2013 [30] the et al., 2015 [43] eng et al., 2019 [45] aso et al., 2011 [40] lasanelin et al., 2018 [53] su et al., 2018 [55] tung et al., 2017 [57]	2:35 35,630 91.03 37.31 0.0000182 122.52 0.00000056 12.7 12.79 30,743.33 11.922	0.12 3,540 2.98 0.245 0.0000003 9.956 0.00000007 1.3	8 6 6 5 8	3.12 52,260 170.51 9.21	0.15 4,740 3.58	8 6	1.2% 1.2%	-5.36 [-7.71, -3.01] -3.67 [-5.79, -1.55]	
aranisrinivasan et al., 2009 [16] ispo et al., 2017 [21] ispo et al., 2017 [25] thang et al., 2017 [26] thang at d., 2017 [29] then et al., 2013 [30] theng and Khong, 2011 [32] tas et al., 2015 [43] eng et al., 2019 [45] ato et al., 2021 [47] tan et al., 2021 [50] lasanein et al., 2018 [53] su et al., 2018 [55] tung et al., 2017 [57]	91.03 37.31 0.0000182 122.52 0.00000056 12.7 12.79 30,743.33 11.922	2.98 0.245 0.0000003 9.956 0.00000007 1.3	6 6 5 8	170.51 9.21	3.58			-3.67 [-5.79, -1.55]	←
isht et al., 2018 [20] ispot et al., 2017 [21] hang et al., 2017 [28] havan et al., 2017 [29] heng and Khong, 2011 [32] ase et al., 2013 [30] u et al., 2015 [43] eng et al., 2019 [45] aso et al., 2019 [45] isasnein et al., 2021 [47] lan et al., 2021 [45] isu et al., 2018 [55] isung et al., 2017 [57]	37.31 0.0000182 122.52 0.00000056 12.7 12.79 30,743.33 11.922	0.245 0.0000003 9.956 0.00000007 1.3	6 5 8	9.21		6	0.206	-22 27 622 21 -11 241	←───
Ispo et al., 2017 [21] ihang et al., 2017 [26] ihang et al., 2013 [26] ihen et al., 2013 [30] ihen et al., 2013 [31] iase et al., 2015 [43] eng et al., 2015 [43] eng et al., 2019 [45] ao et al., 2019 [45] ao et al., 2011 [50] lasanein et al., 2018 [53] su et al., 2018 [55] uang et al., 2017 [57]	0.0000182 122.52 0.00000056 12.7 12.79 30,743.33 11.922	0.0000003 9.956 0.00000007 1.3	5 8						
hang et al., 2017 [26] hang et al., 2017 [26] hen et al., 2013 [30] heng and Khong, 2011 [32] ase et al., 2012 [39] u et al., 2015 [43] eng et al., 2019 [45] aso et al., 2021 [50] lasanelin et al., 2018 [53] su et al., 2018 [55] uang et al., 2017 [57]	122.52 0.00000056 12.7 12.79 30,743.33 11.922	9.956 0.00000007 1.3	8		4.115	6	0.7%	8.90 [4.41, 13.39]	
havan et al., 2017 [29] hen et al., 2013 [30] heng and Khong, 2011 [32] as et al., 2012 [39] u et al., 2015 [43] eng et al., 2019 [45] ao et al., 2021 [47] an et al., 2021 [50] Issu et al., 2018 [53] Issu et al., 2018 [55] uang et al., 2017 [57]	0.00000056 12.7 12.79 30,743.33 11.922	0.00000007		0.000016 115.35	0.0000004 6.901	5	0.9% 1.5%	5.62 [2.22, 9.02]	L
hen et al., 2013 [30] heng and Khong, 2011 [32] as et al., 2015 [43] eng et al., 2019 [45] aco et al., 2019 [45] aco et al., 2021 [50] lasanein et al., 2018 [53] su et al., 2018 [55] tuang et al., 2017 [57]	12.7 12.79 30,743.33 11.922	1.3	6		0.00000007	8 6	1.2%	0.79 [-0.24, 1.82] -3.69 [-5.82, -1.56]	
heng and Khong, 2011 [32] as et al., 2012 [39] u et al., 2015 [43] eng et al., 2019 [45] iao et al., 2021 [47] an et al., 2021 [47] asanein et al., 2018 [55] isu et al., 2018 [55]	12.79 30,743.33 11.922		6	7.8	1.1	6	1.2%	3.76 [1.60, 5.91]	
ras et al., 2012 [39] w et al., 2015 [43] eng et al., 2019 [45] ao et al., 2021 [47] lan et al., 2021 [50] lasanein et al., 2018 [53] isu et al., 2018 [55] luang et al., 2017 [57]	11.922	3.17	12	19.88	3.79	12	1.5%	-1.96 [-2.96, -0.96]	-
eng et al., 2019 [45] (ao et al., 2021 [47] lan et al., 2021 [50] lasanein et al., 2018 [53] su et al., 2018 [55] luang et al., 2017 [57]		4,031.206	18	39,480	590	6	1.4%	-2.37 [-3.55, -1.19]	
aoetal, 2021 [47] Ianetal, 2021 [50] Iasaneinetal, 2018 [53] Isuetal, 2018 [55] Iuangetal, 2017 [57]	19.554	29.702	6	31.891	78.37	6	1.4%	-0.31 [-1.45, 0.83]	+
lan et al., 2021 [50] lasanein et al., 2018 [53] Isu et al., 2018 [55] luang et al., 2017 [57]		4.452	8	36.505	6.624	8	1.4%	-2.84 [-4.34, -1.34]	
lasanein et al., 2018 [53] Isu et al., 2018 [55] Iuang et al., 2017 [57]	0.103	0.022	9	0.138	0.006	9	1.4%	-2.07 [-3.27, -0.87]	
lsu et al., 2018 [55] Iuang et al., 2017 [57]	11.826	2.689	10 7	18.918	1.712	10 7	1.4%	-3.01 [-4.38, -1.65]	
luang et al., 2017 [57]	4.455 28.5	0.178	10	5.762 36.2	0.317	10	1.2% 1.5%	-4.76 [-7.09, -2.43] -1.19 [-2.16, -0.22]	
	57.738	4.086	12	70.585	3.241	12	1.4%	-3.36 [-4.68, -2.05]	
	51,200	4,900	8	79,100	7,600	8	1.3%	-4.13 [-6.04, -2.21]	
in et al., 2010 (62)	82.75	29.916	15	88.03	26.372	15	1.5%	-0.18 [-0.90, 0.54]	+
ose et al., 2018 (63)	2.813	0.137	8	6.344	0.358	8	0.6%	-12.32 [-17.33, -7.30]	
anchana and Jayapriya, 2013 [65]	48.92	3.78	6	78.17	5.41	6	1.0%	-5.79 [-8.83, -2.74]	
ang et al., 2009 [66]	7.27	1.437	4	11.159	1.806	4	1.2%	-2.07 [-4.06, -0.08]	
aviarasan et al., 2008 [68]	44,290	4,030	6	74,510	6,180	6	1.0%	-5.35 [-8.19, -2.50]	
im et al., 2016 [71] pi et al., 2018 [72]	90.93	6.4	5	121.41	2.07	5	0.9%	-5.79 [-9.27, -2.30]	
ai et al., 2019 (73) ee et al., 2015 (74)	0.39 142.6	0.06 14.2	8	0.57 244.8	0.07	8	1.4% 1.1%	-2.61 [-4.04, -1.18] -6.41 [-9.15, -3.67]	
ee et al., 2016 (75)	6.79	14.2	10	244.0	1.771	10	1.4%	-2.28 [-3.46, -1.10]	_
ee et al., 2021 [79]	33.025	28.369	8	169.845	66.283	8	1.4%	-2.54 [-3.95, -1.13]	
ian et al., 2010 [89]	22.025	1.594	10	39.123	2.917	10	1.1%	-6.97 [-9.53, -4.40]	
ietal., 2017 [83]	13.275	0.443	8	15.689	0.547	8	1.2%	-4.59 [-6.66, -2.51]	
i et al., 2021 [85]	7.847	2.047	9	8.028	2.064	9	1.5%	-0.08 [-1.01, 0.84]	+
i et al., 2021 [86]	6.881	0.907	9	6.816	1.633	9	1.5%	0.05 [-0.88, 0.97]	†
i et al., 2021 [88]	6.987	0.341	9	6.863	0.477	9	1.5%	0.28 [-0.65, 1.21]	Ť
in et al., 2021 [91]	0.665	0.119	8	2.455	0.385	8	1.1%	-5.94 [-8.50, -3.37]	
iu et al., 2014 (92) iu et al., 2015 (93)	4.599 39	1.044 9.625	7	6.991 75.25	1.313 7.875	7	1.4% 1.3%	-1.89 [-3.22, -0.55] -3.90 [-5.74, -2.06]	
u et al., 2014 [97]	238.15	30.68	12	300.51	42.02	12	1.5%	-1.64 [-2.58, -0.69]	-
u et al., 2015 [98]	5.66	0.59	10	9.2	1.01	10	1.3%	-4.10 [-5.77, -2.43]	
la et al., 2007 (100)	5.98	0.86	6	7.28	0.28	6	1.4%	-1.88 [-3.33, -0.42]	
lallikarjuna et al., 2008 (104)	287	51	6	384	23	6	1.3%	-2.26 [-3.84, -0.68]	
lehanna et al., 2021 (106)	0.281	0.0952	16	0.947	0.1	8	1.2%	-6.65 [-8.87, -4.42]	
leng et al., 2020 [107]	55.003	5.706	8	72.323	2.359	8	1.3%	-3.75 [-5.54, -1.96]	
lohan et al., 2019 [110]	2.581	0.636	8	6.377	0.892	8	1.2%	-4.63 [-6.73, -2.54]	
anda et al., 2012 [116]	1.5	0.686	6	5.13	2.572	6	1.4%	-1.78 [-3.21, -0.35]	
anda et al., 2015 (117) ari and Suresh, 2008 (118)	15.03 54.41	3.748 5.47	6 6	29.12 76.88	6.001 6.56	6 6	1.3% 1.2%	-2.60 [-4.30, -0.90] -3.43 [-5.46, -1.41]	
an and Suresh, 2006 [116] ark et al., 2017 [120]	54.41 8.805	0.982	6	17.895	0.55	6	0.5%	-10.97 [-16.44, -5.50]	
ark et al., 2019 [121]	11.429	1.593	6	14.338	1.969	6	1.4%	-1.50 [-2.85, -0.15]	_
atere et al., 2011 [122]	98.01	10.9	6	116.7	7.471	6	1.4%	-1.85 [-3.29, -0.40]	
rathibha et al., 2013 (126)	41.76	3.993	6	63.54	6.075	6	1.2%	-3.91 [-6.13, -1.69]	
abelo et al., 2018 [129]	74.5127	10.9176	15	79.5675	24.7796	13	1.5%	-0.26 [-1.01, 0.48]	+
ejitha et al., 2012 [130]	45.83	3.69	6	63.68	6.11	6	1.3%	-3.26 [-5.22, -1.31]	
toede et al., 2009 [132]	10.697	1.529	4	8.043	1.93	4	1.3%	1.33 [-0.33, 2.98]	-
aravanan, 2007 [137]	52.34	2.67	10	75.31	1.72	10	0.9%	-9.80 [-13.29, -6.30]	
aravanan and Nalini, 2007 [[138]	52.34	2.67	10	75.31	1.72	10	0.9%	-9.80 [-13.29, -6.30]	
athiavelu et al., 2009 (139) enthilkumar et al., 2004 (140)	49,900 49.12	3,520 3.68	8 10	76,780 76,18	5,410 3.71	8 10	1.1% 1.1%	-5.57 [-8.00, -3.14] -7.01 [-9.59, -4.43]	
henbagam and Nalini, 2010 [143]	49,816.62	3,549.17	6	77,601.13	5,752.382	6	1.0%	-5.37 [-8.22, -2.51]	
ong et al., 2018 [148]	230.502	13.982	10	610.688	33.322	10	0.6%	-14.25 [-19.26, -9.24]	<u> </u>
ong et al., 2021 [150]	63.767	2.527	10	176.84	6.643	10		-21.55 [-29.05, -14.04]	←
ahir et al., 2013 (153)	46.7	5.879	6	73.8	10.533	6	1.3%	-2.93 [-4.76, -1.11]	
ang et al., 2014 [156]	357.341	26.041	8	862.272	28.524	8		-17.48 [-24.52, -10.44]	
vang et al., 2018 [166]	71.614	6.872	10	219.033	6.872	10		-20.55 [-27.70, -13.39]	•
/ang et al., 2020 [167] /oi.ot.ol	36.528	4.622	8	54.981	5.639	15	1.3%	-3.38 [-5.05, -1.72]	
/ei et al., 2013 [174] /u et al., 2019 [176]	130.262 21.4	96.701 1.8	15 10	289.281 34	128.044 3	15 10	1.5% 1.3%	-1.36 [-2.17, -0.56] -4.88 [-6.78, -2.98]	
iao et al., 2017 (179)	16.77	3.24	10	34 23.54	2.14	10	1.3%	-2.36 [-3.56, -1.16]	
iao et al., 2020 (180)	15.582	2.421	8	25.632	2.832	8	1.3%	-3.61 [-5.35, -1.87]	
an and Yin, 2007 [183]	11.7	1.4	15	20.6	2:002	15	1.4%	-5.02 [-6.55, -3.48]	-
ang et al., 2022 [186]	1.158	0.071	10	1.374	0.118	10	1.4%	-2.12 [-3.27, -0.98]	
ao et al., 2007 [187]	27.943	3.157	8	41.531	4.974	8	1.3%	-3.08 [-4.66, -1.51]	
ou et al., 2010 [190]	4.35	0.79	8	6.96	0.65	8	1.3%	-3.41 [-5.09, -1.73]	
ou et al., 2020 [191]	86.612	41.578	10	118.68	12.85	10	1.5%	-1.00 [-1.94, -0.06]	7
ahid et al., 2018 [196]	8,640	1,296.919	5	17,480	1,118.034	5	0.8%	-6.59 [-10.51, -2.68]	
hang et al., 2020 [201] hao et al., 2008 [204]	19.7 7.14	1.581 0.68	10 8	25 8.77	1.265 0.89	10 8	1.4% 1.4%	-3.55 [-5.05, -2.04] -1.95 [-3.20, -0.70]	<u> </u>
nao et al., 2008 (204) hao et al., 2018 (205)	7.14 313.836	15.562	8 10	8.77 356.17	13.082	10	1.4%	-2.82 [-4.13, -1.51]	
hao et al., 2018 (205) hao et al., 2021 (206)	8.735	0.904	6	18.483	1.48	6	0.8%	-7.34 [-11.09, -3.58]	
hao et al., 2021 (207)	32.17	3	10	39.87	3.26	10	1.4%	-2.35 [-3.55, -1.16]	
heng et al., 2019 [208]	50.72	6.9	10	60.13	2.8	10	1.4%	-1.71 [-2.77, -0.65]	-
heng et al., 2022 [209]	25.384	5.487	8	44.359	13.066	8	1.4%	-1.79 [-3.00, -0.58]	
hou et al., 2021 [212]	5.563	0.259	12	10.8	0.394	12	0.6%	-15.17 [-19.93, -10.41]	<u> </u>
hou et al., 2022 [213]	5.544	0.283	12	10.738	0.45	12	0.7%	-13.34 [-17.55, -9.14]	i
ubtotal (95% CI)			717			695	100.0%	-3.34 [-3.85, -2.84]	•
leterogeneity: Tau ² = 4.27; Chi ² = 679		< 0.00001); I²	= 88%						
est for overall effect: Z = 13.02 (P < 0	.00001)								
otal (95% CI)			717			695	100.0%	-3.34 [-3.85, -2.84]	•
	0 0 4f - 00 /D	~ 0.00001\· IR							
leterogeneity: Tau ² = 4.27; Chi ² = 679			- 0070						-20 -10 0 10 20

Figure 3. Forest plot showing the decrease in catalase (CAT) activity in liver tissue from animals with alcoholic fatty liver disease (AFLD) compared with healthy controls (p < 0.05 for each). The 95% confidence interval is also shown.

• Glutathione Peroxidase (GPx)

GPx activity in the liver of animals was assessed in 88 articles, which used two units of measurement, U/mg (n = 72) and nmol/min/mg (n = 16). The studies showed high heterogeneity ($I^2 = 88\%$, p < 0.00001). When statistical analysis was performed, a reduction in GPx activity was observed in AFLD groups for both subgroups and the overall analysis (SMD: -3.26, 95% CI -3.74, -2.78, p < 0.00001) (Figure 4).

Study or Subgroup	Mean	AFLD SD	Total	C Mean	ontrol SD	Total	Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
.6.1 GPx in liver ae et al., 2015 [14]	29.18	1.34	8	34.52	1.15	8	1.2%	-4.04 [-5.93, -2.16]	
Rae et al., 2013 [14] Rharrhan et al., 2011 [19]	54,916	7,250	8	49,646	4,680	8	1.3%	0.82 [-0.22, 1.85]	
ao et al., 2015 [24]	0.381	0.058	4	0.692	0.082	4	0.9%	-3.81 [-6.77, -0.84]	
chang et al., 2017 [26]	107.35	7.014	8	80.03	4.921	8	1.2%	4.26 [2.30, 6.23]	L
Chen et al., 2013 [30] Cheng and Khong, 2011 [32]	0.29 1.46	0.06 0.58	6 12	0.27 4.03	0.04 0.87	6 12	1.3% 1.3%	0.36 [-0.78, 1.51] -3.36 [-4.67, -2.05]	— T
cheng and Knong, 2011 [32] Chiu et al., 2011 [33]	0.0134	0.0012	6	4.03	0.0008	6	1.3%	-3.30 [-4.07, -2.05] 1.72 [0.31, 3.13]	
as et al., 2012 [39]	56.22	8.9452	18	82.17	1.25	6	1.3%	-3.18 [-4.53, -1.83]	
)eveli et al., 2014 [41]	1,339.7	221.8	8	1,355	273.5	8	1.4%	-0.06 [-1.04, 0.92]	+
)u et al., 2015 [43]	2.954	7.489	6	4.992	11.982	6	1.3%	-0.19 [-1.32, 0.95]	+
eng et al., 2019 [45]	937.846	236.972	8 9	2,385.325	326.687	8 9	1.1%	-4.80 [-6.95, -2.65]	
∋aoetal., 2021 [47] isuetal., 2018 [55]	352.728 18.2	67.197 4.8	10	459.777 32	57.234 4.4	10	1.3% 1.3%	-1.63 [-2.74, -0.53] -2.87 [-4.19, -1.55]	
luang et al., 2017 [57]	226.807	20.648	12	277.635	16.498	12	1.3%	-2.63 [-3.77, -1.49]	
lu et al., 2021 [56]	308.151	56.594	6	387.284	65.449	6	1.3%	-1.19 [-2.47, 0.08]	
iang et al., 2019 [61]	342.132	98.77	10	813.954	90.763	10	1.2%	-4.76 [-6.63, -2.90]	
in et al., 2010 (62)	14.1867	7.7719	15	17.97 11.954	5.284	15	1.4%	-0.55 [-1.29, 0.18]	1
ose et al., 2018 [63] (anchana and Jayapriya, 2013 [65]	6.463 5.07	0.342	8 6	9.54	0.648 0.97	8 6	0.7% 0.9%	-10.02 [-14.14, -5.90] -5.50 [-8.41, -2.59]	·
(ang et al., 2009 (66)	17.696	3.108	4	15.62	2.28	4	1.3%	0.66 [-0.80, 2.12]	
aietal., 2019 [73]	591.25	56.18	8	776.08	56.01	8	1.2%	-3.12 [-4.70, -1.53]	
.ee et al., 2016 [75]	6.6	3.921	10	7.7	2.024	10	1.4%	-0.34 [-1.22, 0.55]	-
.ee et al., 2021 [79]	0.003	0.001	8	0.028	0.007	8	1.1%	-4.73 [-6.85, -2.60]	
ian et al., 2010 [89]	425.045	33.702		1,100.379	73.649	10	0.7%	-11.29 [-15.30, -7.29]	
ietal., 2017 [83] ietal., 2019 [84]	109.889 40.3245	5.318 6.5313	8 16	150.373 62.0065	5.785 6.2685	8 16	0.9%	-6.89 [-9.81, -3.97]	
i et al., 2018 [84] i et al., 2021 [85]	40.3245	6.5313 38.588	16	265.805	6.2685 33.681	16	1.3%	-3.30 [-4.41, -2.19] -2.17 [-3.40, -0.95]	
i et al., 2021 [86]	229.509	59.705	9	308.646	19.496	9	1.3%	-1.70 [-2.81, -0.58]	
.i et al., 2021 [88]	227.106	16.848	9	313.09	18.237	9	1.2%	-4.66 [-6.62, -2.71]	
in et al., 2017 [90]	17.723	2.856	8	21.886	1.907	8	1.3%	-1.62 [-2.80, -0.45]	
in et al., 2021 (91)	0.916	0.053	8	1.003	0.104	8	1.3%	-1.00 [-2.05, 0.06]	
u et al., 2014 [97] (a et al., 2007 [100]	545.9	37.4	12	623.5	35.8	12	1.3%	-2.05 [-3.07, -1.03] -4.04 [-6.32, -1.77]	
fa et al., 2007 (100) fallikarjuna et al., 2008 (104)	37.8 513	1.21 32	6 6	43.1 814	1.21 41	6 6	1.1% 0.7%	-4.04 [-6.32, -1.77] -7.56 [-11.41, -3.70]	
fohan et al., 2019 [110]	5.507	0.806	8	12.004	1.612	8	1.1%	-4.82 [-6.98, -2.66]	
lie et al., 2021 [112]	25.135	5.206	8	46.27	8.005	8	1.3%	-2.96 [-4.49, -1.42]	
lie et al., 2022 [113]	81.576	20.246	8	100.948	15.908	8	1.3%	-1.01 [-2.06, 0.05]	
)saki et al., 2016 [115]	33.09	3.11	12	43.25	3.69	12	1.3%	-2.87 [-4.07, -1.68]	
anda et al., 2012 [116]	1	0.661	6	2.5	0.784	6	1.3%	-1.91 [-3.38, -0.44]	
anda et al., 2015 [117]	3.55 5.22	0.808	6 6	9.35 9.35	1.739 0.85	6 6	1.1% 0.9%	-3.95 [-6.18, -1.71] -5.63 [-8.61, -2.66]	
°ari and Suresh, 2008 [118] °ark et al., 2017 [120]	0.758	0.072	6	1.782	0.331	6	1.1%	-3.95 [-6.18, -1.71]	
Park et al., 2019 [121]	0.861	0.108	6	1.428	0.239	6	1.2%	-2.82 [-4.61, -1.04]	
ri et al., 2021 [125]	785.16	63.85	8	1,107.89	122.63	8	1.2%	-3.12 [-4.71, -1.54]	
rathibha et al., 2013 [126]	5,010	465.403	6	13,220	1,249.24	6	0.7%	-8.04 [-12.12, -3.96]	
i et al., 2017 [127]	423.449	23.051	10	612.199	46.65	10	1.2%	-4.91 [-6.83, -3.00]	
Rabelo et al., 2018 [129] Rejitha et al., 2012 [130]	0.0477 6.04	0.0192 0.58	15 6	0.0645 13.37	0.0142	13 6	1.4% 0.8%	-0.96 [-1.75, -0.17] -6.81 [-10.32, -3.30]	
Roede et al., 2009 [132]	32,924.74	7,830.353	4		1,633.264	4	1.3%	-0.88 [-2.39, 0.63]	
Rong et al., 2012 [133]	28.663	6.41	12	37.576	10.888	12	1.4%	-0.96 [-1.82, -0.11]	
aravanan, 2007 (137)	6	0.48	10	13.22	1.06	10	0.9%	-8.40 [-11.44, -5.37]	——
aravanan and Nalini, 2007 [[138]	6	0.48	10	13.22	1.06	10	0.9%	-8.40 [-11.44, -5.37]	——
Shenbagam and Nalini, 2010 [143]	6,885.547	487.121			1,040.477	6	0.6%	-9.48 [-14.25, -4.72]	
Smathers et al., 2013 [145] Song et al., 2018 [148]	17.983 68.299	2.036 7.024	6 10	26.658 134.015	3.184 11.936	6 10	1.2% 1.1%	-3.00 [-4.85, -1.15] -6.43 [-8.82, -4.04]	
long et al., 2010 [140]	21.561	2.095	10	81.293	2.613	10		-24.16 [-32.56, -15.76]	←
ahir et al., 2013 (153)	236.7	60.012	6	447.6	79.29	6	1.2%	-2.77 [-4.53, -1.01]	
ang et al., 2012 [155]	40.127	6.32	8	54.878	8.599	8	1.3%	-1.85 [-3.07, -0.62]	
ang et al., 2014 [156]	13.388	0.714	8	25.846	1.05	8	0.5%	-13.12 [-18.44, -7.79]	
Vang and Mu, 2021 (173) Vang at al., 2016 (185)	520.452	9.02	6	673.752	18.035	6	0.6%	-9.92 [-14.90, -4.95]	
Vang et al., 2016 (165) Vang et al., 2018 (166)	0.0065 70.576	0.0015 3.781	12 10	0.0167 129.104	0.0007 5.092	6 10	0.9% 0.6%	-7.45 [-10.37, -4.53] -12.50 [-16.91, -8.09]	
Vang et al., 2020 [167]	0.142	0.042	8	0.263	0.032	8	1.2%	-2.99 [-4.54, -1.45]	
Vang et al., 2020 [168]	466.025	128.72	10	718.331	138.989	10	1.3%	-1.80 [-2.88, -0.73]	
Vei et al., 2013 (174)	185.794	96.532	15	402.755	169.058	15	1.4%	-1.53 [-2.36, -0.71]	
Vu et al., 2019 [176]	143.8	10.1	10	269.9	10.1	10	0.7%	-11.96 [-16.18, -7.73]	
Sao et al., 2017 [179]	413.46	54.74	10	518.21	67.17	10	1.3%	-1.64 [-2.68, -0.59]	
liao et al., 2020 (180) 'alcinkava et al., 2007 (182)	435.65 584.2	42.184 62.3	8	564.886 647.2	36.311 53.9	8 6	1.2% 1.3%	-3.10 [-4.68, -1.52] -1.00 [-2.15, 0.14]	
'alçinkaya et al., 2007 (182) 'an and Yin, 2007 (183)	584.2	62.3 1.6	8 15	647.2 31.5	53.9	ь 15	1.3%	-1.00 [-2.15, 0.14] -5.31 [-6.92, -3.70]	· [
ang et al., 2022 [186]	16.288	3.906	10	49.861	3.989	10	0.9%	-8.15 [-11.10, -5.20]	<u> </u>
'ao et al., 2007 (187)	25.743	2.68	8	37.894	3.446	8	1.2%	-3.72 [-5.50, -1.94]	
'ou et al., 2010 (190)	3.38	0.21	8	4.1	0.02	8	1.1%	-4.56 [-6.63, -2.50]	
ou et al., 2020 [191]	2,418.58	916.133		2,681.531	365.7	10	1.4%	-0.36 [-1.25, 0.52]	+
'u et al., 2022 [193] 'bang et al., 2011 [199]	0.0242	0.0053 56.2	10 10	0.05 103.3	0.0046 40.2	10 10	1.2% 1.4%	-4.98 [-6.91, -3.05] 0.48 [-0.41, 1.38]	L
'hang et al., 2011 (198) 'hang et al., 2015 (200)	128 213.109	56.2 26.792	10	103.3 305.162	40.2 21.754	10	1.4%	-3.02 [-6.34, 0.31]	
hang et al., 2020 [201]	83.4	6.641	10	101.6	4.427	10	1.3%	-3.09 [-4.47, -1.71]	
Thang et al., 2021 [203]	43.64	2.566	7	46.07	3.439	7	1.3%	-0.75 [-1.85, 0.35]	-+
(hao et al., 2008 [204]	1.62	0.09	8	2.98	0.52	8	1.2%	-3.45 [-5.13, -1.76]	
hao et al., 2018 [205]	423.025	19.122	10	871.002	47.013	10	0.7%	-11.96 [-16.18, -7.73]	
Thao et al., 2021 [206]	120.903 401.91	10.172	6	144.069	12.428	6	1.3%	-1.88 [-3.34, -0.43]	
'hao et al., 2021 (207) 'heng et al., 2019 (208)	401.91 392.32	68.97 28	10 10	547.4 566.09	83.18 34	10 10	1.3% 1.1%	-1.82 [-2.90, -0.74] -5.34 [-7.39, -3.30]	
heng et al., 2022 [209]	392.32 717.293	28 70.304	8	887.082	34 95.574	8	1.1%	-1.91 [-3.16, -0.67]	
hou et al., 2021 [212]	56.9	3.816	12	82.51	2.656	12	1.0%	-7.52 [-9.98, -5.06]	<u> </u>
'hou et al., 2022 [213]	57.19	3.349	12	82.056	3.225	12	1.1%	-7.30 [-9.70, -4.91]	<u> </u>
hu et al., 2014 [214]	123.71	6.138	8	104.87	11.936	8	1.3%	1.88 [0.64, 3.11]	.
ubtotal (95% CI)			772			750	100.0%	-3.26 [-3.74, -2.78]	•
leterogeneity: Tau ² = 4.14; Chi ² = 75		P < 0.00001	l); l² = 8	8%					
'est for overall effect: Z = 13.37 (P < 0									
otal (95% CI)			772			750	100.0%	-3.26 [-3.74, -2.78]	•
								-	
leterogeneity: Tau² = 4.14; Chi² = 75 est for overall effect: Z = 13.37 (P < 0		P < 0.00001	l); l² = 8	8%					-10 -5 0 5 10

Figure 4. Forest plot showing glutathione peroxidase (GPx) activity in liver tissue. There is evidence of decreased GPx activity in the liver tissue of animals with alcoholic fatty liver disease (AFLD) compared with healthy controls (p < 0.05). 95% Cl: confidence interval.

• Glutathione Reductase (GR)

A total of 34 eligible studies quantified GR activity (22 measured in U/mg and 12 in μ mol/mg/min). High heterogeneity was evident among the studies, with I^2 values of 87%. The results also showed a reduction in GR activity in AFLD groups compared with control groups (SMD: -2.87, 95% Cl -3.58, -2.16) (Figure 5).

Study or Subgroup Near SD Total Mean SD Total Weight N. Random, 95% C1 18.1 GR In New 18.1 GR In New 000218 0.00224 0.0015 8 3.2% -3.021 (-58, 1.47)			AFLD		c	ontrol			Std. Mean Difference	Std. Mean Difference
Base stal, 2015 [14] 0.00218 0.00024 8 0.00224 0.00015 8 0.32% -0.0254.08, -1.47]	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Bharmar etal., 2011 [19] 63.136 4.57 8 00.35 0.366 8 2.5% 00.83 [.65] Chue tal., 2011 [13] 0.00076 0.00076 6 0.0115 6 3.0% -2.87 [.481, -1.13] Das etal., 2012 [149] 10.278 0.00477 16 0.0477 0.0647 0.0006 6 3.3% -3.83 [.553, -2.33] Feng etal., 2019 [145] 11.128 2.327 8 2.5742 4.257 8 3.1% -3.65 [.52, -1.49] Jayaraman et al., 2009 [59] 0.0122 0.00118 8 0.0253 0.0024 6 2.4% -6.56 [.93, 4.3, -376] Lai etal., 2011 [73] 5.531 5.32 8 6.411 3.65 6 1.6% -6.24 [.42, -3.76] Lae etal., 2016 [74] 1.33 0.025 0.027 0.058 0.387 0.058 2.36 [.449, -1.61] Lue etal., 2017 [73] 5.511 5.32 8 6.411 0.36% -3.26 [.449, -1.61] -4.61 Lue etal., 2016 [75] 10 1.468 10.27 2.92 8 3.4% -1.38 [.251, -0.26] -4.61	1.8.1 GR in liver									
Chen et al., 2013 [30] 0.0168 0.0031 6 0.01169 0.0015 6 3.0% - 2.37 [4.61, -1.13]	Bae et al., 2015 [14]	0.00218	0.00024	8	0.00282	0.00015	8	3.2%	-3.02 [-4.58, -1.47]	
Chen et al., 2013 [30] 0.0166 0.0031 6 0.01169 0.0015 6 3.4% 1.37 [0.05, 2.68] Chu et al., 2012 [39] 0.00278 0.0007 18 0.0056 6 0.01169 0.0015 6 3.3% -3.38 5.53, 2.33 Feng et al., 2012 [39] 0.0278 0.0007 18 0.0547 0.0009 6 3.3% -3.35 [5.53, 2.43] Feng et al., 2019 [45] 12.128 2.327 8 2.5742 4.275 8 3.1% -3.375 [5.54, 2.148] Galligan et al., 2019 [45] 0.0233 0.00034 6 0.00402 0.00052 6 2.9% -3.55 [5.62, -1.48] Jayarama et al., 2008 [08] 0.0132 0.00118 6 0.0555 0.0024 8 2.4% -6.55 [9.34, 3.76] Kaviarasan et al., 2008 [08] 0.0133 0.018 6 0.0555 0.0024 8 2.4% -6.55 [9.34, 3.76] La et al., 2015 [74] 1.33 0.02 8 1.53 0.056 8 2.9% -4.77 [7.18, 2.75] Le et al., 2015 [74] 1.33 0.02 8 1.53 0.056 8 2.2% -4.677 [7.18, 2.75] Le et al., 2015 [75] 10 1.486 10 12.96 4.30 110 3.8% -0.088 [1.81, 0.05] Li et al., 2017 [73] 0.0195 0.0059 8 0.0397 0.0058 8 3.2% -3.261 [4.8] Lu et al., 2015 [73] 7.049 0.856 8 10.27 2.992 8 3.5% -1.381 [4.57], 4.125 [] Lu et al., 2015 [93] 7.049 0.856 8 10.27 2.992 8 3.5% -1.381 [4.525], 0.26] Lu et al., 2015 [93] 7.049 0.856 8 10.027 1.29 (3.8% -2.27] [7.44, 0.86] Lu et al., 2015 [93] 7.049 0.856 8 10.027 1.29 (3.8% -2.27] [7.44, 0.86] Lu et al., 2015 [93] 7.049 0.856 8 10.027 2.992 8 3.5% -1.381 [2.53], 0.26] Hu et al., 2015 [93] 7.049 0.856 8 10.027 1.29 (3.8% -3.915 [2.3], 2.23] Hu et al., 2015 [93] 7.049 0.856 8 10.027 1.29 (3.8% -2.27] [7.46, 0.86] Hu et al., 2007 [100] 5.46.6 4.56 6 6.474 37.7 6 3.2% -2.27 [7.34, 0.86] Hu et al., 2007 [100] 5.46.6 4.56 6 6.474 37.7 6 3.2% -3.29 [3.9, 0.93] Hu et al., 2001 [104] 0.30 0.22 6 0.0024 10.00574 11 0.0278 3.0056 8 1.3% -1.022 [1.53], 5.11] Primbiba et al., 2001 [104] 0.515 151.599 6 7.98.32 8.681 6 2.7% Hallikarjuna et al., 2004 [140] 0.01012 0.00033 10 0.0228 10.0026 10 2.5% Hallikarjuna et al., 2004 [140] 0.01012 0.00033 10 0.02248 0.0026 10 2.5% Primbiba et al., 2004 [140] 0.00114 0.00077 8 0.238 0.0016 6 3.1.4% Primotiba et al.,	Bharrhan et al., 2011 [19]	63.136	4.57	8	60.356	3.68	8	3.5%	0.63 [-0.38, 1.65]	+
$ \begin{array}{c} \text{Dase tal}_{2012}(5) \left[1 \\ \text{Ferg et al}_{2012}(5) \left[1 \\ 12128 \\ \text{Calligan et al}_{2012}(146) \\ \text{Ouessal al}_{2012}(146) \\ Oues$	Chen et al., 2013 [30]	0.0168	0.0031	6	0.0127	0.0024	6	3.4%		<u> </u>
Feng etal., 2019 [46] 12.129 2.237 8 2.472 4.267 8 3.1% -3.75 [-5.64, 1.66] Galigan etal., 2012 [46] 0.0857 0.1485 18 0.9167 0.0842 18 3.75 [-5.54, 1.46] Jayaraman et al., 2008 [59] 0.0122 0.00118 6 0.0263 0.0022 6 2.9% -3.55 [-5.62, 1.43] Kavarasan et al., 2008 [59] 0.0122 0.00118 6 0.0253 0.0024 8 2.4% -6.55 [+3.34, -3.76] Lai etal., 2016 [75] 10 1.486 10 12.96 4.301 10 3.8% -3.26 [+4.89, 1.63] Lue etal., 2016 [75] 10 1.486 10 12.96 4.301 10 3.8% -3.26 [+4.89, 1.63] Lue tal., 2014 [92] 6.464 0.951 7 8.999 1.172 7 3.1% -3.30 [+4.70, 1.33] Lue tal., 2014 [97] 0.06569 0.0074 12 3.5% -1.93 [-2.31, 0.68] -1.93 [-2.31, 0.68] Lue tal., 2015 [98] 4.49 0.74 10 6.21 1.1 10 3.2% -2.21 [-3.79, 0.66]	Chiu et al., 2011 [33]	0.00876	0.00058	6	0.01169	0.00115	6	3.0%	-2.97 [-4.81, -1.13]	
Galigan etal., 2012 [46] 0.8657 0.1485 18 0.9167 0.0842 18 3.7% 0.56 [0.11, 1.23] Jayaraman etal., 2013 [50] 0.0122 0.00118 6 0.0402 0.00052 6 2.9% -3.55 [5.62, 1.48] Jayaraman etal., 2008 [68] 0.183 0.018 6 0.355 0.02 6 1.6% 8.34 [1.57, 4.12] La etal., 2015 [74] 1.33 0.02 8 1.53 0.05 8 2.4% -6.55 [+3.4, -3.76] Le etal., 2015 [74] 1.33 0.02 8 1.53 0.05 8 2.4% -6.58 [+3.4, -3.76] Le etal., 2015 [74] 1.33 0.02 8 1.53 0.05 8 2.4% -6.58 [+3.4, -3.76] Le etal., 2015 [74] 1.33 0.02 8 1.53 0.05 8 2.2% -4.97 [7.18, -2.75] Li etal., 2017 [73] 0.0195 0.0059 8 0.0397 0.0058 8 3.2% -3.26 [+4.89, 1.63] Li etal., 2017 [83] 0.0195 0.0059 8 0.0397 0.0058 8 3.2% -3.26 [+4.89, 1.63] Li etal., 2017 [83] 0.0195 0.0059 8 0.027 2.992 8 3.5% -1.38 [+2.51, -0.28] Li etal., 2015 [93] 7.049 0.858 8 10.27 2.992 8 3.5% -1.38 [+2.51, -0.28] Li u etal., 2014 [92] 0.0569 0.0044 12 0.0761 0.00574 12 3.5% -1.39 [+2.91, -0.83] Li etal., 2015 [93] 7.049 0.858 8 10.27 2.992 8 3.5% -1.38 [+2.51, -0.28] Li u etal., 2014 [97] 0.0569 0.0044 12 0.0761 0.00574 12 3.5% -1.39 [+2.91, -0.83] Li u etal., 2014 [97] 0.0569 0.0044 12 0.0761 0.0074 12 3.5% -2.22 [-3.77, -0.66] Haltarjuna etal., 2008 [104] 0.3 0.02 6 0.671 0.048 6 1.4% -3.19 [+2.91, -0.83] Li etal., 2015 [198] 4.49 0.74 10 8.21 1.1 10 3.2% -3.08 [+5.81, -2.79, -0.66] Maltarjuna etal., 2008 [104] 0.3 0.02 6 0.671 0.048 6 1.4% -3.11 [+0.0, 4.63] Hand etal., 2012 [116] 26.615 15.599 6 7.83 2.2 86.81 6 2.2% -3.68 [+5.21, -5.8] Maltarjuna etal., 2008 [104] 0.3 0.02 6 0.271 0.042 6 1.3% -0.21 [+0.6, 0.53] Hand etal., 2012 [117] 231.1 89.014 6 529.4 74.66 6 2.2% -3.69 [+5.2, 1.56] Haltarjuna etal., 2003 [132] 0.244 0.0325 6 0.2262 10 0.227 1.99 6 1.4% -4.05 [+5.31, 1.77] Panda etal., 2012 [116] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [+0.6, 0.53] Heterogenety. 1.301 (1.50 0.48 6 0.20027 1.99 6 1.4% -3.69 [+6.2, 2.85] Haltarjuna etal., 2009 [132] 0.2164 0.00243 0.0016 6 3.4% -1.37 [+2.86, 0.05] Haltarjuna etal., 2012 [151] 0.00168 0.001 6 0.00334 0.001 6 3.4% -1.37 [+2.86,	Das et al., 2012 [39]	0.0278	0.0077	18	0.0547	0.0009	6	3.3%	-3.83 [-5.33, -2.33]	
$\begin{aligned} a a a a a a a a a a a a a a a a a a a$	Feng et al., 2019 [45]	12.128	2.327	8	25.742	4.257	8	3.1%	-3.75 [-5.54, -1.96]	
$Jayaraman et al., 2009 [f69] 0.0122 0.00118 & 8 0.0253 0.0024 & 8 2.4% - 6.65 [e3.4], 376] \\ Kaviarasan et al., 2008 [69] 0.183 0.018 & 6 0.355 0.02 & 6 1.6% - 6.65 [e3.4], 376] \\ La et al., 2016 [73] 1.532 & 6 4.39 1.355 & 8 3.4 (h - 1.87) - 1.01 - 0.63 (h - 1.10) - 0.65 (h - 1.10) - 0.63 (h - 1.10) - 0.63 (h - 1.10) - 0.63 (h - 1.10) - 0.65 (h - 1.10) - 0.63 (h - 1.10) - 0.65 (h - 1.10) - 0.6 (h - 1.10) - 0.05 (h - 1.10) - 0.25 (h - 1.10) - 0.25 (h - 1.10) - 0.05 (h - 1.10) - 0.00 (h - 1.1$	Galligan et al., 2012 [46]	0.9857	0.1485	18	0.9167	0.0842	18	3.7%	0.56 [-0.11, 1.23]	+
	llaiyaraja and Khanum, 2011 [58]	0.00233	0.00034	6	0.00402	0.00052	6	2.9%	-3.55 [-5.62, -1.48]	
Lai et al., 2019 [73] Lee et al., 2015 [74] Lee et al., 2015 [74] Lee et al., 2017 [73] 0.0195 0.0059 0.0195 0.0059 0.0059 0.0037 0.0058 0.0397 0.0058 0.014 0.0177 0.058 0.014 0.0177 12 3.5% -1.38 -2.717 [348, 0.66] + Lu et al., 2015 [19] 0.449 0.74 10	Jayaraman et al., 2009 (59)	0.0122	0.00118	8	0.0253	0.0024	8	2.4%	-6.55 [-9.34, -3.76]	
Lee et al., 2015 [74] 1.33 0.02 8 1.53 0.05 8 2.8% -4.97 [7.18, -2.75]	Kaviarasan et al., 2008 [68]	0.183	0.018	6	0.355	0.02	6	1.6%	-8.34 [-12.57, -4.12]	
Lee et al. 2016 [75] 10 1486 10 12.96 4.301 10 3.6% -0.86[1.81,0.05] + Li et al. 2017 [83] 0.0195 0.0059 8 0.0397 0.0058 8 3.2% -3.26[+4.89,-1.63] + Li et al. 2014 [82] 6.464 0.951 7 9.999 1.172 7 3.1% -3.01 [+7.0,-1.33] + Li et al. 2015 [83] 7.049 0.856 8 10.27 2.992 8 3.5% -1.38 [-2.51,0.26] + Li et al. 2012 [96] 2.315 4.998 18 34.764 5.128 8 3.4% -2.17 [-3.48,0.86] + Li et al. 2014 [97] 0.06559 0.0044 12 0.0761 0.00574 12 3.5% -1.39 [-2.93,0.93] + Li et al. 2015 [98] 4.49 0.74 10 8.21 1.1 10 3.2% -3.80 [-5.38,-2.22] + Am at al. 2005 [104] 0.3 0.02 6 0.671 0.048 6 1.4% -9.31 [-14.00, 4.63] + Am at al. 2007 [100] 546.6 4.56 6 654.7 4.37.7 6 3.2% -3.80 [-5.38,-2.22] + Am at al. 2012 [116] 256.5 151.599 6 798.32 86.81 6 2.7% -4.05 [-6.32,-1.76] + Am at al. 2013 [127] 4.39 0.465 6 2.108 2.009 6 1.3% -0.21 [-16.34,-5.11] + Am at al. 2013 [128] 4.39 0.465 6 2.108 2.009 6 1.4% -9.31 [-14.00, 4.63] + Am at al. 2013 [129] 0.2423 0.0325 15 0.2520 0.0402 13 3.7% -0.21 [-0.36,0.53] + Am at al. 2013 [129] 0.2423 0.0325 15 0.2520 0.0402 13 3.7% -0.21 [-0.36,0.53] + Am at al. 2013 [129] 0.2423 0.0325 15 0.02263 0.00226 10 2.5% -7.01 [-0.5,-3.4] + Am at al. 2009 [132] 0.1014 0.00077 8 0.02243 0.0015 8 1.8% -9.10 [-12.6,-5.34] + Am at al. 2012 [130] 0.518 0.499 6 0.4659 0.04605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [174] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [153] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [153] 0.2384 0.03086 6 0.04659 0.04605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [153] 0.2384 0.03086 6 0.04659 0.04605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [153] 0.2384 0.03086 6 0.04659 0.04605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [153] 0.2384 0.03086 6 0.04659 0.004605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [153] 0.2384 0.03086 6 0.04659 0.004605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [153] 0.2384 0.03086 6 0.04659 0.004605 6 2.4% -5.36 [-0.21,-2.51] + Am at al. 2013 [153] 0.2384 0.03086 6 0.04659 0.004605 6 2.4\% -5.36	Lai et al., 2019 [73]	55.91	5.32	8	64.91	3.65	8	3.4%	-1.87 [-3.10, -0.63]	
Li et al., 2017 [83] 0.0195 0.0059 8 0.0397 0.0058 8 3.2% -3.26 [4.89, -1.63] + 1 Lu et al., 2014 [92] 6.464 0.961 7 9.899 1.172 7 3.1% -3.01 [4.70, -1.33] + 1 Lu et al., 2015 [93] 7.049 0.856 8 10.27 2.992 8 3.5% -1.38 [\geq 51, 0.26] + 1 Lu et al., 2012 [96] 2.3.15 4.981 8 34.764 5.128 8 3.4% -2.17 [\geq 3.4%, -0.66] + 1 Lu et al., 2012 [96] 2.3.15 4.981 8 34.764 5.128 8 3.4% -2.17 [\geq 3.4%, -0.66] + 1 Lu et al., 2015 [93] 4.49 0.74 10 8.21 1.1 10 3.2% -3.80 [\geq 5.38, -2.22] + 1 Lu et al., 2015 [98] 4.49 0.74 10 8.21 1.1 10 3.2% -3.80 [\geq 3.68, -2.77 [\geq 3.69, -0.68] + 1 Lu et al., 2007 [100] 546.6 45.6 6 647.4 37.7 6 3.2% -2.22 [\Rightarrow 3.79, -0.66] + 1 Mallikarjuna et al., 2008 [104] 0.3 0.02 6 0.0671 0.048 6 1.4% -9.31 [1400, -4.63] + 1 Mallikarjuna et al., 2016 [117] 231.1 89.014 6 559.4 74.66 6 2.8% -3.89 [\leq 3.29 [\leq 8.2.1.66] + 1 Parthiba et al., 2013 [126] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [\circ 3.6, -5.51] + 1 Parthiba et al., 2013 [126] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [\circ 4.05 [\sim 5.38] + 2 Parthiba et al., 2018 [129] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [\circ 4.08, -5.38] + 1 Parthiba et al., 2019 [132] 1.206 0.11 4 1.15 0.067 4 3.3% 0.87 [\circ 6.42, 2.38] + 2 Parthiba et al., 2019 [132] 1.206 0.011 4 1.15 0.007 4 3.3% -1.37 [\geq 6.6, -0.05] + 1 Parthiba et al., 2012 [1514] 0.00168 0.0016 6 0.04659 0.02243 0.00226 10 2.5% -7.01 [\neq 5.0.05] + 2 Parthiba et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [\geq 2.50.701 + 2 Parthiba et al., 2012 [1514] 0.00168 0.0016 6 0.04659 6 2.4% -5.36 [\approx 2.168 [\sim 4.28] + 3.29 [\times 4.29 [\times	Lee et al., 2015 [74]	1.33	0.02	8	1.53	0.05	8	2.8%	-4.97 [-7.18, -2.75]	
Liu et al., 2014 [92] 6.464 0.951 7 9.899 1.172 7 3.1% $-3.01[4.70] -1.33]$ Liu et al., 2015 [93] 7.049 0.868 8 10.27 2.992 8 3.5% $-1.38[2.51] -0.26]$ Liu et al., 2021 [96] 2.315 4.981 8 3.4764 5.128 8 3.4% $-2.17[3.48] -0.86]$ Lu et al., 2021 [97] 0.06589 0.0044 12 0.0761 0.00574 12 3.5% $-1.93[2.33] -9.33]$ Lu et al., 2015 [98] 4.49 0.74 10 8.21 1.1 10 3.2% $-3.80[5.38] -2.22]$ Matet al., 2005 [104] 0.3 0.02 6 0.671 0.048 6 1.4% $-9.31[14.00] -4.63]$ Panda et al., 2012 [116] 256.15 151.599 6 798.32 86.81 6 2.7% $-4.05[6.33] -1.77]$ Panda et al., 2013 [126] 4.93 0.465 6 2.108 2.009 6 1.3% $-10.22[15.34] -5.11]$ Rabelo et al., 2013 [126] 4.93 0.465 6 2.108 2.009 6 1.3% $-10.22[15.34] -5.11]$ Rabelo et al., 2018 [129] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% $-0.22[1-0.96] -0.53]$ Reitha et al., 2013 [120] 5.16 0.49 6 2.027 1.99 6 1.4% $-9.02[1-0.96] -5.34]$ Sathiavelu et al., 2009 [132] 1.206 0.111 4 1.115 0.067 4 3.3% $0.87[1-0.64] -3.89]$ Sathiavelu et al., 2009 [132] 1.206 0.111 4 0.00077 8 0.02343 0.0016 8 1.8% $-9.10[1-2.86] -5.34]$ Semthikimer et al., 2001 [130] 0.01104 0.00077 8 0.02343 0.0016 8 1.8% $-9.10[1-2.86] -5.34]$ Subtoat al., 2013 [153] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% $-5.36[8.21] -2.51]$ Wei et al., 2013 [173] 15 81.662 31.512 15 3.6% $-1.52[2.35] -7.01]$ Heterogeneity. Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001) Total (95% CI) 287 273 100.0% $-2.87[-3.58, -2.16]$ Heterogeneity. Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001)	Lee et al., 2016 [75]	10	1.486	10	12.96	4.301	10	3.6%	-0.88 [-1.81, 0.05]	
Liu et al., 2015 [93] 7.049 0.858 8 10.27 2.992 8 3.5% -1.38 [2.51, -0.26] Liu et al., 2022 [86] 23.15 4.881 8 34.764 5.128 8 3.4% -2.17 [3.48, -0.68] + Lu et al., 2014 [97] 0.06589 0.00761 0.0761 0.00774 12 3.5% -1.93 [2.51, -0.26] + Ma et al., 2015 [98] 4.49 0.74 10 8.21 1.1 10 3.2% -3.80 [5.38, 2.22] + Ma et al., 2007 [100] 546.6 45.6 6 647.4 37.7 6 3.2% -2.22 [3.79, -0.66] + Malikarjune at al., 2008 [104] 0.3 0.02 6 0.671 0.048 6 1.4% -9.31 [+1.40, -4.63] - Panda et al., 2005 [101] 256.15 151.599 6 798.32 86.81 6 2.7% -4.05 [6.33, -1.77] + Panda et al., 2013 [126] 4.93 0.465 6 2.10.8 2.009 6 1.3% -10.22 [+5.34, -5.11] + Prathiba et al., 2013 [126] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [-0.96, 0.53] + Rejitha et al., 2013 [120] 5.16 0.49 6 20.27 1.99 6 1.4% -9.82 [+1.46, -4.79] - Roede et al., 2019 [132] 0.01104 0.00077 8 0.02343 0.00165 8 1.8% -9.80 [+0.534] + Senthikumer et al., 2009 [132] 0.01104 0.00077 8 0.02343 0.00165 4 3.3% 0.87 [-0.64, 2.38] + Senthikumer et al., 2009 [132] 0.01104 0.00077 8 0.02343 0.0016 6 3.4% -1.37 [-2.68, -0.05] + Senthikumer et al., 2013 [173] 0.2364 0.03086 6 0.4659 0.04605 6 2.4% -5.36 [-8.21, -2.61] + Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -7.01] + Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.55 [-2.35, -3.01] + Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87%	Li et al., 2017 [83]	0.0195	0.0059	8	0.0397	0.0058	8	3.2%	-3.26 [-4.89, -1.63]	
Liu et al., 2022 [96] 23.15 4.981 6 34.764 5.128 8 3.4% -2.17 [3.46] -0.86] Lu et al., 2014 [97] 0.06689 0.0044 12 0.0761 0.00574 12 3.5% -1.93 [2.3.9.0.93] $+$ Lu et al., 2015 [98] 4.49 0.74 10 8.21 1.1 10 3.2% -3.80 (5.3.8, -2.2] $+$ Ma et al., 2007 [100] 546.6 456.6 6 647.4 37.7 6 3.2% -2.22 [3.7.9, -0.66] $+$ Prada et al., 2012 [16] 266.15 151.599 6 7.98.32 66.81 6 2.7.8 -3.69 (5.6.3.3, -7.7] Panda et al., 2015 [17] 23.1. 89.014 6 559.4 74.66 6 2.8% -3.69 (5.6.3.3, -7.7] Panda et al., 2013 [126] 4.93 0.465 6 21.08 2.009 6 1.3% -10.22 [-15.34, -5.11] Rabelo et al., 2018 [129] 0.2423 0.0325 15 0.2602 0.0402 13 3.7% -0.21 [-0.66, 0.53] Rejitha et al., 2012 [130] 5.16 0.49 6 20.27 1.99 6 1.4% -9.62 [-14.46, -4.79] Roed et al., 2018 [132] 1.206 0.11 4 1.115 0.067 4 3.3% 0.87 [-0.64, 2.38] Senthilkumar et al., 2008 [139] 0.01104 0.00077 8 0.0234 0.0016 8 8 1.8% -9.10 [-12.86, -5.34] Senthilkumar et al., 2008 [139] 0.01104 0.00078 10 0.02258 0.00226 10 2.5% -7.01 [-9.59, -4.43] Subto at al., 2009 [139] 0.01140 0.00088 6 0.4659 0.04605 6 2.4.% -5.36 [6.21.2.51] Wei et al., 2013 [173] 0.2384 0.03086 6 0.4659 0.04605 6 2.4.% -5.36 [6.21.2.51] Wei et al., 2013 [174] 39.03 2.1.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] $+$ You et al., 2013 [174] 0.00243 0.00094 8 0.00478 0.00179 8 3.5% -1.52 [-2.35, -0.70] $+$ Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87% Test for overall effect: Z = 7.92 (P < 0.00001) Total (95% CI) 287 273 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87% Test for overall effect: Z = 7.92 (P < 0.00001)	Liu et al., 2014 [92]	6.464	0.951	7	9.899	1.172	7	3.1%	-3.01 [-4.70, -1.33]	
Lu et al., 2014 [97] 0.066589 0.0044 12 0.0761 0.00574 12 3.5% -1.93 [-2.93, -0.93] Lu et al., 2015 [98] 4.49 0.74 10 8.21 1.1 10 3.2% -3.20 [-5.38, -2.22] Ma et al., 2007 [100] 546.6 456.6 6 647.4 37.7 6 3.2% -3.22 [-3.79, 0.66] Mallikarjuna et al., 2008 [104] 0.3 0.02 6 0.671 0.048 6 1.4% -9.31 [-14.00, -4.63] Panda et al., 2015 [117] 231.1 89.014 6 559.4 74.66 6 2.2% -3.69 [-5.83, -1.76] Panda et al., 2013 [126] 4.93 0.465 6 21.08 2.009 6 1.3% -10.22 [15.34, -5.11] Rejitha et al., 2013 [126] 4.93 0.465 6 21.08 2.009 6 1.3% -0.21 [10.98, 0.63] Rejitha et al., 2013 [126] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [-0.96, 0.53] Rejitha et al., 2018 [129] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [-0.96, 0.53] Rejitha et al., 2019 [132] 1.206 0.11 4 1.115 0.067 4 3.3% 0.87 [-0.64, 2.38] Sathiavelu et al., 2009 [139] 0.01104 0.00077 8 0.02243 0.00165 8 1.8% -9.10 [-12.86, -5.34] Sathiavelu et al., 2012 [130] 0.01104 0.00077 8 0.02248 0.00126 10 2.5% -7.01 [-9.59, -4.43] Sudha et al., 2012 [151] 0.00186 0.0014 6 0.00334 0.001 6 8 2.4% -1.37 [-2.86, -0.5] Tahir et al., 2013 [153] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% -3.66 [-3.21, -2.51] Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.2% -3.29 [-4.33, -1.65] Subtoat (95% C) 287 273 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau" = 3.45; Chi" = 257.00, df = 33 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87% Test for overall effect Z = 7.92 (P < 0.00001); P = 87%	Liu et al., 2015 [93]	7.049	0.858	8	10.27	2.992	8	3.5%	-1.38 [-2.51, -0.26]	
Lu et al., 2015 [98] 4.49 0.74 10 8.21 1.1 10 3.2% -3.80 [-5.38, -2.22] Ma et al., 2007 [100] 546.6 45.6 6 647.4 37.7 6 3.2% -2.22 [-3.79, -0.66] Malikarjuna et al., 2008 [104] 0.3 0.02 6 0.671 0.048 6 1.4% -9.31 [+4.00, -4.63] Panda et al., 2012 [116] 256.15 151.599 6 798.32 86.81 6 2.7% -4.05 [-6.33, -1.77] Panda et al., 2013 [126] 4.93 0.485 6 21.08 2.009 6 1.3% -10.22 [+5.34, -5.11] Prathibha et al., 2013 [129] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [-0.96, 0.53] Rejitha et al., 2012 [130] 5.16 0.49 6 20.27 1.99 6 1.4% -9.62 [+1.46, -4.79] Roede et al., 2019 [132] 1.206 0.11 4 1.115 0.067 4 3.3% 0.87 [-0.64, 2.38] Sathiavelu et al., 2009 [139] 0.01104 0.00077 8 0.02248 0.00226 10 2.5% -7.01 [=9.59, -4.43] Sudha et al., 2012 [151] 0.00186 0.001 6 0.0033 0.00165 8 1.8% -9.01 [+1.268, -0.05] Tahir et al., 2013 [153] 0.2384 0.03086 6 0.4659 0.04025 16 2.4% -5.36 [-8.21, -2.51] Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] Heterogeneity: Tau" = 3.45; Chi" = 257.00, df = 33 (P < 0.00001); I" = 87% Test for overall effect Z = 7.92 (P < 0.00001) Heterogeneity: Tau" = 3.45; Chi" = 257.00, df = 33 (P < 0.00001); I" = 87% Test for overall effect Z = 7.92 (P < 0.00001)	Liu et al., 2022 [96]	23.15	4.981	8	34.764	5.128	8	3.4%	-2.17 [-3.48, -0.86]	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Lu et al., 2014 [97]	0.06589	0.0044	12	0.0761	0.00574	12	3.5%	-1.93 [-2.93, -0.93]	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Lu et al., 2015 [98]	4.49	0.74	10	8.21	1.1	10	3.2%	-3.80 [-5.38, -2.22]	
Panda et al., 2012 [116] 256.15 151.599 6 798.32 86.81 6 2.7% -4.05 [-6.33, -1.77] Panda et al., 2015 [117] 231.1 89.014 6 559.4 74.66 6 2.8% -3.69 [-5.34, -5.16] Prathibha et al., 2013 [126] 4.93 0.465 6 21.08 2.009 6 1.3% -0.21 [-0.96, 0.53] Rabelo et al., 2018 [129] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [-0.96, 0.53] Rejitha et al., 2012 [130] 5.16 0.49 6 20.27 1.99 6 1.4% -9.62 [-14.46, -4.79] Roede et al., 2009 [132] 1.206 0.11 4 1.115 0.067 4 3.3% 0.87 [-0.84, 2.38] Sathiavelu et al., 2004 [140] 0.01012 0.00077 8 0.0226 10 2.5% -7.01 [-9.59, -4.43] Sudha et al., 2013 [173] 0.2344 0.00344 0.001 6 3.4% -1.37 [-2.68, -0.05] -4.33 Sudha et al., 2013 [174] 39.303 21.673 15 8.6.38 0.44 8<	Ma et al., 2007 [100]	546.6	45.6	6	647.4	37.7	6	3.2%	-2.22 [-3.79, -0.66]	
Panda et al., 2015 [117] 231.1 89.014 6 559.4 74.66 6 2.0% -3.69 [-5.82, -1.56] Prathibha et al., 2013 [126] 4.93 0.465 6 21.08 2.009 6 1.3% -10.22 [-15.34, -5.11] Rebit a tal., 2012 [130] 5.16 0.49 6 20.27 1.99 6 1.4% -9.62 [-14.46, -4.79] Reith a et al., 2019 [132] 1.206 0.11 4 1.15 0.0677 4 3.3% -0.87 [-0.64, 2.38] Sathiavelu et al., 2009 [132] 0.0106 0.002268 0.00226 10 2.5% -7.01 [-9.59, -4.43] Subda et al., 2012 [151] 0.00186 0.00126 8 1.8% -9.10 [-12.86, -5.34] Sudha et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2008 [204] 0.00243 0.000179 8 3.5% -1.55 [-2.71, -0.39] -16 Su	Mallikarjuna et al., 2008 [104]	0.3	0.02	6	0.671	0.048	6	1.4%	-9.31 [-14.00, -4.63]	
Prathibha et al., 2013 [126] 4.93 0.465 6 21.08 2.009 6 1.3% -10.22 [$\cdot 15.34$, -5.11] Rabelo et al., 2018 [129] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [$\cdot 0.96$, 0.53] Rejitha et al., 2012 [130] 5.16 0.49 6 20.27 1.99 6 1.4% -9.62 [$\cdot 14.46$, -4.79] Roede et al., 2009 [132] 1.206 0.11 4 1.115 0.067 4 3.3% 0.87 [$\cdot 0.64$, 2.38] Sathiavelu et al., 2009 [132] 0.01104 0.00077 8 0.02248 0.00126 8 1.8% -9.10 [$\cdot 12.86$, -5.34] Senthilkumar et al., 2012 [151] 0.01186 0.001 6 0.02258 0.00226 10 2.5% -7.01 [$\cdot 9.59$, -4.43] Wei et al., 2013 [174] 39.303 21.673 15 81.682 31.512 15 3.6% -1.55 [$\cdot 2.35$, -0.70] -10 -5 -10 -10 -5 -10 -10 -5 -10 -10 -5 -10 -10 -10 -5 0	Panda et al., 2012 [116]	256.15	151.599	6	798.32	86.81	6	2.7%	-4.05 [-6.33, -1.77]	
Rabelo et al., 2018 [129] 0.2423 0.0325 15 0.2502 0.0402 13 3.7% -0.21 [-0.96 0.53] Rejitha et al., 2012 [130] 5.16 0.49 6 20.27 1.99 6 1.4% -9.62 [-14.46 , -4.79] Rede et al., 2009 [132] 1.206 0.11 4 1.115 0.067 4 3.3% 0.87 [-0.64 , 2.38] Sathiavelu et al., 2009 [132] 0.0104 0.00077 8 0.02343 0.00126 8 1.8% -9.10 [$-9.59, -4.43$] Senthikumar et al., 2012 [151] 0.00186 0.001 6 0.04605 6 2.4% -5.36 [$8.21, -2.51$] Wei et al., 2013 [173] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% -5.36 [$8.21, -2.51$] Wei et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.2% -3.29 [$4.93, -1.65$] -1.55 [$2.71, -0.39$] Zhao et al., 2008 [204] 0.00243 0.00001); P= 87% 287 273 100.0% -2.87 [$-3.58, -2.16$] <t< td=""><td>Panda et al., 2015 [117]</td><td>231.1</td><td>89.014</td><td>6</td><td>559.4</td><td>74.66</td><td>6</td><td>2.8%</td><td>-3.69 [-5.82, -1.56]</td><td> </td></t<>	Panda et al., 2015 [117]	231.1	89.014	6	559.4	74.66	6	2.8%	-3.69 [-5.82, -1.56]	
Rejitha et al., 2012 [130] 5.16 0.49 6 20.27 1.99 6 1.4% -9.62 [-14.46, -4.79] Roede et al., 2009 [132] 1.206 0.11 4 1.115 0.067 4 3.3% 0.87 [-0.64, 2.38] Sathiavelu et al., 2009 [139] 0.01104 0.00077 8 0.02258 0.00226 10 2.5% -7.01 [-9.59, -4.43] Sutha et al., 2013 [151] 0.00166 0.01 6 0.0334 0.001 6 3.4% -1.37 [-2.68, -0.05] Tahir et al., 2013 [153] 0.2384 0.03086 6 0.4659 0.4605 6 2.4% -5.36 [-8.21, -2.51] Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2010 [190] 4.83 0.4478 0.30079 8 3.5% -1.55 [-2.71, -0.39] -1.65] Subtotal (95% CI) 287 273 100.0% -2.87 [-3.58, -2.16] -4 Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87%	Prathibha et al., 2013 [126]	4.93	0.465	6	21.08	2.009	6	1.3%	-10.22 [-15.34, -5.11]	
Roade et al., 2009 [132] 1.206 0.11 4 1.115 0.067 4 3.3% 0.87 [-0.64, 2.38] Sathiavelu et al., 2009 [139] 0.01104 0.00077 8 0.02243 0.00165 8 1.8% -9.10 [-12.86, -5.34] Senthilkumar et al., 2004 [140] 0.01012 0.00083 10 0.02268 10 2.5% -7.01 [-9.59, -4.43] Sudha et al., 2012 [151] 0.00186 0.001 6 0.04605 6 2.4% -5.36 [-8.21, -2.51] Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.2% -3.29 [-4.93, -1.65] Zhao et al., 2008 [204] 0.00243 0.000478 8 0.0079 8 3.5% -1.55 [-2.71, -0.39] Subtotal (95% CI) 287 273 100.0% -2.87 [-3.58, -2.16] -10 -5 0 5 10 Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87%	Rabelo et al., 2018 [129]	0.2423	0.0325	15	0.2502	0.0402	13	3.7%	-0.21 [-0.96, 0.53]	-
Sathiavelue et al., 2009 [139] 0.01104 0.00077 8 0.02343 0.00165 8 1.8% -9.10 [-12.86, -5.34] Senthilkumar et al., 2004 [140] 0.01012 0.00083 10 0.02258 0.00226 10 2.5% -7.01 [-9.59, -4.43] Sudha et al., 2012 [151] 0.00186 0.001 6 0.00334 0.001 6 3.4% -1.37 [-2.68, -0.05] Tahir et al., 2013 [153] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% -5.36 [-8.21, -2.51] Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.2% -3.29 [4.93, -1.65] Zhao et al., 2008 [204] 0.00243 0.00094 8 0.00179 8 3.5% -1.55 [-2.71, -0.39] Subtotal (95% Cl) 287 273 100.0% -2.87 [-3.58, -2.16] -10 Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87%	Rejitha et al., 2012 [130]	5.16	0.49	6	20.27	1.99	6	1.4%	-9.62 [-14.46, -4.79]	
Senthilkumar et al., 2004 [140] 0.01012 0.00083 10 0.02258 0.00226 10 2.5% -7.01 [9.59], -4.43] Sudha et al., 2012 [151] 0.00186 0.001 6 0.00334 0.001 6 3.4% -1.37 [-2.68, -0.05] Tahir et al., 2013 [153] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% -5.36 [-8.21, -2.51] Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.2% -3.29 [4.93, -1.65] Zhao et al., 2008 [204] 0.00243 0.00094 8 0.00478 0.00179 8 3.5% -1.55 [-2.71, -0.39] Subtotal (95% CI) 287 273 100.0% -2.87 [-3.58, -2.16] \bullet Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P = 87%	Roede et al., 2009 [132]	1.206	0.11	4	1.115	0.067	4	3.3%	0.87 [-0.64, 2.38]	+
Sudha et al., 2012 [151] 0.00186 0.001 6 0.00334 0.001 6 3.4% -1.37 [-2.68, -0.05] Tahir et al., 2013 [153] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% -5.36 [-8.21, -2.51] Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.2% -3.29 [4.93, -1.65] Zhao et al., 2008 [204] 0.00243 0.00094 8 0.00478 0.00179 8 3.5% -1.55 [-2.71, -0.39] Subtotal (95% CI) 287 273 100.0% -2.87 [-3.58, -2.16] \bullet Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% 773 100.0% -2.87 [-3.58, -2.16] \bullet Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% 773 100.0% -2.87 [-3.58, -2.16] \bullet -10 -5 0 5 10 Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% -10 -5 0	Sathiavelu et al., 2009 [139]	0.01104	0.00077	8	0.02343	0.00165	8	1.8%	-9.10 [-12.86, -5.34]	
Tahir et al., 2013 [153] 0.2384 0.03086 6 0.4659 0.04605 6 2.4% -5.36 [8.21, -2.51] Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.2% -3.29 [-4.93, -1.65] Zhao et al., 2008 [204] 0.00243 0.00094 8 0.00179 8 3.5% -1.55 [-2.71, -0.39] Subtotal (95% CI) 287 273 100.0% -2.87 [-3.58, -2.16] - Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% - - - - - - - - - - - - - - - - - - - 0 5 0 5 10 Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% - - - - - - - - - - - - - - - - - - - <td>Senthilkumar et al., 2004 [140]</td> <td>0.01012</td> <td>0.00083</td> <td>10</td> <td>0.02258</td> <td>0.00226</td> <td>10</td> <td>2.5%</td> <td>-7.01 [-9.59, -4.43]</td> <td></td>	Senthilkumar et al., 2004 [140]	0.01012	0.00083	10	0.02258	0.00226	10	2.5%	-7.01 [-9.59, -4.43]	
Wei et al., 2013 [174] 39.303 21.673 15 81.662 31.512 15 3.6% -1.52 [-2.35, -0.70] You et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.2% -3.29 [-4.93, -1.65] Zhao et al., 2008 [204] 0.00243 0.00094 8 0.00179 8 3.5% -1.55 [-2.71, -0.39] Subtotal (95% Cl) 287 273 100.0% -2.87 [-3.58, -2.16] + Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P ² = 87% 73 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); P ² = 87% -10 -5 0 5 10 Test for overall effect: Z = 7.92 (P < 0.00001)	Sudha et al., 2012 [151]	0.00186	0.001	6	0.00334	0.001	6	3.4%	-1.37 [-2.68, -0.05]	
You et al., 2010 [190] 4.83 0.45 8 6.38 0.44 8 3.29 -3.29 [4.93 , -1.65] Zhao et al., 2008 [204] 0.00243 0.00094 8 0.00179 8 3.5% -1.55 [2.71 , -0.39] Subtotal (95% CI) 287 273 100.0% -2.87 [-3.58 , -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% 73 100.0% -2.87 [-3.58 , -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% 73 100.0% -2.87 [-3.58 , -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% -10 -5 0 5 10 Test for overall effect: Z = 7.92 (P < 0.00001)	Tahir et al., 2013 [153]	0.2384	0.03086	6	0.4659	0.04605	6	2.4%	-5.36 [-8.21, -2.51]	
Zhao et al., 2008 [204] 0.00243 0.00094 8 0.00179 8 3.5% -1.55 [-2.71, -0.39] Subtotal (95% Cl) 287 273 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% 273 100.0% -2.87 [-3.58, -2.16] Total (95% Cl) 287 273 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% -10 -5 0 5 10 Test for overall effect: Z = 7.92 (P < 0.00001)	Wei et al., 2013 [174]	39.303	21.673	15	81.662	31.512	15	3.6%	-1.52 [-2.35, -0.70]	+
Subtotal (95% Cl) 287 273 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% 273 100.0% -2.87 [-3.58, -2.16] Total (95% Cl) 287 273 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% 273 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% 273 100.0% -2.87 [-3.58, -2.16] Test for overall effect: Z = 7.92 (P < 0.00001)	You et al., 2010 (190)	4.83	0.45	8	6.38	0.44	8	3.2%	-3.29 [-4.93, -1.65]	
Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% Test for overall effect: Z = 7.92 (P < 0.00001)	Zhao et al., 2008 [204]	0.00243	0.00094	8	0.00478	0.00179	8	3.5%	-1.55 [-2.71, -0.39]	
Test for overall effect: Z = 7.92 (P < 0.00001)	Subtotal (95% CI)			287			273	100.0%	-2.87 [-3.58, -2.16]	◆
Total (95% Cl) 287 273 100.0% -2.87 [-3.58, -2.16] Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% -10 -5 0 5 10 Test for overall effect: Z = 7.92 (P < 0.00001)	Heterogeneity: Tau ² = 3.45; Chi ² = 2	257.00, df=	: 33 (P < 0.	.00001)	; I ² = 87%					
Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% Test for overall effect: Z = 7.92 (P < 0.00001) AFLD Control	Test for overall effect: Z = 7.92 (P <	0.00001)								
Heterogeneity: Tau ² = 3.45; Chi ² = 257.00, df = 33 (P < 0.00001); I ² = 87% Test for overall effect: Z = 7.92 (P < 0.00001) AFLD Control	Total (95% CI)			287			273	100.0%	-2.87 [-3.58, -2.16]	•
Test for overall effect: Z = 7.92 (P < 0.00001)	Heterogeneity: Tau ² = 3.45: Chi ² = 2	257.00, df=	: 33 (P < 0	00001	; I² = 87%					
AFLD CONTO										
										AFLD CONTO

Figure 5. Forest plot showing the results of combining studies that analyzed glutathione reductase (GR) activity in the liver. Animals with alcoholic fatty liver disease (AFLD) had lower GR activity compared with healthy controls (p < 0.05). 95% Cl: confidence interval.

• Glutathione Transferase (GST)

Analysis of GST activity was performed in 20 studies, which mainly used the measurements units U/mg (n = 10) and μ ol/mg (n = 10). There was a reduction in GST activity in AFLD groups compared with control groups (SMD: -1.74; 95% Cl -2.85, -0.63, p = 0.002). The studies showed high heterogeneity, with $I^2 = 91\%$ (Figure 6).

		AFLD			ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.7.1 GST in liver									
Bae et al., 2015 [14]	18.52	2.23	8	29.94	1.52	8	4.9%	-5.66 [-8.12, -3.20]	
Balasubramaniyan et al., 2003 [15]	10.53	0.14	6	19.2	0.18	6	0.2%	-49.63 [-73.89, -25.38]	•
Chandra et al., 2000 [25]	0.000289	0.000014	8	0.000171	0.000018	8	4.4%	6.92 [3.99, 9.85]	
Chiu et al., 2011 [33]	0.0596	0.0031	6	0.0681	0.0031	6	5.6%	-2.53 [-4.21, -0.86]	
Das et al., 2012 [39]	10.58	0.7511	18	6.88	0.09	6	5.4%	5.40 [3.49, 7.31]	
De Souza et al., 2015 [40]	0.00000266	0.00000047	10	0.00000304	0.00000017	10	6.1%	-1.03 [-1.98, -0.09]	-
Develi et al., 2014 [41]	0.000576	0.000077	8	0.000648	0.000092	8	6.1%	-0.80 [-1.83, 0.23]	-
Du et al., 2015 [43]	23.029	56.156	6	31.078	75.621	6	6.0%	-0.11 [-1.24, 1.02]	+
Galligan et al., 2012 [46]	9.235	3.1006	18	7.0017	1.9329	18	6.3%	0.85 [0.16, 1.53]	-
Jayaraman et al., 2009 [59]	5.6	0.5	8	9.5	0.9	8	5.1%	-5.06 [-7.31, -2.82]	
Lee et al., 2016 [75]	0.56	0.063	10	0.7	0.095	10	6.1%	-1.66 [-2.71, -0.62]	+
Pari and Suresh, 2008 [118]	3.46	0.26	6	5.81	0.44	6	4.2%	-6.00 [-9.14, -2.86]	
Roede et al., 2009 [132]	3.973	0.273	4	3.626	0.298	4	5.7%	1.06 [-0.51, 2.62]	+
Rong et al., 2012 [133]	7.918	4.358	12	11.024	5.387	12	6.2%	-0.61 [-1.43, 0.21]	-
Sathiavelu et al., 2009 [139]	4.62	0.32	8	8.46	0.59	8	4.2%	-7.65 [-10.86, -4.44]	_ —
Shenbagam and Nalini, 2010 [143]	4.571	0.334	6	8.452	0.56	6	3.5%	-7.77 [-11.73, -3.81]	
Sudha et al., 2012 [151]	0.018	0.001	6	0.032	0.001	6	2.0%	-12.92 [-19.33, -6.51]	
Tang et al., 2012 [155]	11.592	1.789	8	16.719	2.313	8	5.9%	-2.34 [-3.70, -0.99]	
Yalçinkaya et al., 2007 [182]	0.4301	0.0465	8	0.462	0.0492	6	6.1%	-0.63 [-1.72, 0.47]	
You et al., 2010 [190]	7.51	0.42	8	8.67	0.55	8	5.9%	-2.24 [-3.57, -0.91]	
Subtotal (95% CI)			172			158	100.0%	-1.74 [-2.85, -0.63]	◆
Heterogeneity: Tau ² = 4.98; Chi ² = 21	0.76, df = 19 (F	^o < 0.00001); l ^a	²= 91%						
Test for overall effect: Z = 3.08 (P = 0.	002)								
Total (95% CI)			172			158	100.0%	-1.74 [-2.85, -0.63]	◆
Heterogeneity: Tau ² = 4.98; Chi ² = 21	0.76. df = 19 (F	[,] < 0.00001); I [≥]	²= 91%						
Test for overall effect: Z = 3.08 (P = 0.									-20 -10 0 10 20
Test for subgroup differences: Not ar	,								AFLD Control

Test for subgroup differences; Not applicable

Figure 6. The evidence suggests a decrease in glutathione transferase (GST) activity in the liver tissue of animals with alcoholic fatty liver disease (AFLD) compared with healthy controls. This is supported by the forest plot, which shows a significant reduction in GST activity (p < 0.05 for each), with 95% confidence intervals (Cl) reported.

Reduced Glutathione (GSH)

A total of 118 manuscripts analyzed GSH, of which 102 used μ mol/mg and 16 used mg/g. There was high heterogeneity among the studies included in this analysis ($I^2 = 84\%$, p < 0.00001). It was evident that there was a reduction of GSH in AFLD groups compared with control groups in both subgroups and the overall analysis (SMD -3.20, 95% CI -3.55, −2.85, *p* < 0.00001) (Figure 7).

Reduced Glutathione (GSH)/Oxidized Glutathione (GSSG) Ratio

A total of 24 articles included GSH/GSSG ratio analysis. The results showed a significant reduction in GSH compared with GSSG in AFLD groups, with a MD of -5.09 (95% CI -6.28, -3.91, p < 0.00001). These findings provide evidence that ethanol consumption leads to increased glutathione oxidation (Figure 8).

Factor 2 Related to Erythroid Nuclear Factor 2 (Nrf2)

A total of 24 manuscripts analyzed the expression of Nrf2, with high heterogeneity among the studies ($I^2 = 99\%$). The MD of -0.23 and 95% CI -0.41, -0.04, showed that there was a reduction in the expression of this transcription factor in AFLD groups compared with control groups (Supplementary Figure S8).

Study or Subgroup .9.1 GSH in liver	Mean	AFLD SD	Total	Mean	Control SD	Total	Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
bdelhamid et al., 2020 (10)	30.769	5.57	12	80.371	4.244	12	0.6%	-9.67 [-12.77, -6.57]	←
bdelhamid et al., 2021 (11) I-Rejaie, 2012 (12)	30.923 0.00133	5.301 0.00014	6 6	80.493 0.00194	11.575 0.00015	6 6	0.7% 0.8%	-5.08 [-7.81, -2.36] -3.88 [-6.09, -1.67]	
lefetal., 2018 [13] ae etal., 2015 [14]	61.591 4.62	9.637 0.57	6	106.786	8.151 0.61	6	0.7% 0.9%	-4.67 [-7.22, -2.13] -4.31 [-6.29, -2.33]	
alasubramaniyan et al., 2003 (15)	0.289	0.02	6	0.453	0.04	6	0.7%	-4.79 [-7.38, -2.19]	
ihamhan et al., 2011 (19) lispo et al., 2017 (21)	0.276 29 364 530 81	0.07 2,756,610.503	8 5	0.536	0.11 5,608,781.208	8 5	1.0% 0.1%	-2.67 [-4.11, -1.22] -19.43 [-30.44, -8.42]	←
3uko et al., 2019 [22]	0.0095	0.0005	8	0.0154	0.0013	8	0.8%	-5.66 [-8.13, -3.20]	
ao et al., 2015 [24] :handra et al., 2000 [25]	0.3382 0.0229	0.0382 0.0076	4	0.5331 0.0791	0.0805	4	0.8%	-2.69 [-5.00, -0.38] -6.42 [-9.16, -3.68]	
hang et al., 2017 (26)	0.0324	0.0065	8	0.0526	0.0082	8	1.0%	-2.58 [-4.00, -1.16]	
chang et al., 2021 [27] Chen et al., 2016 [31]	0.0078	0.0003	10 10	0.0105	0.001 0.0234	10 10	1.0% 1.1%	-3.50 [-5.00, -2.01] 0.08 [-0.80, 0.95]	
heng and Khong, 2011 [32]	5.1 0.006	0.64	12	7.49	0.89 0000.0	12	1.0%	-2.98 [-4.20, -1.76]	
>hiu et al., 2011 [33] >hu et al., 2021 [34]	0.006	0.0005	6 6	0.0079 0.0057	0.0006	6 6	0.9% 0.8%	-3.18 [-5.10, -1.26] -3.50 [-5.55, -1.45]	
Colontoni et al., 2000 [35] Cui et al., 2014 [36]	5.0143 0.0018	1.7364	28 12	5.8286 0.0022	1.018 0.0006	28 12	1.1%	-0.56 [-1.10, -0.03] -0.86 [-1.71, -0.02]	
cui et al., 2014 [36] cui et al., 2014 [37]	0.0018	0.0002	12	0.0022	0.0011	12	1.1%	-0.85 [-1.70, -0.02]	
es et al., 2012 [39] Se Souza et al., 2015 [40]	0.042 6.075	0.0077 0.689	18 10	0.0679 7.658	0.0012 2.692	6 10	1.0%	-3.68 [-5.15, -2.21] -0.77 [-1.69, 0.14]	
Develi et al., 2014 [41]	0.003	0.0004	8	0.0043	0.0005	8	1.0%	-2.71 [-4.18, -1.25]	
ou et al., 2013 [42] eng et al., 2019 [45]	0.0223 0.0253	0.0027	6 8	0.0365 0.0541	0.0035 0.0078	6 8	0.8% 1.0%	-4.19 [-6.53, -1.85] -3.11 [-4.70, -1.53]	
Falligan et al., 2012 [46]	0.0023	0.0004	18	0.0028	0.0006	18	1.1%	-0.96 [-1.65, -0.26]	
>aoetal., 2021 [47] Han etal., 2021 [50]	0.032 0.0139	0.0064 0.0019	9 10	0.0421 0.0209	0.0049 0.0039	9 10	1.1% 1.0%	-1.69 [-2.80, -0.57] -2.19 [-3.34, -1.03]	
lao et al., 2018 (51)	0.1702	0.0621	8	0.4009	0.042	8	0.9%	-4.11 [-6.03, -2.20]	
lasanein et al., 2018 [53] le et al., 2021 [54]	0.0188 11,340	0.0018 1,780	7 12	0.0272 21,150	0.0005 2,450	7	0.7%	-5.95 [-8.76, -3.15] -4.42 [-6.01, -2.84]	
lsu et al., 2018 (55)	17,700	2,600	10	15,300	2,300	10	1.1%	0.94 [0.00, 1.87]	<u> </u>
łu et al., 2021 (56) aiyaraja and Khanum, 2011 (58)	0.0965 5.02	0.0182 0.66	6 6	0.1216 9.05	0.0187 1.15	6 6	1.0% 0.8%	-1.26 [-2.54, 0.03] -3.97 [-6.21, -1.72]	
ayaraman et al., 2009 (59)	10,930	1,050	8	19,690	1,890	8	0.8%	-5.42 [-7.79, -3.04]	, <u> </u>
liang et al., 2016 [60] lin et al., 2010 [62]	0.0047 0.0305	0.0001 0.008	8 15	0.0109 0.0467	0.0002	8 15	0.1% 1.1%	-37.07 [-51.90, -22.25] -1.68 [-2.53, -0.83]	· _
(anbak et al., 2001 (64)	220	79.196	8	400	67.882	8	1.0%	-2.31 [-3.65, -0.96]	
(anchana and Jayapriya, 2013 (65) (aviarasan et al., 2008 (68)	0.5533 100.2	0.0239 8.1	6 6	0.9141 162.9	0.029 13.7	6 6	0.3% 0.7%	-12.53 [-18.76, -6.31] -5.14 [-7.90, -2.39]	·
(hanal et al., 2009 [69]	0.0041	0.0001	4	0.0058	0.0001	4	0.1%	-14.78 [-25.04, -4.52]	· ⊥
(im et al., 2012 [70] (umar et al., 2019 [72]	0.0089 15.852	0.003 5.552	8 6	0.0102 38.081	0.003 4.826	8 6	1.1% 0.8%	-0.41 [-1.40, 0.58] -3.94 [-6.18, -1.71]	T
.ee et al., 2015 (74)	3,780,000	250,000	8	5,210,000	540,000	8	0.9%	-3.21 [-4.83, -1.60]	
.ian et al., 2010 (89) .i et al., 2013 (80)	6.874 0.0522	0.438 0.0273	10 12	11.376 0.0562	1.228 0.0274	10 12	0.9% 1.1%	-4.68 [-6.52, -2.84] -0.14 [-0.94, 0.66]	
i et al., 2015 [81]	0.1173	0.046	30	0.17	0.02	10	1.1%	-1.25 [-2.02, -0.48]	
ietal., 2017 [83] ietal., 2021 [85]	6.732 0.00186	0.453 0.00036	8 9	14.933 0.00367	1.423 0.00068	8 9	0.6% 1.0%	-7.34 [-10.43, -4.25] -3.17 [-4.66, -1.68]	
i et al., 2021 (86)	0.00183	0.00036	9 9	0.00364	0.00066	9 9	1.0% 0.9%	-3.24 [-4.76, -1.73]	
.i et al., 2021 (88) .in et al., 2017 (90)	0.00194	0.00023	8	0.00385	0.00069	8	1.0%	-3.73 [-5.39, -2.07] -2.69 [-4.14, -1.24]	
in et al., 2021 [91] in et al., 2014 [92]	0.068	0.023	8 7	0.09	0.013	8	1.1% 1.0%	-1.11 [-2.19, -0.04] -2.64 [-4.20, -1.08]	
iu et al., 2014 [92] iu et al., 2015 [93]	0.03729	0.00469	8	0.05995	0.00456	8	0.8%	-4.63 [-6.72, -2.54]	
iu et al., 2020 [94] iu et al., 2022 [95]	0.0655 20.145	0.0094 4.812	9 9	0.0972 31.781	0.0175 5.459	9	1.0%	-2.15 [-3.37, -0.93] -2.15 [-3.37, -0.93]	
iu et al., 2022 [96]	371.712	55.584	8	519.963	35.393	8	1.0%	-3.01 [-4.56, -1.46]	
.u et al., 2014 [97] .u et al., 2015 [98]	0.0595 0.1077	0.0072 0.0125	12 10	0.0681 0.2063	0.0093	12 10	1.1% 0.9%	-1.00 [-1.86, -0.14] -4.11 [-5.78, -2.44]	
fai et al., 2022 [102]	0.00554	0.00129	6	0.01144	0.00194	6	0.9%	-3.31 [-5.28, -1.33]	
faimaitimin et al., 2018 (103) fallikarjuna et al., 2008 (104)	0.06795 51.081	0.00463 2.533	7 6	0.1637 108.925	0.00737 1.258	7 6	0.2%	-14.56 [-21.01, -8.12] -26.70 [-39.78, -13.62]	
fandal et al., 2013 (105)	0.0029	0.0011	5	0.0271	0.0028	5	0.3%	-10.28 [-16.19, -4.36]	←
fehanna et al., 2021 (106) feng et al., 2020 (107)	0.0008 0.009	0.0004	16 8	0.0024 0.0196	0.0002	8	0.9%	-4.43 [-6.04, -2.81] -4.26 [-6.23, -2.30]	
fing et al., 2021 [109]	0.000007	0.0000038	8	0.00001	0.0000024	8	1.1%	-0.89 [-1.94, 0.15]	
1ohan et al., 2019 (110) Jagappan et al., 2018 (111)	319.17 1.763	41.778 0.381	8 6	477.597 3.413	71.023 0.5	8	1.0% 0.9%	-2.57 [-3.99, -1.15] -3.43 [-5.45, -1.41]	
Dsaki et al., 2016 [115]	4.89	1.78	12	9.65	2.1	12	1.1%	-2.36 [-3.44, -1.28]	
?anda et al., 2012 [116] ?anda et al., 2015 [117]	0.00104 0.00046	0.00005 0.0001	6 6	0.00133	0.00007 0.00054	6 6	0.8%	-4.40 [-6.83, -1.97] -3.78 [-5.94, -1.62]	
ari and Suresh, 2008 [118]	0.26	0.02	6	0.446	0.034	6	0.6%	-6.16 [-9.37, -2.94]	
Park et al., 2013 (119) Prathibha et al., 2013 (126)	0.0128 3.756	0.0022	10 6	0.0155 4.978	0.0033	10 6	1.1%	-0.92 [-1.85, 0.01] -2.67 [-4.40, -0.94]	
ou et al., 2019 [128]	12,376.571	1,158.186	8	17,116.462	1,631.455	8	0.9%	-3.17 [-4.77, -1.57]	
Roede et al., 2008 [131] Roede et al., 2009 [132]	1,297.715 1,305.953	289.72 262.909	8	1,696.98 1,707.561	241.362 214.43	8	1.1%	-1.42 [-2.55, -0.28] -1.58 [-2.75, -0.42]	
Rong et al., 2012 [133]	0.782	0.873	12	0.98	0.424	12	1.1%	-0.28 [-1.08, 0.53]	-+
Ronis et al., 2004 (134) Ronis et al., 2010 (135)	0.0026 0.0148	0.00051	8 18	0.0036	0.00042 0.00194	8 15	1.0% 1.1%	-2.02 [-3.29, -0.75] -3.07 [-4.11, -2.02]	
Saravanan, 2007 (137) Saravanan and Nalini, 2007 (129)	10,020	390	10	17,640	370	10	0.2%	-19.20 [-25.90, -12.50]	
Saravanan and Nalini, 2007 [[138] Sathiavelu et al., 2009 [139]	10,020 11,780	390 830	10 8	17,640 18,360	370 1,290	10 8	0.2% 0.7%	-19.20 [-25.90, -12.50] -5.74 [-8.23, -3.25]	
enthilkumar et al., 2004 (140) Sheam et al., 2014 (142)	98.6	5.6 0.00016	10	174.8	14.6	10	0.8%	-6.60 [-9.05, -4.16] -2.03 [-3.54, -0.53]	
henbagam and Nalini, 2010 [143]	10,000	700	6	17,500	1,200	ь 6	0.5%	-7.05 [-10.67, -3.43]	
3mathers et al., 2013 (145) 3ong et al., 2006 (147)	2,516 0.00909	384.57 0.0035	6 6	3,367 0.02915	585.428 0.00613	6 6	1.0%	-1.59 [-2.96, -0.21] -3.71 [-5.85, -1.57]	
udha et al., 2012 [151]	53.557	0.001	6	66.153	0.001	6	0.0%	-11627.08 [-17303.00, -5951.16]	<u>:</u>
ahir et al., 2013 [153] ang et al., 2012 [155]	0.28 0.00412	0.049 0.00093	6 8	0.64 0.00804	0.024 0.00098	6 8	0.4% 0.9%	-8.61 [-12.97, -4.26] -3.88 [-5.71, -2.05]	·
ang et al., 2014 (156)	0.26818	0.01642	8	0.79047	0.02182	8	0.1%	-25.57 [-35.83, -15.32]	•
'ang et al., 2014 (157) Vang et al., 2020 (167)	0.06117 23,089.521	0.01143 7,656.679	12	0.09131 45,456.012	0.00259 7,882.243	12	1.0% 1.0%	-3.51 [-4.86, -2.16] -2.72 [-4.18, -1.26]	
Vang et al., 2022 [171]	344,320	21,610	10	550,750	39,000	10	0.8%	-6.27 [-8.61, -3.93]	——
(iao et al., 2017 [179] (iao et al., 2020 [180]	0.00399 0.00366	0.00079 0.00042	10	0.00652 0.00536	0.00126 0.00061	10	1.0% 1.0%	-2.30 [-3.49, -1.12] -3.07 [-4.64, -1.50]	
'alçinkaya et al., 2007 (182)	0.02727	0.00144	8	0.02787	0.0015	6	1.1%	-0.38 [-1.46, 0.69]	+
'an and Yin, 2007 [183] 'ang et al., 2013 [184]	0.0105 0.00427	0.0014 0.00044	15 5	0.0228 0.00563	0.0021 0.00072	15 5	0.9% 0.9%	-6.71 [-8.66, -4.75] -2.06 [-3.76, -0.36]	
ang et al., 2021 [185]	0.01389	0.00339	10	0.02378	0.00793	10	1.1%	-1.55 [-2.58, -0.53]	
ang et al., 2022 [186] ao et al., 2007 [187]	5.112 0.094	0.344 0.013	10	7.834	0.833	10	0.9% 0.8%	-4.09 [-5.76, -2.43] -4.60 [-6.68, -2.52]	
eh et al., 2020 [188]	0.01885	0.00561	10	0.02511	0.01432	10	1.1%	-0.55 [-1.45, 0.35]	-+
oon et al., 2012 (189) ou et al., 2010 (190)	0.00323 9.8	0.00204	8	0.00921	0.00291	8	1.0% 0.9%	-2.25 [-3.58, -0.92] -3.62 [-5.37, -1.88]	
(ahid et al., 2018 [196]	1.96	0.246	5	5.73	0.335	5	0.2%	-11.59 [-18.23, -4.95]	←
leng et al., 2013 [197] Chang et al., 2014 [199]	0.00653	0.00162	10	0.00851	0.00078	10	1.1% 0.9%	-1.49 [-2.51, -0.47] -3.85 [-5.68, -2.03]	
(hang et al., 2015 (200)	0.00821	0.00163	3	0.01204	0.00222	3	0.8%	-1.57 [-3.78, 0.63]	+
(hao et al., 2008 (204) (hao et al., 2018 (205)	0.02046 0.496	0.00251 0.048	8 10	0.02499	0.00325	8 10	1.0%	-1.47 [-2.62, -0.33] -3.50 [-4.99, -2.00]	
(hao et al., 2021 [206]	0.00186	0.00017	6	0.00281	0.0003	6	0.8%	-3.60 [-5.69, -1.51]	<u> </u>
(hou et al., 2002 [210] (hou et al., 2018 [211]	0.00716 3.963	0.00031 0.726	5 10	0.00894 5.932	0.00058 1.442	5 10	0.8% 1.1%	-3.46 [-5.76, -1.15] -1.65 [-2.70, -0.61]	
(hou et al., 2021 [212]	0.00071	0.00007	12	0.00125	0.00012	12	0.9%	-5.31 [-7.13, -3.48]	<u> </u>
(hou et al., 2022 [213] Subtotal (95% Cl)	0.00069	0.00004	12 1047	0.00125	0.00013	12 1002	0.9% 100.0%	-5.62 [-7.54, -3.71] -3.20 [-3.55, -2.85]	
leterogeneity: Tau# = 2.78; Chi# = 74		< 0.00001); I² = 8							
est for overall effect: Z = 17.68 (P < 0	J.UOOO1)								
otal (95% CI)			1047			1002	100.0%	-3.20 [-3.55, -2.85]	· · · · · · · · · · · · · · · · · · ·
leterogeneity: Tau ² = 2.78; Chi ² = 74									

Figure 7. The evidence suggests a decrease in reduced glutathione (GSH) in the liver tissue of animals with alcoholic fatty liver disease (AFLD) compared with healthy controls. This is supported by the forest plot, which shows a significant reduction in GSH (p < 0.05 for each), with 95% confidence intervals (Cl) reported.

		AFLD		C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Chen et al., 2013 [30]	7.7	1.4	6	10.8	1.3	6	6.6%	-3.10 [-4.63, -1.57]	+
Colontoni et al., 2000 [35]	7.4286	5.243	28	11.8829	3.4243	28	5.8%	-4.45 [-6.77, -2.13]	+
Das et al., 2012 [39]	6.7727	14.6333	18	13.063	13.222	6	0.8%	-6.29 [-18.85, 6.26]	
Dou et al., 2013 [42]	2.197	0.551	6	4.938	0.367	6	7.4%	-2.74 [-3.27, -2.21]	•
Feng et al., 2019 [45]	16.997	5.706	8	86.886	9.814	8	1.7%	-69.89 [-77.76, -62.02]	•
Galligan et al., 2012 [46]	15.9653	18.2077	18	17.8327	23.543	18	0.7%	-1.87 [-15.62, 11.88]	
Lee et al., 2020 [78]	2.217	0.187	20	5.424	0.245	20	7.5%	-3.21 [-3.34, -3.07]	-
Li et al., 2016 [82]	4.686	0.8	12	8.297	0.708	12	7.3%	-3.61 [-4.22, -3.01]	•
Liu et al., 2014 [92]	39.115	10.927	7	96.058	18.376	7	0.5%	-56.94 [-72.78, -41.11]	
Liu et al., 2015 [93]	55.53	8.654	8	113.221	8.414	8	1.6%	-57.69 [-66.05, -49.33]	
Liu et al., 2022 [95]	11.111	2.663	9	19.869	3.24	9	5.3%	-8.76 [-11.50, -6.02]	+
Liu et al., 2022 [96]	618.275	134.925	8	924.284	83.078	8	0.0%	-306.01 [-415.81, -196.21]	•
Lu et al., 2020 [99]	4.26	0.268	5	5.18	0.313	5	7.4%	-0.92 [-1.28, -0.56]	
Peng et al., 2011 (123)	8.6	2.6	10	8.9	1.6	10	6.3%	-0.30 [-2.19, 1.59]	+
Peng et al., 2013 [124]	21.2	6.008	10	26.9	8.854	10	2.2%	-5.70 [-12.33, 0.93]	
Rabelo et al., 2018 [129]	19.551	9.4998	15	9.2752	7.3337	13	2.4%	10.28 [4.03, 16.52]	
Ronis et al., 2004 [134]	10	9	8	18	5	8	2.0%	-8.00 [-15.13, -0.87]	
Shearn et al., 2014 [142]	3.688	0.779	6	5.935	0.669	6	7.2%	-2.25 [-3.07, -1.43]	•
Smathers et al., 2013 [145]	16.423	3.322	6	19.435	3.187	6	4.3%	-3.01 [-6.70, 0.67]	
Varghese et al., 2016 [161]	0.7933	0.4104	12	0.997	0.001	12	7.5%	-0.20 [-0.44, 0.03]	4
Xiao et al., 2017 [179]	1.673	0.341	10	3.086	0.87	10	7.3%	-1.41 [-1.99, -0.83]	•
Xiao et al., 2020 [180]	1.757	0.312	8	2.884	0.46	8	7.4%	-1.13 [-1.51, -0.74]	•
Yan and Yin, 2007 [183]	9.906	10.769	15	69.091	30	15	0.5%	-59.18 [-75.32, -43.05]	←
Zhou et al., 2002 [210]	28.269	11.029	5	53.714	41.918	5	0.1%	-25.45 [-63.44, 12.55]	
Total (95% CI)			258			244	100.0%	-5.09 [-6.28, -3.91]	•
Heterogeneity: Tau ² = 4.86; C	≿hi ² = 1233.	.58, df = 23	3 (P < 0	.00001); I ^z	= 98%			-	-50 -25 0 25 50
Test for overall effect: Z = 8.4	5 (P < 0.00	001)							-50 -25 0 25 50 AFLD Control

Figure 8. Analysis of the reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio in the livers of rats with AFLD and control groups. The forest plot shows that the AFLD groups had reduced GSH/GSSG ratios compared with the control group (p < 0.05 for each), with 95% confidence intervals (Cl) reported.

Oxidative Damage in AFLD

Lipid Peroxidation

With regard to lipid peroxidation, 158 articles included analyses of Thiobarbituric Acid Reactive Substances (TBARS), Malondialdehyde (MDA), Lipoperoxidation (LPO), and Lipid Hydroperoxides (LOOH). The data from these articles were combined, and the units were converted to nmol/mg. The results demonstrate that there was an increase in peroxidation in AFLD groups compared with control groups (SMD: 3.85, 95% CI 3.52, 4.19, *p* < 0.00001). There was high heterogeneity among the articles ($I^2 = 86\%$, *p* < 0.00001) (Figure 9).

Carbonylated Protein

A total of 11 articles analyzed protein carbonyl in the livers of animals with AFLD or healthy controls. There was high heterogeneity among the studies ($I^2 = 85\%$), although all were converted to the same measurement unit (nmol/mg). When statistically analyzed, it was evident that there was a greater amount of carbonyl protein in AFLD groups compared with control groups (MD: 4.02, 95% CI 3.03, 5.00, p < 0.00001) (Figure 10).




Figure 9. Analysis of lipid peroxidation in the livers of rats with AFLD and healthy controls. The forest plot shows that AFLD groups had increased lipid peroxidation compared with control groups (p < 0.05 for each), with 95% confidence intervals (Cl) reported.

	AFLD		0	Control			Mean Difference	Mear	Difference	
Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Rar	idom, 95% Cl	
20.936	2.157	6	2.668	0.902	6	7.4%	18.27 [16.40, 20.14]			•
0.00413	0.000359	6	0.002384	0.000206	6	10.0%	0.00 [0.00, 0.00]		+	
3.06	0.29	8	0.83	0.08	8	10.0%	2.23 [2.02, 2.44]			
2.55	0.12	6	0.72	0.04	6	10.0%	1.83 [1.73, 1.93]			
2.4	0.6	5	1.3	0.2	5	9.7%	1.10 [0.55, 1.65]			
24.98	2.376	6	7.24	0.686	6	7.1%	17.74 [15.76, 19.72]			•
3.478	0.5377	15	2.547	0.6267	13	9.8%	0.93 [0.49, 1.37]		-	
3.8	0.36	6	0.88	0.08	6	9.9%	2.92 [2.62, 3.22]			
4.977	0.577	8	3.491	0.826	6	9.4%	1.49 [0.71, 2.26]			
7.204	2.853	10	4.556	1.803	10	6.9%	2.65 [0.56, 4.74]			
3.072	0.646	5	1.151	0.308	5	9.6%	1.92 [1.29, 2.55]		-	
		81			77	100.0%	4.02 [3.03, 5.00]		•	
:831.76, df 0.00001)	= 10 (P < 0	00001;	; I ² = 100%					-10 -5	0 5	10
	20.936 0.00413 3.06 2.55 2.4 24.98 3.478 3.8 4.977 7.204 3.072 831.76, df	Mean SD 20.936 2.157 0.00413 0.000359 3.06 0.29 2.55 0.12 2.4 0.6 24.98 2.376 3.478 0.5377 3.8 0.36 4.977 0.577 7.204 2.853 3.072 0.646 :831.76, df = 10 (P < 0.	Mean SD Total 20.936 2.157 6 0.00413 0.00359 6 3.06 0.29 8 2.55 0.12 6 2.4 0.6 5 24.98 2.376 6 3.478 0.65377 16 3.8 0.36 6 4.977 0.577 8 7.204 2.853 10 3.072 0.646 5 981.76, df = 10 (P < 0.00001)	Mean SD Total Mean 20.936 2.157 6 2.668 0.00413 0.00359 6 0.02384 3.06 0.29 8 0.83 2.55 0.12 6 0.72 2.4 0.6 5 1.3 24.98 2.376 6 7.24 3.8 0.36 6 0.88 4.977 0.577 8 3.491 7.204 2.863 10 4.556 3.072 0.646 5 1.151 81.76, df = 10 (P < 0.00001); I ^p = 100% 10 15	Mean SD Total Mean SD 20.936 2.157 6 2.668 0.902 0.00413 0.000359 6 0.002384 0.000208 3.06 0.29 8 0.83 0.008 2.55 0.12 6 0.72 0.04 2.4 0.6 5 1.3 0.2 24.98 2.376 6 7.24 0.686 3.478 0.5377 15 2.547 0.6267 3.8 0.36 6 0.88 0.088 4.977 0.577 8 3.491 0.826 7.204 2.853 10 4.556 1.803 3.072 0.646 5 1.151 0.308	Mean SD Total Mean SD Total 20.936 2.157 6 2.668 0.902 6 0.00413 0.000359 6 0.002384 0.000206 6 3.06 0.29 8 0.83 0.004 6 2.55 0.12 6 0.72 0.04 6 2.498 2.376 6 7.24 0.686 6 3.478 0.5377 15 2.547 0.6267 13 3.8 0.36 6 0.88 0.088 6 4.977 0.577 8 3.491 0.826 6 7.204 2.853 10 4.556 1.803 10 3.072 0.646 5 1.151 0.308 5 81 77 81 77	Mean SD Total Mean SD Total Weight 20.936 2.157 6 2.668 0.902 6 7.4% 0.00413 0.00359 6 0.002384 0.00206 6 10.0% 3.06 0.29 8 0.83 0.08 8 10.0% 2.55 0.12 6 0.72 0.04 6 10.0% 2.4 0.6 5 1.3 0.2 5 9.7% 24.98 2.376 6 7.24 0.686 6 7.1% 3.478 0.5377 15 2.547 0.6267 13 9.8% 3.8 0.36 6 0.88 0.08 6 9.9% 4.977 0.577 8 3.491 0.826 6 9.4% 7.204 2.853 10 4.556 1.803 10 6.9% 3.072 0.646 5 1.151 0.308 5 9.6%	Mean SD Total Mean SD Total Weight V, Random, 95% C1 20.936 2.157 6 2.668 0.902 6 7.4% 18.27 [16.40, 20.14] 0.00413 0.00359 6 0.002384 0.00206 6 10.0% 0.00 [0.00, 0.00] 3.06 0.29 8 0.83 0.08 8 10.0% 2.23 [2.02, 2.44] 2.55 0.12 6 0.72 0.04 6 10.0% 1.83 [1.73, 1.93] 2.4 0.6 5 1.3 0.2 5 9.7% 1.10 [0.55, 1.65] 24.98 2.376 6 7.24 0.686 6 7.1% 17.74 [15.76, 19.72] 3.478 0.5377 15 2.547 0.6267 13 9.8% 0.93 [0.49, 1.37] 3.8 0.36 6 0.88 0.08 6 9.4% 1.49 [0.71, 2.26] 7.204 2.853 10 4.556 1.803 10 6.9% 2.65 [0.56,	Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Rar 20.936 2.157 6 2.668 0.902 6 7.4% 18.27 [16.40, 20.14] 0.00413 0.000359 6 0.002384 0.000206 6 10.0% 0.00 [0.00, 0.00] 3.06 0.29 8 0.83 0.008 8 10.0% 2.23 [2.02, 2.44] 2.55 0.12 6 7.24 0.686 6 7.1% 1.10 [0.55, 1.65] 24 0.6 5 1.3 0.2 5 9.7% 1.10 [0.55, 1.65] 24.98 2.376 6 7.24 0.686 6 7.1% 17.74 [15.76, 19.72] 3.478 0.5377 15 2.547 0.6267 13 9.8% 0.03 [0.49, 1.37] 3.8 0.38 6 0.88 0.08 6 9.9% 2.92 [2.62, 3.22] 4.977 0.577 8 3.491 0.826 6 9.4% <td>Mean SD Total Mean SD Total Weight V, Random, 95% CI V, Random, 95% CI 20.936 2.157 6 2.668 0.902 6 7.4% 18.27 [16.40, 20.14] 0.00413 0.00359 6 0.002384 0.000206 6 10.0% 0.00 [0.00, 0.00] 0.00 0.00 0.00 1.0 1.0 0.00 [0.00, 0.00] 0.00 1.0 1.0 0.00 1.0 1.0 0.00 0.00 1.0<!--</td--></td>	Mean SD Total Mean SD Total Weight V, Random, 95% CI V, Random, 95% CI 20.936 2.157 6 2.668 0.902 6 7.4% 18.27 [16.40, 20.14] 0.00413 0.00359 6 0.002384 0.000206 6 10.0% 0.00 [0.00, 0.00] 0.00 0.00 0.00 1.0 1.0 0.00 [0.00, 0.00] 0.00 1.0 1.0 0.00 1.0 1.0 0.00 0.00 1.0 </td

Figure 10. Analysis of protein carbonyl in the livers of rats with AFLD and healthy controls. The forest plot shows that AFLD groups had increased protein carbonyl levels compared with control groups (p < 0.05 for each), with 95% confidence intervals (Cl) reported.

3.3.5. Inflammation in AFLD

Tumor Necrosis Factor- α (TNF- α)

A total of 66 manuscripts focused on TNF- α . Among these, 50 assessed the effect of TNF- α on the liver, with 14 of them using pg/mL and the remaining 36 using pg/mg for measurements. In addition, 19 manuscripts evaluated TNF- α levels in serum/plasma, and all measurements were taken in pg/mL. Thus, the analysis was carried out using two subgroups, with an increase of TNF- α being evidenced in all subgroups of the AFLD group. When the subgroups were analyzed together, it was possible to confirm the increase in TNF- α in the AFLD group (SMD: 3.81, 95% CI 3.29, 4.34, *p* < 0.00001) (Supplementary Figure S9).

Interleukin 1 beta (IL-1 β)

A total of 41 articles quantified IL-1 β in the liver (10 in pg/mL and 23 in pg/mg) and 9 in serum/plasma (pg/mL). Thus, we performed the analysis using two subgroups. The forest plot shows that IL-1 β increased in AFLD groups compared with control groups for both liver and serum/plasma. The SMD was 3.69, 95% CI 3.03, 4.35, *p* < 0.00001 (Supplementary Figure S10).

Interleukin-6 (IL-6)

A total of 43 manuscripts measured IL-6; of these, 32 performed the analysis in the liver (10 measured it in pg/mL and 22 in pg/mg), and 13 performed it in serum/plasma (pg/mL). Although the analysis was conducted in two subgroups, the heterogeneity among the studies was high ($I^2 = 88\%$, p < 0.00001). With regard to the effects, it was possible to observe an increase in IL-6 levels in AFLD groups compared with control groups for both liver and serum/plasma (SMD: 4.79, 95% CI 3.99, 5.60, p < 0.00001) (Supplementary Figure S11).

Interleukin-10 (IL-10)

Seven manuscripts measured IL-10; of these, four performed the analysis in the liver (measured it in pg/mg), and three performed it in serum (pg/mL). Although the analysis was conducted using three subgroups, the heterogeneity among the studies was high ($I^2 = 89\%$, p < 0.00001). With regard to the effects, it was possible to observe that there was no difference between the AFLD and control groups, neither in the subgroup analysis nor in the overall analysis (SMD: -0.32, 95% CI -1.69, 1.06, p = 0.65) (Supplementary Figure S12).

Histological Analysis of the Liver

Fourteen articles examined the presence of inflammation in liver histological slides, with 4 measuring the number of inflammatory cells and 10 using an inflammation score.

Statistical analysis revealed a greater degree of inflammation in AFLD groups compared with control groups (SMD: 2.27, 95% CI 1.37, 3.17, p < 0.00001) (Supplementary Figure S13).

3.3.6. Apoptosis in AFLD Caspase-3

Eighteen manuscripts analyzed caspase-3 in the liver of animals with or without AFLD. Of these, 14 performed protein expression and 4 measured activity (pmol/mg/min). There was high heterogeneity among the studies ($I^2 = 83\%$). With regard to the effects, it was observed that AFLD groups exhibited increased caspase-3 expression and activity compared with control groups. This suggests an increased occurrence of cell death following ethanol consumption. (SMD: 5.58, 95% CI 4.22, 6.94, p < 0.00001) (Supplementary Figure S14).

BCL-2-Associated Protein X (BAX)/B-Cell CLL/Lymphoma 2 (BCL-2) Ratio

A total of 13 articles quantified the Bax/Bcl-2 ratio. There was moderate heterogeneity among the studies ($I^2 = 65\%$). With regard to the statistical analysis, there was a significant increase in Bax/Bcl-2 ratios in AFLD groups compared with control groups (MD: 2.50, 95% CI 1.74, 3.26, p < 0.00001) (Supplementary Figure S15). These data suggest that the utilization of ethanol triggers cell death in hepatocytes.

3.3.7. Risk of Bias in Individual Studies

In our systematic review, we employed the SYRCLE scale, as described in the Materials and Methods section, to assess the risk of bias for each primary study. A comprehensive set of 206 manuscripts was included in our analysis. Upon evaluation, we noted that there was a moderate risk of bias, as evidenced by the questions receiving responses of Unclear (1337 = 64.9%), Yes (630 = 30.6%), and No (93 = 4.4%) (Table 2).

	Sel	ection Bi	as	Perforn	nance Bias	Detecti	on Bias	Attrition Bias	Reporting Bias	Other
Author and Year	1	2	3	4	5	6	7	8	9	10
Abdelhamid et al., 2020 [10]	Y	U	U	Y	U	U	U	Y	Y	Y
Abdelhamid et al., 2021 [11]	Y	U	U	Y	U	U	U	Y	Y	Y
Al-Rejaie, 2012 [12]	Y	U	U	U	U	U	U	Y	Y	U
Atef et al., 2018 [13]	Y	U	U	Y	U	U	U	Y	Y	Y
Bae et al., 2015 [14]	Y	U	U	Y	U	U	U	Y	Y	Y
Balasubramaniyan et al., 2003 [15]	U	U	U	Y	U	U	U	Ν	Y	U
Baranisrinivasan et al., 2009 [16]	Y	U	U	U	U	U	U	Y	Y	U
Bardag-Gorce et al., 2011 [17]	U	U	U	U	U	U	U	Y	Y	U
Bhakuni et al., 2017 [18]	Y	U	U	U	U	U	U	Y	Y	U
Bharrhan et al., 2011 [19]	Y	U	U	U	U	U	U	Ν	Y	Y
Bisht et al., 2018 [20]	U	U	U	U	U	U	U	Y	Y	Y
Bispo et al., 2017 [21]	U	U	U	U	U	U	U	Y	Y	U
Buko et al., 2019 [22]	U	U	U	U	U	U	U	Y	Y	Y
Bulle et al., 2015 [23]	U	U	U	U	U	U	U	Y	Y	U
Cao et al., 2015 [24]	Y	U	U	Y	U	U	U	Ν	Y	U
Chandra et al., 2000 [25]	U	U	U	U	U	U	U	Y	Y	U
Chang et al., 2017 [26]	Y	U	U	Y	U	Y	U	Ν	Y	Y
Chang et al., 2021 [27]	U	U	U	U	U	U	U	Ν	Y	Y
Chaturvedi et al., 2007 [28]	U	U	U	U	U	U	U	Y	Y	U

Table 2. Risk of bias in the included studies.

	Sel	ection Bi	as	Perform	ance Bias	Detecti	on Bias	Attrition Bias	Reporting Bias	Other
Author and Year	1	2	3	4	5	6	7	8	9	10
Chavan et al., 2017 [29]	Y	U	U	U	U	U	U	Y	Y	Y
Chen et al., 2013 [30]	Ν	Y	U	Y	U	U	U	N	Y	Y
Chen et al., 2016 [31]	U	U	U	Y	U	U	U	Ν	Y	Y
Cheng and Khong, 2011 [32]	U	U	U	U	U	U	U	Y	Y	U
Chiu et al., 2011 [33]	Y	U	U	U	U	U	U	Y	Y	Y
Chu et al., 2021 [34]	U	U	U	U	U	U	U	Ν	Y	U
Colontoni et al., 2000 [35]	Ν	Y	U	U	U	U	U	Y	Y	U
Cui et al., 2014 [36]	Y	U	U	U	U	U	U	Ν	Y	U
Cui et al., 2014 [37]	Y	U	U	U	U	U	U	Ν	Y	U
Das et al., 2007 [38]	U	U	U	U	U	U	U	Y	Y	U
Das et al., 2012 [39]	Y	U	U	U	U	U	U	Ν	Y	Y
De Souza et al., 2015 [40]	U	U	U	Y	U	U	U	Ν	Y	U
Develi et al., 2014 [41]	U	U	U	U	U	U	U	Y	Y	Y
Dou et al., 2013 [42]	U	U	U	U	U	U	U	Y	Y	Y
Du et al., 2015 [43]	U	U	U	U	U	U	U	Ν	Y	Y
Duryee et al., 2018 [44]	U	U	U	U	U	U	U	Ν	Y	U
Feng et al., 2019 [45]	Y	U	U	Y	U	U	U	Y	Y	Y
Galligan et al., 2012 [46]	U	U	U	U	U	U	U	Ν	Y	U
Gao et al., 2021 [47]	Y	U	U	Y	U	U	U	Y	Y	Y
George and Chaturvedi, 2009 [48]	Y	U	U	U	U	U	U	Y	Y	Y
Gustot et al., 2006 [49]	U	U	U	U	U	U	U	Ν	Y	U
Han et al., 2021 [50]	Y	U	U	U	U	U	U	Y	Y	Y
Hao et al., 2018 [51]	U	U	U	U	U	U	U	Y	Y	Y
Hao et al., 2021 [52]	U	U	U	U	U	U	U	Y	Y	U
Hasanein and Seifi, 2018 [53]	Y	U	U	U	U	U	U	Y	Y	Y
He et al., 2021 [54]	U	U	U	U	U	U	U	Y	Y	U
Hsu et al., 2018 [55]	Y	U	U	U	U	U	U	Ν	Y	Y
Hu et al., 2021 [56]	Y	U	U	U	U	U	U	Ν	Y	Y
Huang et al., 2017 [57]	Y	U	U	U	U	U	U	Ν	Y	Y
Ilaiyaraja and Khanum, 2011 [58]	Y	U	U	U	U	U	U	Y	Y	Y
Jayaraman et al., 2009 [59]	U	U	U	U	U	U	U	Y	Y	Y
Jiang et al., 2016 [60]	Y	U	U	U	U	U	U	Y	Y	Y
Jiang et al., 2019 [61]	Y	U	U	Y	U	U	U	Y	Y	Y
Jin et al., 2010 [62]	U	U	U	U	U	U	U	Y	Y	U
Jose et al., 2018 [63]	Y	U	U	U	U	U	U	N	Y	N
Kanbak et al., 2001 [64]	U	U	U	Y	U	U	U	Y	Y	U
Kanchana and Jayapriya, 2013 [65]	U	U	U	U	U	U	U	Y	Y	U
Kang et al., 2010 [66]	U	U	U	U	U	U	U	N	Y	U
Kang et al., 2021 [67]	U	U	U	U	U	U	U	Y	Y	Y
Kaviarasan et al., 2008 [68]	Y	U	U	U	U	U	U	Y	Y	Y
Khanal et al., 2009 [69]	U	U	U	U	U	U	U	Y	Y	Y
Kim et al., 2012 [70]	U	U	U	U	U	U	U	N	Y	Y

	Sel	ection Bi	as	Perform	ance Bias	Detecti	on Bias	Attrition Bias	Reporting Bias	Other
Author and Year	1	2	3	4	5	6	7	8	9	10
Kim et al., 2016 [71]	Y	U	U	U	U	U	U	Y	Y	Y
Kumar et al., 2019 [72]	Y	U	U	U	U	U	U	Y	Y	Y
Lai et al., 2019 [73]	Y	U	U	U	U	U	U	Y	Y	Y
Lee et al., 2015 [74]	U	U	U	U	U	U	U	Y	Y	U
Lee et al., 2016 [75]	U	U	U	U	U	U	U	Y	Y	U
Lee et al., 2016 [76]	Y	U	U	U	U	U	U	Y	Y	Y
Lee et al., 2020 [77]	Y	U	U	U	U	U	U	Ν	Y	Y
Lee et al., 2020 [78]	Y	U	U	U	U	U	U	Ν	Y	Y
Lee et al., 2021 [79]	Ν	Y	U	Y	U	U	U	Y	Y	Y
Li et al., 2013 [80]	Y	U	U	U	U	U	U	Y	Y	Y
Li et al., 2015 [81]	Y	U	U	U	U	U	U	Y	Y	U
Li et al., 2016 [82]	Y	U	U	U	U	U	U	Ν	Y	Y
Li et al., 2017 [83]	Y	U	U	U	U	U	U	Ν	Y	Y
Li et al., 2018 [84]	Ν	Y	U	U	U	U	U	Y	Y	Y
Li et al., 2021 [85]	Ν	Y	U	U	U	U	U	Y	Y	Y
Li et al., 2021 [86]	Ν	Y	U	U	U	U	U	Y	Y	Y
Li et al., 2021 [87]	U	U	U	U	U	U	U	Y	Y	Y
Li et al., 2021 [88]	Y	U	U	Y	U	U	U	Y	Y	Y
Lian et al., 2010 [89]	Y	U	U	U	U	U	U	Y	Y	U
Lin et al., 2017 [90]	U	U	U	U	U	U	U	Y	Y	Y
Lin et al., 2021 [91]	Y	U	U	Y	U	U	U	Y	Y	Y
Liu et al., 2014 [92]	Y	U	U	Y	U	U	U	Ν	Y	Y
Liu et al., 2015 [93]	Y	U	U	U	U	U	U	Ν	Y	Y
Liu et al., 2020 [94]	Y	U	U	U	U	U	U	Ν	Y	Y
Liu et al., 2022 [95]	Y	U	U	U	U	U	U	Y	Y	Y
Liu et al., 2022 [96]	Y	U	U	U	U	U	U	Ν	Y	Y
Lu et al., 2014 [97]	Y	U	U	Y	U	U	U	Ν	Y	U
Lu et al., 2015 [98]	Y	U	U	U	U	U	U	Y	Y	Y
Lu et al., 2020 [99]	Ν	Y	U	Y	U	U	U	Y	Y	Y
Ma et al., 2007 [100]	U	U	U	U	U	U	U	Y	Y	U
Madushani Herath et al., 2018 [101]	U	U	U	U	U	U	U	Y	Y	Y
Mai et al., 2022 [102]	Y	U	U	U	U	U	U	N	Y	Ν
Maimaitimin et al., 2018 [103]	Y	U	U	U	U	U	U	Y	Y	U
Mallikarjuna et al., 2008 [104]	U	U	U	Y	U	U	U	Y	Y	U
Mandal et al., 2013 [105]	U	U	U	U	U	U	U	Y	Y	Y
Mehanna et al., 2021 [106]	Y	U	U	U	U	U	U	Ν	Y	Y
Meng et al., 2020 [107]	Y	U	U	U	U	U	U	Y	Y	Y
Miñana et al., 2002 [108]	U	U	U	U	U	U	U	Ν	Y	U
Ming et al., 2021 [109]	Y	U	U	U	U	U	U	Y	Y	Y
Mohan et al., 2019 [110]	Y	U	U	U	U	U	U	Ν	Y	Ν
Nagappan et al., 2018 [111]	Y	U	U	U	U	U	U	Ν	Y	Y
Nie et al., 2021 [112]	Y	U	U	U	U	U	U	Y	Y	Y
Nie et al., 2022 [113]	Y	U	U	U	U	U	U	Y	Y	Y
Oh et al., 2002 [114]	Ν	Y	U	Y	U	U	U	Y	Y	U

Author and Varia	Sel	ection Bi	as	Perform	ance Bias	Detecti	on Bias	Attrition Bias	Reporting Bias	Other
Author and Year	1	2	3	4	5	6	7	8	9	10
Osaki et al., 2016 [115]	U	U	U	U	U	U	U	Y	Y	U
Panda et al., 2012 [116]	Y	U	U	U	U	U	U	Y	Y	U
Panda et al., 2015 [117]	Y	U	U	U	U	U	U	Y	Y	U
Pari and Suresh, 2008 [118]	Y	U	U	U	U	U	U	Y	Y	Y
Park et al., 2013 [119]	Y	U	U	Y	U	U	U	Y	Y	Y
Park et al., 2017 [120]	Y	U	U	U	U	U	U	Y	Y	Y
Park et al., 2019 [121]	Y	U	U	U	U	U	U	Y	Y	Y
Patere et al., 2011 [122]	Y	U	U	U	U	U	U	Y	Y	U
Peng et al., 2011 [123]	Ν	Y	U	Y	U	U	U	Y	Y	U
Peng et al., 2013 [124]	Ν	Y	U	U	U	U	U	Y	Y	Y
Pi et al., 2021 [125]	Y	U	U	U	U	U	U	Ν	Y	Y
Prathibha et al., 2013 [126]	Ν	Y	U	U	U	U	U	Y	Y	U
Qi et al., 2017 [127]	U	U	U	U	U	U	U	Y	Y	Y
Qu et al., 2019 [128]	Y	U	U	U	U	U	U	Ν	Y	U
Rabelo et al., 2018 [129]	U	U	U	U	U	U	U	U	Y	Y
Rejitha et al., 2012 [130]	N	Y	U	U	U	U	U	Y	Y	Y
Roede et al., 2008 [131]	U	U	U	U	U	U	U	Ν	Y	U
Roede et al., 2009 [132]	U	U	U	U	U	U	U	Ν	Y	U
Rong et al., 2012 [133]	Y	U	U	Y	U	U	U	Y	Y	U
Ronis et al., 2004 [134]	U	U	U	U	U	U	U	Ν	Y	U
Ronis et al., 2010 [135]	U	U	U	U	U	U	U	Ν	Y	U
Samuhasaneeto et al., 2009 [136]	Y	U	U	U	U	U	U	Y	Y	U
Saravanan, 2007 [137]	U	U	U	U	U	U	U	Y	Y	U
Saravanan and Nalini, 2007 [138]	U	U	U	U	U	U	U	Y	Y	U
Sathiavelu et al., 2009 [139]	U	U	U	U	U	U	U	Y	Y	Y
Senthilkumar et al., 2004 [140]	U	U	U	U	U	U	U	Y	Y	U
Shankari et al., 2010 [141]	Y	U	U	U	U	U	U	Y	Y	U
Shearn et al., 2014 [142]	U	U	U	U	U	U	U	Y	Y	U
Shenbagam and Nalini, 2010 [143]	U	U	U	U	U	U	U	Y	Y	U
Shi et al., 2018 [144]	Y	U	U	U	U	U	U	Ν	Y	Y
Smathers et al., 2013 [145]	U	U	U	U	U	U	U	Y	Y	U
Sönmez et al., 2012 [146]	Y	U	U	U	U	U	U	Y	Y	Y
Song et al., 2006 [147]	U	U	U	U	U	U	U	Y	Y	U
Song et al., 2018 [148]	Y	U	U	U	U	U	U	Y	Y	Y
Song et al., 2020 [149]	Y	U	U	U	U	U	U	Y	Y	Y
Song et al., 2021 [150]	Y	U	U	U	U	U	U	Y	Y	Y
Sudha et al., 2012 [151]	Y	U	U	U	U	U	U	Y	Y	U
Sun et al., 2016 [152]	U	U	U	U	U	U	U	N	Y	Y
Tahir et al., 2013 [153]	U	U	U	U	U	U	U	Y	Y	U
Tan et al., 2016 [154]	Ŷ	U	U	U	U	U	U	N	Y	N
Tang et al., 2012 [155]	Ŷ	U	U	U	U	U	U	Ŷ	Ŷ	Y
Tang et al., 2014 [156]	U	U	U	U	U	U	U	N	Ŷ	U
Tang et al., 2014 [157]	Y	U	U	U	U	U	U	N	Ŷ	Y
Tang et al., 2017 [158]	Y	U	U	U	U	U	U	Y	Ŷ	Ŷ

Author and Year	Selection Bias			Performance Bias		Detection Bias		Attrition Bias	Reporting Bias	Othe
	1	2	3	4	5	6	7	8	9	10
Tao et al., 2021 [159]	Y	U	U	U	U	U	U	Y	Y	Y
Valansa et al., 2020 [160]	Y	U	U	U	U	U	U	Y	Y	Y
Varghese et al., 2016 [161]	U	U	U	Y	U	U	U	Ν	Y	Y
Velvizhi et al., 2002 [162]	Y	U	U	U	U	U	U	Y	Y	U
Wang et al., 2014 [163]	Y	U	U	U	U	U	U	Y	Y	Y
Wang et al., 2015 [164]	Y	U	U	U	U	U	U	Y	Y	Y
Wang et al., 2016 [165]	Y	U	U	U	U	U	U	Y	Y	Y
Wang et al., 2018 [166]	Y	U	U	U	U	U	U	Y	Y	Y
Wang et al., 2020 [167]	Y	U	U	Y	U	U	U	Ν	Y	Y
Wang et al., 2020 [168]	Ν	Y	U	U	U	U	U	Ν	Y	Y
Wang et al., 2020 [169]	Y	U	U	Y	U	U	U	Ν	Y	Y
Wang et al., 2021 [170]	U	U	U	U	U	U	U	Y	Y	Y
Wang et al., 2022 [171]	Y	U	U	U	U	U	U	Y	Y	Y
Wang et al., 2022 [172]	U	U	U	U	U	U	U	N	Y	Y
Wang and Mu, 2021 [173]	U	U	U	U	U	U	U	N	Y	Y
Wei et al., 2013 [174]	U	U	U	U	U	U	U	Y	Y	Y
Wu et al., 2019 [175]	Y	U	U	U	U	U	U	N	Y	Y
Wu et al., 2019 [176]	Y	U	U	U	U	U	U	N	Y	Y
Xia et al., 2018 [177]	Y	U	U	U	U	U	U	N	Y	Y
Xiao et al., 2014 [178]	Y	U	U	U	U	U	U	Y	Y	Y
Xiao et al., 2017 [179]	Ŷ	U	U	Ŷ	U	U	U	N	Ŷ	Ŷ
Xiao et al., 2020 [180]	Y	U	U	Y	U	U	U	N	Ŷ	Y
Xu et al., 2021 [181]	Ŷ	U	U	U	U	U	U	N	Ŷ	Y
Yalçinkaya et al., 2007 [182]	U	U	U	U	U	U	U	Y	Ŷ	U
Yan and Yin, 2007 [183]	U	U	U	U	U	U	U	Y	Y	U
Yang et al., 2013 [184]	U	U	U	U	U	U	U	Y	Y	Y
Yang et al., 2021 [185]	<u> </u>	U	U	U	U	U	U	Y	Y	Y
Yang et al., 2022 [186]	Y	U	U	<u>- С</u> - Y	U	U	U	N	Y	Y
	Y	U	U	U	U	U	U	N	Y	U
Yao et al., 2007 [187] Yeh et al., 2020 [188]	Y	U	U	U	U	U	U	Y	Y	- U Y
	Y		U	U	U	U	U U	N I		
Yoon et al., 2012 [189]		U			U		U		Y	Y
You et al., 2010 [190]	U	U	U	U				Y	Y	Y
You et al., 2020 [191]	Y	U	U	U	U	U	U	N	Y	Y
Yu et al., 2019 [192]	U	U	U	U	U	U	U	N	Y	Y
Yu et al., 2021 [193]	Y	U	U	U	U	U	U	N	Y	U
Yuan et al., 2018 [194]	Y	U	U	U	U	U	U	Y	Y	Y
Yuan et al., 2020 [195]	U	U	U	U	U	U	U	N	Y	Y
Zahid et al., 2018 [196]	Y	U	U	U	U	U	U	Y	Y	Y
Zeng et al., 2013 [197]	Y	U	U	U	U	U	U	Y	Y	Y
Zhang et al., 2010 [198]	Y	U	U	U	U	U	U	Ν	Y	Y
Zhang et al., 2014 [199]	Y	U	U	U	U	U	U	Ν	Y	Y
Zhang et al., 2015 [200]	U	U	U	U	U	U	U	Ν	Y	U
Zhang et al., 2020 [201]	Y	U	U	U	U	U	U	Ν	Y	Y
Zhang et al., 2020 [202]	U	U	U	U	U	U	U	Y	Y	Y

Author and Year	Selection Bias			Performance Bias		Detection Bias		Attrition Bias	Reporting Bias	Other
	1	2	3	4	5	6	7	8	9	10
Zhang et al., 2021 [203]	Y	U	U	U	U	U	U	Ν	Y	Y
Zhao et al., 2008 [204]	U	U	U	U	U	U	U	Ν	Y	U
Zhao et al., 2018 [205]	Y	U	U	U	U	U	U	Y	Y	Y
Zhao et al., 2021 [206]	U	U	U	U	U	U	U	Ν	Y	Y
Zhao et al., 2021 [207]	Y	U	U	U	U	U	U	Ν	Y	Y
Zheng et al., 2019 [208]	Y	U	U	U	U	U	U	Y	Y	Y
Zheng et al., 2022 [209]	Y	U	U	U	U	U	U	Y	Y	Y
Zhou et al., 2002 [210]	U	U	U	U	U	U	U	Ν	Y	U
Zhou et al., 2018 [211]	Y	U	U	U	U	U	U	Ν	Y	U
Zhou et al., 2021 [212]	Y	U	U	U	U	U	U	Y	Y	Y
Zhou et al., 2022 [213]	Y	U	U	U	U	U	U	Y	Y	Y
Zhu et al., 2014 [214]	U	U	U	U	U	U	U	Y	Y	U
Zhu et al., 2021 [215]	Y	U	U	U	U	U	U	Y	Y	Y

Y = Yes, N = No, U = Unclear.

In addition, for all the analyzed parameters (including liver damage, lipid profile, oxidative stress, inflammation, and apoptosis) we conducted a risk analysis using more than 10 articles to identify publication bias. Our findings revealed considerable asymmetry in the funnel plot, as none conformed to the typical funnel shape, indicating potential bias in the publication of primary articles (see Supplementary Figure S16).

4. Discussion

To the best of our knowledge, this systematic review and meta-analysis is the first to provide a summary of the effects of ethanol metabolism on oxidative stress and examine the evidence of its impact on AFLD. Here, we used a compilation of 206 primary studies with rats and/or mice that induced AFLD with oral ethanol and measured different parameters related to pathological conditions of AFLD. The results indicated an increase in liver damage alongside alterations in the lipid profile. These data demonstrate an established model of AFLD that reflects an increase in oxidative stress and inflammatory processes and stimulates the death of hepatocytes by apoptotic processes.

It is known that ethanol metabolism in the liver involves oxidation reactions. Initially, ALD converts ethanol to acetaldehyde, generating NADH from NAD+ as an electron acceptor. In cases of high ethanol levels or chronic consumption, the microsomal ethanol oxidant system CYP2E1 contributes to acetaldehyde production. Subsequently, ALDH converts acetaldehyde to acetate, utilizing NAD+ and producing NADH. The decrease in the NAD+/NADH ratio from ethanol metabolism alters the body's homeostasis and generates serious disturbances [216]. Indeed, this review and meta-analysis showed that animals in the ALFD groups had higher CYP2E1 expression compared with control groups. This was also reflected in increased liver damage, as shown by an increase in ALT and AST activity.

Alcohol intake has been found to impact lipid metabolism through the increased expression of lipogenic genes (such as SREBP-1c and its target genes) and inhibition of genes involved in fatty acid oxidation (for example, PPAR and its target genes) [4,186]. These processes lead to several outcomes. First, increased acetyl-CoA-carboxylase and ATP citrate lyase activity, which contribute to fatty acid and TAG synthesis. Second, there is a concurrent reduction in the activity of lipoprotein lipase, which is the key enzyme responsible for TAG hydrolysis. Third, there is an increase in the activity of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, which is a key enzyme in the mevalonate pathway and cholesterol synthesis. Fourth, cholesterol accumulates, as evidenced by

elevated levels of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), while high-density lipoprotein (HDL) levels decrease [217]. These changes collectively contribute to the dysregulation of lipid metabolism and have implications for AFLD [6,186]. These characteristics were corroborated by our systematic review and meta-analysis, which revealed an elevation in both serum/plasma and liver TAG levels. Furthermore, our findings demonstrated a decrease in PPAR- α expression accompanied by an increase in SREBP-1c levels. These alterations collectively contributed to the notable presence of micro and macro fat vesicles within the hepatic histological sections of the examined experimental subjects.

The reoxidation of NADH to NAD+ in mitochondria has been associated with the leakage of electrons from the mitochondrial respiratory chain and subsequent production of ROS, thereby contributing to increased oxidative stress [7]. Normally, in a healthy liver, acetaldehyde is rapidly metabolized to acetate by ALDH. However, in individuals with chronic alcohol consumption, the ALDH pathway becomes overwhelmed and produces reactive aldehydes and lipid hydroperoxides. These harmful compounds can form adducts with DNA and proteins, contributing to hepatocyte damage and inflammation and exacerbating the negative effects of alcohol on the liver [2]. Notably, there is also CYP2E1-dependent ROS production, which has been shown to inhibit PPAR-mediated fatty acid oxidation genes and contribute to the oxidation of cellular components [218].

Under normal circumstances, the body depends on various endogenous antioxidant defense enzymes, including GR, SOD, CAT, and GPx, to neutralize the harmful effects of free radicals. However, individuals with AFLD undergo excessive production of free radicals and macromolecule oxidation induced by ethanol metabolism. This hampers the efficiency of the antioxidant defense system, exacerbating oxidative stress and thereby intensifying the overall pathogenesis of AFLD [6,219]. In addition, in AFLD, the transcription factor Nrf2 is impaired [220]. Under normal conditions, NRF2 is bound to KEAP1 and is degraded by the proteasome. However, during oxidative stress, ROS or electrophiles modify KEAP1, disrupting its binding to NRF2. This allows NRF2 to translocate to the nucleus and activate antioxidant response elements, leading to genetic transactivation [221].

This systematic review and meta-analysis confirmed the deleterious effects of ethanol metabolism. The evidence clearly indicated the presence of oxidative stress, as evidenced by a marked decline in antioxidant defense, including reduced levels of SOD, CAT, GPx, GR, GST, GSH, GSH/GSSG ratios, and Nrf2 transcription factor. In addition, we observed an elevated level of lipid peroxidation, as reflected by increased TBARS, MDA, LOOH, and protein carbonylation.

Studies have also shown that ROS contributes significantly to the development of ethanol-induced inflammation. One factor linking inflammation to oxidative stress is the depletion of mitochondrial GSH owing to CYP2E1 activation, which impairs hepatocyte tolerance to pro-inflammatory cytokines such as TNF- α and IL-1 β [2]. Oxidative stress caused by ethanol or acetaldehyde alters mitochondrial membrane permeability and transition potential. This leads to the release of cytochrome c and other pro-apoptotic factors, stimulating the intrinsic pathway of apoptosis and, consequently, the death of hepatocytes. These typical characteristics of AFLD were observed in this meta-analysis and were evident from the marked increase in pro-inflammatory cytokines (TNF- α , IL-1 β , and IL-6) and the heightened degree of inflammation observed in hepatic slides from animals with ALFD. We also observed upregulation in caspase-3 and Bax/Bcl2, which contributed to the hepatocyte death process. Ethanol metabolism appears to generate a vicious cycle between fat accumulation, oxidative stress, inflammation, and hepatocyte death, thereby contributing to AFLD.

5. Conclusions

This comprehensive review and meta-analysis effectively consolidated evidence regarding the adverse effects of oxidative stress on AFLD, yielding informative results detailing the wide range of systemic complications associated with the condition. The data indicate that ethanol metabolism in animals with AFLD disrupts the redox system, rendering liver cells more susceptible to inflammation and cell death.

It is essential to acknowledge that considerable statistical heterogeneity was observed across most of the outcomes reported in the meta-analysis, and the primary studies were preclinical. The primary articles also demonstrated a high risk of publication bias and a moderate risk of bias overall. However, we emphasize that this review and meta-analysis represent a significant milestone, providing robust data on the impact of oxidative stress on AFLD and offering clarity on the underlying biochemical mechanisms driving this disease.

Supplementary Materials: The following supporting information can be downloaded at: https://www.action.com/actionals //www.mdpi.com/article/10.3390/nu16081174/s1, Supplementary Figure S1: Forest plot showing the alanine aminotransferase (ALT) activity in the serum/plasma from animals with or without AFLD. It is possible to observe that there was an increase in ALT activity in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S2: Forest plot showing the aspartate aminotransferase (AST) activity in the serum/plasma from animals with or without AFLD. It is possible to observe that there was an increase in AST activity in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S3: Forest plot showing the Triacylglycerol (TAG) levels in the serum/plasma and liver from animals with or without AFLD. It is possible to observe that there was an increase in TAG in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S4: Forest plot showing the Sterol regulatory element binding transcription factor 1c (SREBP-1c) expression in the liver from animals with or without AFLD. It is possible to observe that there was an increase in SREBP-1c expression in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S5: Forest plot showing the Peroxisome Proliferator Activated Receptor Alpha (PPAR- α) expression in the liver from animals with or without AFLD. It is possible to observe that there was a decrease in PPAR- α expression in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S6: Forest plot showing the steatosis profile in liver slices from animals with or without AFLD. It is possible to observe that there was an increase in histology steatosis in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S7: Forest plot showing the Cytochrome P450 2E (CYP2E1) expression and activity in liver from animals with or without AFLD. It is possible to observe that there was an increase in both CYP2E1 expression and activity in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S8: Forest plot showing Factor 2 related to erythroid nuclear factor 2 (Nrf2) analysis in liver from animals with or without AFLD. It is possible to observe that there was a reduction in Nrf2 expression in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S9: Forest plot showing Tumor Necrosis Factor- α (TNF- α) analysis in liver and serum/plasma from animals with or without AFLD. The analysis was carried out in two subgroups, where an increase in TNF- α can be observed in both liver and serum/plasma from the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S10: Forest plot showing Interleukin 1 beta (IL-1 β) analysis in liver and serum/plasma from animals with or without AFLD. The analysis was carried out in two subgroups, where an increase in IL-1 β can be observed in both liver and serum/plasma from the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S11: Forest plot showing Interleukin 6 (IL-6) analysis in liver and serum/plasma from animals with or without AFLD. The analysis was carried out in two subgroups, where an increase in IL-6 can be observed in both liver and serum/plasma from the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S12: Forest plot showing Interleukin 10 (IL-10) analysis in liver and serum from animals with or without AFLD. The analysis was carried out in two subgroups, and there was no difference between the AFLD and control group. 95% Cl: confidence interval. Supplementary Figure S13: Forest plot showing the inflammation profile in liver slices from animals with or without AFLD. It is possible to observe that there was an increase in histology inflammation in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S14: Forest plot showing caspase-3 expression and activity in liver from animals with or without AFLD. The analysis indicated increase in caspase-3 from AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S15: Forest plot showing Bax/Bcl-2 ratio in liver from animals with or without AFLD. An increase in Bax/Bcl-2 ratio can be observed in the AFLD group (p < 0.05). 95% Cl: confidence interval. Supplementary Figure S16: Funnel plot for the assessment of publication bias.

Author Contributions: A.C.S.R.: performed all stages of the systematic review and meta-analysis and wrote the draft and final version. A.K.d.L.A.: performed all stages of the systematic review and meta-analysis. D.C.C.: supervised the study and corrected the final version. All authors have read and agreed to the published version of the manuscript.

Funding: Pró-reitoria de Pesquisa, Pós-graduação e Inovação (PROPPI); Federal University of Ouro Preto; Federal University of Alfenas; Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

Conflicts of Interest: The authors declare no conflicts of interest.

References

- 1. World Health Organization—WHO. No Level of Alcohol Consumption Is Safe for Our Health. Available online: https://www.who.int/europe/news/item/04-01-2023-no-level-of-alcohol-consumption-is-safe-for-our-health (accessed on 10 February 2023).
- Salete-Granado, D.; Carbonell, C.; Puertas-Miranda, D.; Vega-Rodríguez, V.J.; García-Macia, M.; Herrero, A.B.; Marcos, M. Autophagy, Oxidative Stress, and Alcoholic Liver Disease: A Systematic Review and Potential Clinical Applications. *Antioxidants* 2023, 12, 1425. [CrossRef] [PubMed]
- Zima, T.; Fialová, L.; Mestek, O.; Janebová, M.; Crkovská, J.; Malbohan, I.; Stípek, S.; Mikulíková, L.; Popov, P. Oxidative stress, metabolism of ethanol and alcohol-related diseases. J. Biomed. Sci. 2001, 8, 59–70. [CrossRef] [PubMed]
- You, M.; Fischer, M.; Deeg, M.A.; Crabb, D.W. Ethanol Induces Fatty Acid Synthesis Pathways by Activation of Sterol Regulatory Element-Binding Protein (SREBP). J. Biol. Chem. 2002, 277, 29342–29347. [CrossRef] [PubMed]
- Tan, H.K.; Yates, E.; Lilly, K.; Dhanda, A.D. Oxidative Stress in Alcohol-Related Liver Disease. World J. Hepatol. 2020, 12, 332–349. [CrossRef] [PubMed]
- Lívero, F.A.R.; Acco, A. Molecular Basis of Alcoholic Fatty Liver Disease: From Incidence to Treatment. *Hepatol. Res.* 2016, 46, 111–123. [CrossRef] [PubMed]
- Diesinger, T.; Buko, V.; Lautwein, A.; Dvorsky, R.; Belonovskaya, E.; Lukivskaya, O.; Naruta, E.; Kirko, S.; Andreev, V.; Buckert, D. Drug Targeting CYP2E1 for the Treatment of Early-Stage Alcoholic Steatohepatitis. *PLoS ONE* 2020, 15, e0235990. [CrossRef] [PubMed]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. *J. Clin. Epidemiol.* 2021, 134, 178–189. [CrossRef] [PubMed]
- 9. Hooijmans, C.R.; Rovers, M.M.; De Vries, R.B.M.; Leenaars, M.; Ritskes-Hoitinga, M.; Langendam, M.W. SYRCLE's Risk of Bias Tool for Animal Studies. *BMC Med. Res. Methodol.* **2014**, *14*, 43. [CrossRef]
- Abdelhamid, A.M.; Elsheakh, A.R.; Abdelaziz, R.R.; Suddek, G.M. Empagliflozin Ameliorates Ethanol-Induced Liver Injury by Modulating NF-KB/Nrf-2/PPAR-γ Interplay in Mice. *Life Sci.* 2020, 256, 117908. [CrossRef] [PubMed]
- Abdelhamid, A.M.; Elsheakh, A.R.; Suddek, G.M.; Abdelaziz, R.R. Telmisartan Alleviates Alcohol-Induced Liver Injury by Activation of PPAR-γ/ Nrf-2 Crosstalk in Mice. *Int. Immunopharmacol.* 2021, 99, 107963. [CrossRef] [PubMed]
- 12. Al-Rejaie, S.S. Effect of Oleo-Gum-Resin on Ethanol-Induced Hepatotoxicity in Rats. J. Med. Sci. 2012, 12, 1–9. [CrossRef]
- 13. Atef, M.M.; Hafez, Y.M.; Alshenawy, H.A.; Emam, M.N. Ameliorative Effects of Autophagy Inducer, Simvastatin on Alcohol-Induced Liver Disease in a Rat Model. *J. Cell Biochem.* **2019**, *120*, 7679–7688. [CrossRef] [PubMed]
- 14. Bae, D.; Kim, J.; Lee, S.Y.; Choi, E.J.; Jung, M.A.; Jeong, C.S.; Na, J.R.; Kim, J.J.; Kim, S. Hepatoprotective Effects of Aqueous Extracts from Leaves of *Dendropanax Morbifera Leveille* against Alcohol-Induced Hepatotoxicity in Rats and in Vitro Anti-Oxidant Effects. *Food Sci. Biotechnol.* **2015**, *24*, 1495–1503. [CrossRef]
- Balasubramaniyan, V.; Sailaja, J.K.; Nalini, N. Role of Leptin on Alcohol-Induced Oxidative Stress in Swiss Mice. *Pharmacol. Res.* 2003, 47, 211–216. [CrossRef] [PubMed]
- 16. Baranisrinivasan, P.; Elumalai, E.K.; Sivakumar, C.; Therasa, S.V.; David, E. Hepatoprotective Effect of *Enicostemma Littorale Blume* and *Eclipta Alba* during Ethanol Induced Oxidative Stress in Albino Rats. *Int. J. Pharmacol.* 2009, *5*, 268–272. [CrossRef]
- 17. Bardag-Gorce, F.; Oliva, J.; Lin, A.; Li, J.; French, B.A.; French, S.W. Proteasome Inhibitor up Regulates Liver Antioxidative Enzymes in Rat Model of Alcoholic Liver Disease. *Exp. Mol. Pathol.* **2011**, *90*, 123–130. [CrossRef] [PubMed]
- 18. Bedi, O.; Bariwal, J.; Kumar, P.; Bhakuni, G.S. Hepatoprotective Activity of Morin and its Semi-Synthetic Derivatives Against Alcohol Induced Hepatotoxicity in Rats. *Indian J. Physiol. Pharmacol.* **2017**, *61*, 175–190.
- 19. Bharrhan, S.; Koul, A.; Chopra, K.; Rishi, P. Catechin Suppresses an Array of Signalling Molecules and Modulates Alcohol-Induced Endotoxin Mediated Liver Injury in a Rat Model. *PLoS ONE* **2011**, *6*, e20635. [CrossRef] [PubMed]
- Bisht, P.; Chandrashekhara, S.; Das, K.; Tribedi, S. Effect of Cultural Condition on Evaluation of Hepatoprotective Activity of Methanolic Bark Extract of Anogeissus Latifolia on Ethanol-Induced Hepatotoxicity. *Asian J. Pharm. Clin. Res.* 2018, 11, 247–252. [CrossRef]
- Bispo, V.S.; Dantas, L.S.; Chaves Filho, A.B.; Pinto, I.F.D.; da Silva, R.P.; Otsuka, F.A.M.; Santos, R.B.; Santos, A.C.; Trindade, D.J.; Matos, H.R. Reduction of the DNA Damages, Hepatoprotective Effect and Antioxidant Potential of the Coconut Water, Ascorbic and Caffeic Acids in Oxidative Stress Mediated by Ethanol. An. Acad. Bras. Cienc. 2017, 89, 1095–1109. [CrossRef]

- Buko, V.; Kuzmitskaya, I.; Kirko, S.; Belonovskaya, E.; Naruta, E.; Lukivskaya, O.; Shlyahtun, A.; Ilyich, T.; Zakreska, A.; Zavodnik, I. Betulin Attenuated Liver Damage by Prevention of Hepatic Mitochondrial Dysfunction in Rats with Alcoholic Steatohepatitis. *Physiol. Int.* 2019, 106, 323–334. [CrossRef] [PubMed]
- 23. Bulle, S.; Reddyvari, H.; Reddy Vaddi, D.; Pannuru, P.; Nch, V. Therapeutic potential of *P. santalinus* against alcohol-induced histo-pathological changes and oxidative damage in heart and lungs. *Int. J. Res. Pharm. Sci.* **2015**, *6*, 30–311.
- 24. Cao, Y.W.; Jiang, Y.; Zhang, D.Y.; Wang, M.; Chen, W.S.; Su, H.; Wang, Y.T.; Wan, J.B. Protective Effects of *Penthorum Chinense* Pursh against Chronic Ethanol-Induced Liver Injury in Mice. J. Ethnopharmacol. **2015**, 161, 92–98. [CrossRef]
- 25. Chandra, R.; Aneja, R.; Rewal, C.; Konduri, R.; Dass, S.K.; Agarwal, S. An opium alkaloid-papaverine ameliorates ethanol-induced hepatotoxicity: Diminution of oxidative stress. *Indian J. Clin. Biochem.* **2000**, *15*, 155–160. [CrossRef]
- Chang, Y.Y.; Liu, Y.C.; Kuo, Y.H.; Lin, Y.L.; Wu, Y.H.S.; Chen, J.W.; Chen, Y.C. Effects of Antrosterol from *Antrodia Camphorata* Submerged Whole Broth on Lipid Homeostasis, Antioxidation, Alcohol Clearance, and Anti-Inflammation in Livers of Chronic-Alcohol Fed Mice. *J. Ethnopharmacol.* 2017, 202, 200–207. [CrossRef] [PubMed]
- Chang, B.Y.; Kim, H.J.; Kim, T.Y.; Kim, S.Y. Enzyme-Treated Zizania Latifolia Extract Protects against Alcohol-Induced Liver Injury by Regulating the Nrf2 Pathway. Antioxidants 2021, 10, 960. [CrossRef]
- Chaturvedi, P.; George, S.; John, A. Preventive and Protective Effects of Wild Basil in Ethanol-Induced Liver Toxicity in Rats. Br. J. Biomed. Sci. 2007, 64, 10–12. [CrossRef]
- Chavan, T.; Ghadge, A.; Karandikar, M.; Pandit, V.; Ranjekar, P.; Kulkarni, O.; Kuvalekar, A.; Mantri, N. Activity of Satwa against Alcohol Injury in rats. *Altern. Ther. Health Med.* 2017, 23, 34–40.
- Chen, Y.L.; Peng, H.C.; Tan, S.W.; Tsai, C.Y.; Huang, Y.H.; Wu, H.Y.; Yang, S.C. Amelioration of Ethanol-Induced Liver Injury in Rats by Nanogold Flakes. *Alcohol* 2013, 47, 467–472. [CrossRef] [PubMed]
- Chen, Y.; Singh, S.; Matsumoto, A.; Manna, S.K.; Abdelmegeed, M.A.; Golla, S.; Murphy, R.C.; Dong, H.; Song, B.J.; Gonzalez, F.J.; et al. Chronic Glutathione Depletion Confers Protection against Alcohol-Induced Steatosis: Implication for Redox Activation of AMP-Activated Protein Kinase Pathway. *Sci. Rep.* 2016, *6*, 29743. [CrossRef] [PubMed]
- Cheng, D.; Kong, H. The Effect of *Lycium Barbarum* Polysaccharide on Alcohol-Induced Oxidative Stress in Rats. *Molecules* 2011, 16, 2542–2550. [CrossRef] [PubMed]
- 33. Chiu, P.Y.; Lam, P.Y.; Leung, H.Y.; Leong, P.K.; Ma, C.W.; Tang, Q.T.; Ko, K.M. Co-Treatment with Shengmai San-Derived Herbal Product Ameliorates Chronic Ethanol-Induced Liver Damage in Rats. *Rejuvenation Res.* **2011**, *14*, 17–23. [CrossRef] [PubMed]
- 34. Chu, J.; Yan, R.; Wang, S.; Li, G.; Kang, X.; Hu, Y.; Lin, M.; Shan, W.; Zhao, Y.; Wang, Z.; et al. Sinapic Acid Reduces Oxidative Stress and Pyroptosis via Inhibition of BRD4 in Alcoholic Liver Disease. *Front. Pharmacol.* **2021**, *12*, 668708. [CrossRef] [PubMed]
- Colantoni, A.; Paglia, N.L.; De Maria, N.; Emanuele, M.A.; Emanuele, N.V.; Idilman, R.; Harig, J.; Van Thiel, D.H. Influence of Sex Hormonal Status on Alcohol-Induced Oxidative Injury in Male and Female Rat Liver. *Alcohol. Clin. Exp. Res.* 2000, 24, 1467–1473. [PubMed]
- Cui, Y.; Ye, Q.; Wang, H.; Li, Y.; Xia, X.; Yao, W.; Qian, H. Aloin Protects against Chronic Alcoholic Liver Injury via Attenuating Lipid Accumulation, Oxidative Stress and Inflammation in Mice. *Arch. Pharmacal Res.* 2014, 37, 1624–1633. [CrossRef] [PubMed]
- Cui, Y.; Ye, Q.; Wang, H.; Li, Y.; Yao, W.; Qian, H. Hepatoprotective Potential of Aloe Vera Polysaccharides against Chronic Alcohol-Induced Hepatotoxicity in Mice. J. Sci. Food Agric. 2014, 94, 1764–1771. [CrossRef] [PubMed]
- Das, S.K.; Vasudevan, D.M. Effect of Lecithin in the Treatment of Ethanol Mediated Free Radical Induced Hepatotoxicity. *Indian J. Clin. Biochem.* 2006, 21, 62–69. [CrossRef]
- Das, S.K.; Mukherjee, S.; Vasudevan, D.M. Effects of Long Term Ethanol Consumption Mediated Oxidative Stress on Neovessel Generation in Liver. *Toxicol. Mech. Methods* 2012, 22, 375–382. [CrossRef] [PubMed]
- De Souza, C.E.A.; Stolf, A.M.; Dreifuss, A.A.; Lívero, F.R.; Gomes, L.O.; Petiz, L.; Beltrame, O.; Dittrich, R.L.; Telles, J.E.Q.; Cadena, S.M. Characterization of an Alcoholic Hepatic Steatosis Model Induced by Ethanol and High-Fat Diet in Rats. *Braz. Arch. Biol. Technol.* 2015, 58, 367–378. [CrossRef]
- 41. Develi, S.; Evran, B.; Kalaz, E.B.; Koçak-Toker, N.; Erata, G.Ö. Protective Effect of *Nigella Sativa* Oil against Binge Ethanol-Induced Oxidative Stress and Liver Injury in Rats. *Chin. J. Nat. Med.* **2014**, *12*, 495–499. [CrossRef] [PubMed]
- Dou, X.; Shen, C.; Wang, Z.; Li, S.; Zhang, X.; Song, Z. Protection of Nicotinic Acid against Oxidative Stress-Induced Cell Death in Hepatocytes Contributes to Its Beneficial Effect on Alcohol-Induced Liver Injury in Mice. J. Nutr. Biochem. 2013, 24, 1520–1528. [CrossRef] [PubMed]
- Du, S.-Y.; Zhang, Y.-L.; Bai, R.-X.; Ai, Z.-L.; Xie, B.-S.; Yang, H.-Y. Lutein Prevents Alcohol-Induced Liver Disease in Rats by Modulating Oxidative Stress and Inflammation. *Int. J. Clin. Exp. Med.* 2015, *8*, 8785–8793. [PubMed]
- Duryee, M.J.; Dusad, A.; Hunter, C.D.; Kharbanda, K.K.; Bruenjes, J.D.; Easterling, K.C.; Siebler, J.C.; Thiele, G.M.; Chakkalakal, D.A. N-Acetyl Cysteine Treatment Restores Early Phase Fracture Healing in Ethanol-Fed Rats. *Alcohol Clin. Exp. Res.* 2018, 42, 1206–1216. [CrossRef] [PubMed]
- 45. Feng, R.; Chen, J.H.; Liu, C.H.; Xia, F.B.; Xiao, Z.; Zhang, X.; Wan, J.B. A Combination of Pueraria Lobata and Silybum Marianum Protects against Alcoholic Liver Disease in Mice. *Phytomedicine* **2019**, *58*, 152824. [CrossRef] [PubMed]
- Galligan, J.J.; Smathers, R.L.; Shearn, C.T.; Fritz, K.S.; Backos, D.S.; Jiang, H.; Franklin, C.C.; Orlicky, D.J.; MacLean, K.N.; Petersen, D.R. Oxidative Stress and the ER Stress Response in a Murine Model for Early-Stage Alcoholic Liver Disease. *J. Toxicol.* 2012, 2012, 207594. [CrossRef] [PubMed]

- 47. Gao, L.; Yuan, J.; Cheng, Y.; Chen, M.; Zhang, G.; Wu, J. Selenomethionine-Dominated Selenium-Enriched Peanut Protein Ameliorates Alcohol-Induced Liver Disease in Mice by Suppressing Oxidative Stress. *Foods* **2021**, *10*, 2979. [CrossRef] [PubMed]
- 48. George, S.; Chaturvedi, P. A comparative study of the antioxidant properties of two different species of Ocimum of southern Africa on alcohol-induced oxidative stress. *J. Med. Food.* **2009**, *12*, 1154–1158. [CrossRef] [PubMed]
- Gustot, T.; Lemmers, A.; Moreno, C.; Nagy, N.; Quertinmont, E.; Nicaise, C.; Franchimont, D.; Louis, H.; Devière, J.; Le Moine, O. Differential Liver Sensitization to Toll-like Receptor Pathways in Mice with Alcoholic Fatty Liver. *Hepatology* 2006, 43, 989–1000. [CrossRef] [PubMed]
- 50. Han, X.; Liu, J.; Bai, Y.; Hang, A.; Lu, T.; Mao, C. An Iridoid Glycoside from Cornus Officinalis Balances Intestinal Microbiome Disorder and Alleviates Alcohol-Induced Liver Injury. *J. Funct. Foods* **2021**, *82*, 104488. [CrossRef]
- Hao, L.; Sun, Q.; Zhong, W.; Zhang, W.; Sun, X.; Zhou, Z. Mitochondria-Targeted Ubiquinone (MitoQ) Enhances Acetaldehyde Clearance by Reversing Alcohol-Induced Posttranslational Modification of Aldehyde Dehydrogenase 2: A Molecular Mechanism of Protection against Alcoholic Liver Disease. *Redox Biol.* 2018, 14, 626–636. [CrossRef] [PubMed]
- Hao, L.; Zhong, W.; Sun, X.; Zhou, Z. TLR9 Signaling Protects Alcohol-Induced Hepatic Oxidative Stress but Worsens Liver Inflammation in Mice. *Front. Pharmacol.* 2021, 12, 709002. [CrossRef] [PubMed]
- Hasanein, P.; Seifi, R. Beneficial effects of rosmarinic acid against alcohol-induced hepatotoxicity in rats. *Can. J. Physiol. Pharmacol.* 2018, 96, 32–37. [CrossRef] [PubMed]
- 54. He, Y.; Xia, F.; Nan, M.; Li, L.; Wang, X.; Zhang, Y. Regulation of Bcl-2 and the NF-KB Signaling Pathway by Succinyl Rotundic Acid in Livers of Rats with Alcoholic Hepatitis. *Int. J. Agric. Biol.* **2021**, *25*, 730–734. [CrossRef]
- 55. Hsu, J.Y.; Lin, H.H.; Hsu, C.C.; Chen, B.C.; Chen, J.H. Aqueous Extract of Pepino (Solanum Muriactum Ait) Leaves Ameliorate Lipid Accumulation and Oxidative Stress in Alcoholic Fatty Liver Disease. *Nutrients* **2018**, *10*, 931. [CrossRef] [PubMed]
- Hu, B.; Jiang, W.; Yang, Y.; Xu, W.; Liu, C.; Zhang, S.; Qian, H.; Zhang, W. Gut-Liver Axis Reveals the Protective Effect of Exopolysaccharides Isolated from Sporidiobolus Pararoseus on Alcohol-Induced Liver Injury. J. Funct. Foods 2021, 87, 104737. [CrossRef]
- 57. Huang, Q.H.; Xu, L.Q.; Liu, Y.H.; Wu, J.Z.; Wu, X.; Lai, X.P.; Li, Y.C.; Su, Z.R.; Chen, J.N.; Xie, Y.L. Polydatin Protects Rat Liver against Ethanol-Induced Injury: Involvement of CYP2E1/ROS/Nrf2 and TLR4/NF- B P65 Pathway. *Evid. Based Complement. Alternat. Med.* 2017, 2017, 7953850. [CrossRef] [PubMed]
- Ilaiyaraja, N.; Khanum, F. Amelioration of Alcohol-Induced Hepatotoxicity and Oxidative Stress in Rats by Acorus Calamus. J. Diet Suppl. 2011, 8, 331–345. [CrossRef] [PubMed]
- 59. Jayaraman, J.; Veerappan, M.; Namasivayam, N. Potential Beneficial Effect of Naringenin on Lipid Peroxidation and Antioxidant Status in Rats with Ethanol-Induced Hepatotoxicity. J. Pharm. Pharmacol. 2009, 61, 1383–1390. [CrossRef] [PubMed]
- 60. Jiang, Z.; Chen, C.; Wang, J.; Xie, W.; Wang, M.; Li, X.; Zhang, X. Purple Potato (*Solanum tuberosum* L.) Anthocyanins Attenuate Alcohol-Induced Hepatic Injury by Enhancing Antioxidant Defense. *J. Nat. Med.* **2016**, *70*, 45–53. [CrossRef] [PubMed]
- 61. Jiang, X.; Lin, D.; Shao, H.; Yang, X. Antioxidant Properties of Komagataeibacter Hansenii CGMCC 3917 and Its Ameliorative Effects on Alcohol-Induced Liver Injury in Mice. *CYTA J. Food* **2019**, *17*, 355–364. [CrossRef]
- 62. Jin, D.C.; Jeong, S.W.; Park, P.S. Effects of Green Tea Extract on Acute Ethanol-Induced Hepatotoxicity in Rats. J. Korean Soc. Food Sci. Nutr. 2010, 39, 343–349. [CrossRef]
- Jose, S.P.; Mohanan, R.; Sandya, S.; Asha, S.; Krishnakumar, I.M. A Novel Powder Formulation of Coconut Inflorescence Sap Inhibits Alcoholic Liver Damage by Modulating Inflammatory Markers, Extracellular Matrix Metalloproteinase, and Oxidative Stress. J. Food Biochem. 2018, 42, e12543. [CrossRef]
- 64. Kanbak, G.; Inal, M.; Bayçu, C. Ethanol-Induced Hepatotoxicity and Protective Effect of Betaine. *Cell Biochem. Funct.* **2001**, *19*, 281–285. [CrossRef] [PubMed]
- 65. Kanchana, G.; Jayapriya, K. Antioxidant Effect of Livomap, a Polyherbal Formulation on Ethanol Induced Hepatotoxicity in Albino Wistar Rats. *J. Appl. Pharm. Sci.* 2013, *3*, 52–56. [CrossRef]
- Kang, X.; Zhong, W.; Liu, J.; Song, Z.; McClain, C.J.; Kang, Y.J.; Zhou, Z. Zinc Supplementation Reverses Alcohol-Induced Steatosis in Mice through Reactivating Hepatocyte Nuclear Factor-4α and Peroxisome Proliferator-Activated Receptor-α. *Hepatology* 2009, 50, 1241–1250. [CrossRef] [PubMed]
- Kang, H.; Kim, M.B.; Park, Y.K.; Lee, J.Y. A Mouse Model of the Regression of Alcoholic Hepatitis: Monitoring the Regression of Hepatic Steatosis, Inflammation, Oxidative Stress, and NAD+ Metabolism upon Alcohol Withdrawal. J. Nutr. Biochem. 2022, 99, 108852. [CrossRef] [PubMed]
- 68. Kaviarasan, S.; Sundarapandiyan, R.; Anuradha, C.V. Epigallocatechin Gallate, a Green Tea Phytochemical, Attenuates Alcohol-Induced Hepatic Protein and Lipid Damage. *Toxicol. Mech. Methods* **2008**, *18*, 645–652. [CrossRef] [PubMed]
- 69. Khanal, T.; Choi, J.H.; Hwang, Y.P.; Chung, Y.C.; Jeong, H.G. Saponins Isolated from the Root of Platycodon Grandiflorum Protect against Acute Ethanol-Induced Hepatotoxicity in Mice. *Food Chem.Toxicol.* **2009**, *47*, 530–535. [CrossRef] [PubMed]
- Kim, S.J.; Park, J.G.; Lee, S.M. Protective Effect of Heme Oxygenase-1 Induction against Hepatic Injury in Alcoholic Steatotic Liver Exposed to Cold Ischemia/Reperfusion. *Life Sci.* 2012, 90, 169–176. [CrossRef] [PubMed]
- Kim, D.; Kim, G.W.; Lee, S.H.; Han, G.D. Ligularia Fischeri Extract Attenuates Liver Damage Induced by Chronic Alcohol Intake. *Pharm. Biol.* 2016, 54, 1465–1473. [CrossRef] [PubMed]

- 72. Kumar, D.; Dwivedi, D.K.; Lahkar, M.; Jangra, A. Hepatoprotective Potential of 7,8-Dihydroxyflavone against Alcohol and High-Fat Diet Induced Liver Toxicity via Attenuation of Oxido-Nitrosative Stress and NF-KB Activation. *Pharmacol. Rep.* 2019, 71, 1235–1243. [CrossRef] [PubMed]
- Lai, J.R.; Ke, B.J.; Hsu, Y.W.; Lee, C.L. Dimerumic Acid and Deferricoprogen Produced by *Monascus purpureus* Attenuate Liquid Ethanol Diet-Induced Alcoholic Hepatitis via Suppressing NF-KB Inflammation Signalling Pathways and Stimulation of AMPK-Mediated Lipid Metabolism. *J. Funct. Foods* 2019, 60, 103393. [CrossRef]
- 74. Lee, M.; Kim, Y.; Yoon, H.G.; You, Y.; Park, J.; Lee, Y.H.; Kim, S.; Hwang, K.; Lee, J.; Jun, W. Prevention of Ethanol-Induced Hepatotoxicity by Fermented Curcuma Longa L. in C57BL/6 Mice. *Food Sci. Biotechnol.* **2014**, *23*, 925–930. [CrossRef]
- Lee, J.Y.; An, Y.J.; Kim, J.W.; Choi, H.K.; Lee, Y.H. Effect of Angelica Keiskei Koidzumi Extract on Alcohol-Induced Hepatotoxicity in Vitro and in Vivo. J. Korean Soc. Food Sci. Nutr. 2016, 45, 1391–1397. [CrossRef]
- Lee, Y.J.; Hsu, J.D.; Lin, W.L.; Kao, S.H.; Wang, C.J. Upregulation of Caveolin-1 by Mulberry Leaf Extract and Its Major Components, Chlorogenic Acid Derivatives, Attenuates Alcoholic Steatohepatitis: Via Inhibition of Oxidative Stress. *Food Funct.* 2017, 8, 397–405. [CrossRef] [PubMed]
- Lee, H.Y.; Nam, Y.; Choi, W.S.; Kim, T.W.; Lee, J.; Sohn, U.D. The Hepato-Protective Effect of Eupatilin on an Alcoholic Liver Disease Model of Rats. *Korean J. Physiol. Pharmacol.* 2020, 24, 385–394. [CrossRef] [PubMed]
- Lee, D.H.; Lee, J.S.; Lee, I.H.; Hong, J.T. Therapeutic Potency of Fermented Field Water in Ethanol-Induced Liver Injury. *RSC Adv.* 2020, 10, 1544–1551. [CrossRef] [PubMed]
- Lee, Y.J.; Tsai, M.C.; Lin, H.T.; Wang, C.J.; Kao, S.H. Aqueous Mulberry Leaf Extract Ameliorates Alcoholic Liver Injury Associating with Upregulation of Ethanol Metabolism and Suppression of Hepatic Lipogenesis. *Evid. Comp. Alt. Med.* 2021, 2021, 6658422. [CrossRef] [PubMed]
- Li, Y.; Gao, C.; Shi, Y.; Tang, Y.; Liu, L.; Xiong, T.; Du, M.; Xing, M.; Yao, P. Carbon Monoxide Alleviates Ethanol-Induced Oxidative Damage and Inflammatory Stress through Activating P38 MAPK Pathway. *Toxicol. Appl Pharmacol.* 2013, 273, 53–58. [CrossRef] [PubMed]
- Li, B.; Zhu, L.; Wu, T.; Zhang, J.; Jiao, X.; Liu, X.; Wang, Y.; Meng, X. Effects of Triterpenoid from Schisandra Chinensis on Oxidative Stress in Alcohol-Induced Liver Injury in Rats. *Cell Biochem. Biophys.* 2015, *71*, 803–811. [CrossRef] [PubMed]
- Li, Y.; Chen, M.; Xu, Y.; Yu, X.; Xiong, T.; Du, M.; Sun, J.; Liu, L.; Tang, Y.; Yao, P. Iron-Mediated Lysosomal Membrane Permeabilization in Ethanol-Induced Hepatic Oxidative Damage and Apoptosis: Protective Effects of Quercetin. Oxid. Med. Cell Longev. 2016, 2016, 4147610. [CrossRef] [PubMed]
- Li, L.; Wu, Y.; Yin, F.; Feng, Q.; Dong, X.; Zhang, R.; Yin, Z.; Luo, L. Fructose 1, 6-Diphosphate Prevents Alcohol-Induced Liver Injury through Inhibiting Oxidative Stress and Promoting Alcohol Metabolism in Mice. *Eur. J. Pharmacol.* 2017, 815, 274–281. [CrossRef] [PubMed]
- 84. Li, D.; Sun, L.; Yang, Y.; Wang, Z.; Yang, X.; Guo, Y. Preventive and Therapeutic Effects of Pigment and Polysaccharides in Lycium Barbarum on Alcohol-Induced Fatty Liver Disease in Mice. *CYTA J. Food* **2018**, *16*, 938–949. [CrossRef]
- Li, B.; Mao, Q.; Zhou, D.; Luo, M.; Gan, R.; Li, H.; Huang, S.; Saimaiti, A.; Shang, A.; Li, H. Effects of Tea against Alcoholic Fatty Liver Disease by Modulating Gut Microbiota in Chronic Alcohol-Exposed Mice. *Foods* 2021, 10, 1232. [CrossRef] [PubMed]
- Li, B.Y.; Li, H.Y.; Zhou, D.D.; Huang, S.Y.; Luo, M.; Gan, R.Y.; Mao, Q.Q.; Saimaiti, A.; Shang, A.; Li, H. Bin Effects of Different Green Tea Extracts on Chronic Alcohol Induced-Fatty Liver Disease by Ameliorating Oxidative Stress and Inflammation in Mice. Oxid. Med. Cell Longev. 2021, 2021, 5188205. [CrossRef] [PubMed]
- Li, H.; Shi, J.; Zhao, L.; Guan, J.; Liu, F.; Huo, G.; Li, B. Lactobacillus Plantarum KLDS1.0344 and Lactobacillus Acidophilus KLDS1.0901 Mixture Prevents Chronic Alcoholic Liver Injury in Mice by Protecting the Intestinal Barrier and Regulating Gut Microbiota and Liver-Related Pathways. J. Agric. Food Chem. 2021, 69, 183–197. [CrossRef] [PubMed]
- Li, B.Y.; Mao, Q.Q.; Gan, R.Y.; Cao, S.Y.; Xu, X.Y.; Luo, M.; Li, H.Y.; Li, H. Bin Protective Effects of Tea Extracts against Alcoholic Fatty Liver Disease in Mice via Modulating Cytochrome P450 2E1 Expression and Ameliorating Oxidative Damage. *Food Sci. Nutr.* 2021, 9, 5626–5640. [CrossRef] [PubMed]
- Lian, L.H.; Wu, Y.L.; Song, S.Z.; Wan, Y.; Xie, W.X.; Li, X.; Bai, T.; Ouyang, B.Q.; Nan, J.X. Gentiana Manshurica Kitagawa Reverses Acute Alcohol-Induced Liver Steatosis through Blocking Sterol Regulatory Element-Binding Protein-1 Maturation. J. Agric. Food Chem. 2010, 58, 13013–13019. [CrossRef] [PubMed]
- Lin, C.P.; Chuang, W.C.; Lu, F.J.; Chen, C.Y. Anti-Oxidant and Anti-Inflammatory Effects of Hydrogen-Rich Water Alleviate Ethanol-Induced Fatty Liver in Mice. World J. Gastroenterol. 2017, 23, 4920–4934. [CrossRef] [PubMed]
- Lin, T.A.; Ke, B.J.; Cheng, S.C.; Lee, C.L. Red Quinoa Bran Extract Prevented Alcoholic Fatty Liver Disease via Increasing Antioxidative System and Repressing Fatty Acid Synthesis Factors in Mice Fed Alcohol Liquid Diet. *Molecules* 2021, 26, 6973. [CrossRef] [PubMed]
- Liu, J.; Wang, X.; Liu, R.; Liu, Y.; Zhang, T.; Fu, H.; Hai, C. Oleanolic Acid Co-Administration Alleviates Ethanol-Induced Hepatic Injury via Nrf-2 and Ethanol-Metabolizing Modulating in Rats. *Chem. Biol. Interact.* 2014, 221, 88–98. [CrossRef] [PubMed]
- Liu, J.; Wang, X.; Peng, Z.; Zhang, T.; Wu, H.; Yu, W.; Kong, D.; Liu, Y.; Bai, H.; Liu, R.; et al. The Effects of Insulin Pre-Administration in Mice Exposed to Ethanol: Alleviating Hepatic Oxidative Injury through Anti-Oxidative, Anti-Apoptotic Activities and Deteriorating Hepatic Steatosis through SRBEP-1c Activation. *Int. J. Biol. Sci.* 2015, *11*, 569–586. [CrossRef] [PubMed]

- 94. Liu, J.; He, H.; Wang, J.; Guo, X.; Lin, H.; Chen, H.; Jiang, C.; Chen, L.; Yao, P.; Tang, Y. Oxidative Stress-Dependent Frataxin Inhibition Mediated Alcoholic Hepatocytotoxicity through Ferroptosis. *Toxicology* **2020**, 445, 152584. [CrossRef] [PubMed]
- Liu, S.X.; Liu, H.; Wang, S.; Zhang, C.L.; Guo, F.F.; Zeng, T. Diallyl Disulfide Ameliorates Ethanol-Induced Liver Steatosis and Inflammation by Maintaining the Fatty Acid Catabolism and Regulating the Gut-Liver Axis. *Food Chem. Toxicol.* 2022, 164, 113108. [CrossRef] [PubMed]
- Liu, J.; Kong, D.; Ai, D.; Xu, A.; Yu, W.; Peng, Z.; Peng, J.; Wang, Z.; Liu, R.; Li, W.; et al. Insulin Resistance Enhances Binge Ethanol-Induced Liver Injury through Promoting Oxidative Stress and up-Regulation CYP2E1. *Life Sci.* 2022, 303, 120681. [CrossRef] [PubMed]
- 97. Lu, K.H.; Tseng, H.C.; Liu, C.T.; Huang, C.J.; Chyuan, J.H.; Sheen, L.Y. Wild Bitter Gourd Protects against Alcoholic Fatty Liver in Mice by Attenuating Oxidative Stress and Inflammatory Responses. *Food Funct.* **2014**, *5*, 1027–1037. [CrossRef] [PubMed]
- 98. Lu, C.; Xu, W.; Zhang, F.; Jin, H.; Chen, Q.; Chen, L.; Shao, J.; Wu, L.; Lu, Y.; Zheng, S. Ligustrazine Prevents Alcohol-Induced Liver Injury by Attenuating Hepatic Steatosis and Oxidative Stress. *Int. Immunopharmacol.* **2015**, *29*, 613–621. [CrossRef] [PubMed]
- 99. Lu, N.S.; Chiu, W.C.; Chen, Y.L.; Peng, H.C.; Shirakawa, H.; Yang, S.C. Fish Oil Up-Regulates Hepatic Autophagy in Rats with Chronic Ethanol Consumption. J. Nutr. Biochem. 2020, 77, 108314. [CrossRef] [PubMed]
- Ma, J.; Liu, X.Y.; Noh, K.H.; Kim, M.J.; Song, Y.S. Protective Effects of Persimmon Leaf and Fruit Extracts against Acute Ethanol-Induced Hepatotoxicity. J. Food Sci. Nutr. 2007, 12, 202–208. [CrossRef]
- Madushani Herath, K.H.I.N.; Bing, S.J.; Cho, J.; Kim, A.; Kim, G.; Kim, J.S.; Kim, J.B.; Doh, Y.H.; Jee, Y. Sasa Quelpaertensis Leaves Ameliorate Alcohol-Induced Liver Injury by Attenuating Oxidative Stress in HepG2 Cells and Mice. *Acta Histochem.* 2018, 120, 477–489. [CrossRef] [PubMed]
- 102. Mai, B.; Han, L.; Zhong, J.; Shu, J.; Cao, Z.; Fang, J.; Zhang, X.; Gao, Z.; Xiao, F. Rhoifolin Alleviates Alcoholic Liver Disease In Vivo and In Vitro via Inhibition of the TLR4/NF-KB Signaling Pathway. *Front. Pharmacol.* **2022**, *13*, 878898. [CrossRef] [PubMed]
- Maimaitimin, K.; Jiang, Z.; Aierken, A.; Shayibuzhati, M.; Zhang, X. Hepatoprotective Effect of *Alhagi sparsifolia* against Alcoholic Liver Injury in Mice. *Braz. J. Pharm. Sci.* 2018, 54, e17732. [CrossRef]
- Mallikarjuna, K.; Sahitya Chetan, P.; Sathyavelu Reddy, K.; Rajendra, W. Ethanol Toxicity: Rehabilitation of Hepatic Antioxidant Defense System with Dietary Ginger. *Fitoterapia* 2008, 79, 174–178. [CrossRef] [PubMed]
- 105. Mandal, S.; Nelson, V.K.; Mukhopadhyay, S.; Bandhopadhyay, S.; Maganti, L.; Ghoshal, N.; Sen, G.; Biswas, T. 14-Deoxyandrographolide Targets Adenylate Cyclase and Prevents Ethanol-Induced Liver Injury through Constitutive NOS Dependent Reduced Redox Signaling in Rats. *Food Chem. Toxicol.* 2013, 59, 236–248. [CrossRef] [PubMed]
- 106. Mehanna, E.T.; Ali, A.S.A.; El-Shaarawy, F.; Mesbah, N.M.; Abo-Elmatty, D.M.; Aborehab, N.M. Anti-Oxidant and Anti-Inflammatory Effects of Lipopolysaccharide from *Rhodobacter sphaeroides* against Ethanol-Induced Liver and Kidney Toxicity in Experimental Rats. *Molecules* 2021, 26, 7437. [CrossRef] [PubMed]
- Meng, X.; Tang, G.Y.; Zhao, C.N.; Liu, Q.; Xu, X.Y.; Cao, S.Y. Hepatoprotective Effects of Hovenia Dulcis Seeds against Alcoholic Liver Injury and Related Mechanisms Investigated via Network Pharmacology. World J. Gastroenterol. 2020, 26, 3432–3446. [CrossRef] [PubMed]
- 108. Miana, J.B.; Gómez-Cambronero, L.; Lloret, A.; Pallardó, F.V.; Del Olmo, J.; Escudero, A.; Rodrigo, J.M.; Pellíin, A.; Via, J.R.; Viña, J.; et al. Mitochondrial Oxidative Stress and CD95 Ligand: A Dual Mechanism for Hepatocyte Apoptosis in Chronic Alcoholism. *Hepatology* 2002, 35, 1205–1214. [CrossRef] [PubMed]
- Ming, L.; Qi, B.; Hao, S.; Ji, R. Camel Milk Ameliorates Inflammatory Mechanisms in an Alcohol-Induced Liver Injury Mouse Model. Sci. Rep. 2021, 11, 22811. [CrossRef] [PubMed]
- 110. Mohan, R.; Jose, S.; Sukumaran, S.; Asha, S.; Sheethal, S.; John, G.; Krishnakumar, I.M. Curcumin-Galactomannosides Mitigate Alcohol-Induced Liver Damage by Inhibiting Oxidative Stress, Hepatic Inflammation, and Enhance Bioavailability on TLR4/MMP Events Compared to Curcumin. J. Biochem. Mol. Toxicol. 2019, 33, e22315. [CrossRef] [PubMed]
- 111. Nagappan, A.; Jung, D.Y.; Kim, J.H.; Lee, H.; Jung, M.H. Gomisin N Alleviates Ethanol-Induced Liver Injury through Ameliorating Lipid Metabolism and Oxidative Stress. *Int. J. Mol. Sci.* 2018, *19*, 2601. [CrossRef]
- 112. Nie, W.; Du, Y.Y.; Xu, F.R.; Zhou, K.; Wang, Z.M.; Al-Dalali, S.; Wang, Y.; Li, X.M.; Ma, Y.H.; Xie, Y. Oligopeptides from Jinhua Ham Prevent Alcohol-Induced Liver Damage by Regulating Intestinal Homeostasis and Oxidative Stress in Mice. *Food Funct.* 2021, 12, 10053–10070. [CrossRef]
- Nie, W.; Xu, F.; Zhou, K.; Yang, X.; Zhou, H.; Xu, B. Stearic Acid Prevent Alcohol-Induced Liver Damage by Regulating the Gut Microbiota. *Food Res. Int.* 2022, 155, 111095. [CrossRef] [PubMed]
- 114. Oh, S.I.; Lee, M.S.; Kim, C.I.; Song, K.Y.; Park, S.C. Aspartate Modulates the Ethanol-Induced Oxidative Stress and Glutathione Utilizing Enzymes in Rat Testes. *Exp. Mol. Med.* **2002**, *34*, 47–52. [CrossRef] [PubMed]
- 115. Osaki, K.; Arakawa, T.; Kim, B.; Lee, M.; Jeong, C.; Kang, N. Hepatoproteetive Effects of Oyster (Crassostrea Gigas) Extract in a Rat Model of Alcohol-Induced Oxidative Stress. *J. Korean Soc. Food Sci. Nutr.* **2016**, *45*, 805–811. [CrossRef]
- Panda, V.; Ashar, H.; Srinath, S. Antioxidant and Hepatoprotective Effect of Garcinia Indica Fruit Rind in Ethanolinduced Hepatic Damage in Rodents. *Interdiscip. Toxicol.* 2012, 5, 207–213. [CrossRef] [PubMed]
- 117. Panda, V.; Kharat, P.; Sudhamani, S. Hepatoprotective Effect of the Macrotyloma Uniflorum Seed (Horse Gram) in Ethanol-Induced Hepatic Damage in Rats. *J. Biol. Act. Prod. Nat.* **2015**, *5*, 178–191.
- Pari, L.; Suresh, A. Effect of Grape (*Vitis vinifera* L.) Leaf Extract on Alcohol Induced Oxidative Stress in Rats. *Food Chem. Toxicol.* 2008, 46, 1627–1634. [CrossRef] [PubMed]

- Park, H.Y.; Ha, S.K.; Eom, H.; Choi, I. Narirutin Fraction from Citrus Peels Attenuates Alcoholic Liver Disease in Mice. *Food Chem. Toxicol.* 2013, 55, 637–644. [CrossRef] [PubMed]
- 120. Park, S.Y.; Ahn, G.; Um, J.H.; Han, E.J.; Ahn, C.B.; Yoon, N.Y.; Je, J.Y. Hepatoprotective Effect of Chitosan-Caffeic Acid Conjugate against Ethanol-Treated Mice. *Exp. Toxicol. Pathol.* **2017**, *69*, 618–624. [CrossRef] [PubMed]
- 121. Park, S.Y.; Fernando, I.P.S.; Han, E.J.; Kim, M.J.; Jung, K.; Kang, D.S.; Ahn, C.B.; Ahn, G. In Vivo Hepatoprotective Effects of a Peptide Fraction from Krill Protein Hydrolysates against Alcohol-Induced Oxidative Damage. *Mar. Drugs* 2019, 17, 690. [CrossRef] [PubMed]
- 122. Patere, S.N.; Majumdar, A.S.; Saraf, M.N. Exacerbation of Alcohol-Induced Oxidative Stress in Rats by Polyunsaturated Fatty Acids and Iron Load. *Indian J. Pharm. Sci.* 2011, 73, 152–158. [PubMed]
- 123. Peng, H.C.; Chen, Y.L.; Chen, J.R.; Yang, S.S.; Huang, K.H.; Wu, Y.C.; Lin, Y.H.; Yang, S.C. Effects of Glutamine Administration on Inflammatory Responses in Chronic Ethanol-Fed Rats. J. Nutr. Biochem. 2011, 22, 282–288. [CrossRef] [PubMed]
- 124. Peng, H.C.; Chen, Y.L.; Yang, S.Y.; Ho, P.Y.; Yang, S.S.; Hu, J.T.; Yang, S.C. The Antiapoptotic Effects of Different Doses of β-Carotene in Chronic Ethanol-Fed Rats. *Hepatobiliary Surg. Nutr.* **2013**, *2*, 132–141. [PubMed]
- 125. Pi, A.; Jiang, K.; Ding, Q.; Lai, S.; Yang, W.; Zhu, J.; Guo, R.; Fan, Y.; Chi, L.; Li, S. Alcohol Abstinence Rescues Hepatic Steatosis and Liver Injury via Improving Metabolic Reprogramming in Chronic Alcohol-Fed Mice. *Front. Pharmacol.* 2021, 12, 752148. [CrossRef] [PubMed]
- 126. Prathibha, P.; Rejitha, S.; Harikrishnan, R.; Das, S.S.; Abhilash, P.A.; Indira, M. Additive Effect of Alpha-Tocopherol and Ascorbic Acid in Combating Ethanol-Induced Hepatic Fibrosis. *Redox Rep.* **2013**, *18*, 36–46. [CrossRef] [PubMed]
- 127. Qi, N.; Liu, C.; Yang, H.; Shi, W.; Wang, S.; Zhou, Y.; Wei, C.; Gu, F.; Qin, Y. Therapeutic Hexapeptide (PGPIPN) Prevents and Cures Alcoholic Fatty Liver Disease by Affecting the Expressions of Genes Related with Lipid Metabolism and Oxidative Stress. Oncotarget 2017, 8, 88079–88093. [CrossRef] [PubMed]
- Qu, L.; Zhu, Y.; Liu, Y.; Yang, H.; Zhu, C.; Ma, P.; Deng, J.; Fan, D. Protective Effects of Ginsenoside Rk3 against Chronic Alcohol-Induced Liver Injury in Mice through Inhibition of Inflammation, Oxidative Stress, and Apoptosis. *Food Chem. Toxicol.* 2019, 126, 277–284. [CrossRef] [PubMed]
- 129. Rabelo, A.C.S.; de Pádua Lúcio, K.; Araújo, C.M.; de Araújo, G.R.; de Amorim Miranda, P.H.; Carneiro, A.C.A.; de Castro Ribeiro, É.M.; de Melo Silva, B.; de Lima, W.G.; Costa, D.C. Baccharis Trimera Protects against Ethanol Induced Hepatotoxicity in Vitro and in Vivo. J. Ethnopharmacol. 2018, 215, 1–13. [CrossRef]
- Rejitha, S.; Prathibha, P.; Indira, M. Amelioration of Alcohol-Induced Hepatotoxicity by the Administration of Ethanolic Extract of Sida Cordifolia Linn. *Brit. J. Nutr.* 2012, 108, 1256–1263. [CrossRef] [PubMed]
- Roede, J.R.; Stewart, B.J.; Petersen, D.R. Decreased Expression of Peroxiredoxin 6 in a Mouse Model of Ethanol Consumption. *Free Radic. Biol. Med.* 2008, 45, 1551–1558. [CrossRef] [PubMed]
- Roede, J.R.; Orlicky, D.J.; Fisher, A.B.; Petersen, D.R. Overexpression of Peroxiredoxin 6 Does Not Prevent Ethanol-Mediated Oxidative Stress and May Play a Role in Hepatic Lipid Accumulation. J. Pharmacol. Exp. Ther. 2009, 330, 79–88. [CrossRef] [PubMed]
- 133. Rong, S.; Zhao, Y.; Bao, W.; Xiao, X.; Wang, D.; Nussler, A.K.; Yan, H.; Yao, P.; Liu, L. Curcumin Prevents Chronic Alcohol-Induced Liver Disease Involving Decreasing ROS Generation and Enhancing Antioxidative Capacity. *Phytomedicine* 2012, 19, 545–550. [CrossRef] [PubMed]
- 134. Ronis, M.J.J.; Butura, A.; Sampey, B.P.; Shankar, K.; Prior, R.L.; Korourian, S.; Albano, E.; Ingelman-Sundberg, M.; Petersen, D.R.; Badger, T.M. Effects of N-Acetylcysteine on Ethanol-Induced Hepatotoxicity in Rats Fed via Total Enteral Nutrition. *Free Radic. Biol. Med.* 2005, *39*, 619–630. [CrossRef] [PubMed]
- 135. Ronis, M.J.; Korourian, S.; Blackburn, M.L.; Badeaux, J.; Badger, T.M. The Role of Ethanol Metabolism in Development of Alcoholic Steatohepatitis in the Rat. *Alcohol* 2010, 44, 157–169. [CrossRef] [PubMed]
- 136. Samuhasaneeto, S.; Thong-Ngam, D.; Kulaputana, O.; Suyasunanont, D.; Klaikeaw, N. Curcumin Decreased Oxidative Stress, Inhibited Nf-k b Activation, and Improved Liver Pathology in Ethanol-Induced Liver Injury in Rats. J. Biomed. Biotechnol. 2009, 2009, 981963. [CrossRef] [PubMed]
- 137. Saravanan, N.; Rajasankar, S.; Nalini, N. Antioxidant Effect of 2-Hydroxy-4-Methoxy Benzoic Acid on Ethanol-Induced Hepatotoxicity in Rats. J. Pharm. Pharmacol. 2010, 59, 445–453. [CrossRef] [PubMed]
- Saravanan, N.; Nalini, N. Antioxidant Effect of Hemidesmus Indicus on Ethanol-Induced Hepatotoxicity in Rats. J. Med. Food 2007, 10, 675–682. [CrossRef] [PubMed]
- 139. Sathiavelu, J.; Senapathy, G.J.; Devaraj, R.; Namasivayam, N. Hepatoprotective Effect of Chrysin on Prooxidant-Antioxidant Status during Ethanol-Induced Toxicity in Female Albino Rats. *J. Pharm. Pharmacol.* **2009**, *61*, 809–817. [CrossRef] [PubMed]
- Senthilkumar, R.; Sengottuvelan, M.; Nalini, N. Protective Effect of Glycine Supplementation on the Levels of Lipid Peroxidation and Antioxidant Enzymes in the Erythrocyte of Rats with Alcohol-Induced Liver Injury. *Cell Biochem. Funct.* 2004, 22, 123–128. [CrossRef] [PubMed]
- Shankari, S.G.; Karthikesan, K.; Jalaludeen, A.M.; Ashokkumar, N.; Ashokkumar, N.; Patill, S.; Brid, S. Hepatoprotective effect of morin on ethanol-induced hepatotoxicity in rats. *J. Basic Clin. Physiol. Pharmacol.* 2010, 21, 277–294. [CrossRef] [PubMed]
- 142. Shearn, C.T.; Backos, D.S.; Orlicky, D.J.; Smathers-McCullough, R.L.; Petersen, D.R. Identification of 5' AMP-Activated Kinase as a Target of Reactive Aldehydes during Chronic Ingestion of High Concentrations of Ethanol. *J. Biol. Chem.* 2014, 289, 15449–15462. [CrossRef] [PubMed]

- 143. Shenbagam, M.; Nalini, N. Dose Response Effect of Rutin a Dietary Antioxidant on Alcohol-Induced Prooxidant and Antioxidant Imbalance—A Histopathologic Study. *Fundam. Clin. Pharmacol.* **2011**, *25*, 493–502. [CrossRef] [PubMed]
- 144. Shi, X.; Zhao, Y.; Ding, C.; Wang, Z.; Ji, A.; Li, Z.; Feng, D.; Li, Y.; Gao, D.; Zhou, J. Salvianolic Acid A Alleviates Chronic Ethanol-Induced Liver Injury via Promotion of β-Catenin Nuclear Accumulation by Restoring SIRT1 in Rats. *Toxicol. Appl. Pharmacol.* 2018, 350, 21–31. [CrossRef] [PubMed]
- 145. Smathers, R.L.; Galligan, J.J.; Shearn, C.T.; Fritz, K.S.; Mercer, K.; Ronis, M.; Orlicky, D.J.; Davidson, N.O.; Petersen, D.R. Susceptibility of L-FABP -/- Mice to Oxidative Stress in Early-Stage Alcoholic Liver. J. Lipid. Res. 2013, 54, 1335–1345. [CrossRef] [PubMed]
- 146. Sönmez, M.F.; Narin, F.; Akkuş, D.; Türkmen, A.B. Melatonin and Vitamin C Ameliorate Alcohol-Induced Oxidative Stress and ENOS Expression in Rat Kidney. *Ren. Fail* **2012**, *34*, 480–486. [CrossRef] [PubMed]
- 147. Song, Z.; Deaciuc, I.; Song, M.; Lee, D.Y.W.; Liu, Y.; Ji, X.; McClain, C. Silymarin Protects against Acute Ethanol-Induced Hepatotoxicity in Mice. *Alcohol Clin. Exp. Res.* **2006**, *30*, 407–413. [CrossRef] [PubMed]
- 148. Song, X.; Liu, Z.; Zhang, J.; Zhang, C.; Dong, Y.; Ren, Z.; Gao, Z.; Liu, M.; Zhao, H.; Jia, L. Antioxidative and Hepatoprotective Effects of Enzymatic and Acidic-Hydrolysis of *Pleurotus geesteranus* Mycelium Polysaccharides on Alcoholic Liver Diseases. *Carbohydr. Polym.* 2018, 201, 75–86. [CrossRef] [PubMed]
- Song, Y.; Wu, X.; Yang, D.; Fang, F.; Meng, L.; Liu, Y.; Cui, W. Protective Effect of Andrographolide on Alleviating Chronic Alcoholic Liver Disease in Mice by Inhibiting Nuclear Factor Kappa B and Tumor Necrosis Factor Alpha Activation. *J. Med. Food* 2020, 23, 409–415. [CrossRef]
- 150. Song, X.; Sun, W.; Cui, W.; Jia, L.; Zhang, J. A Polysaccharide of PFP-1 from: Pleurotus Geesteranus Attenuates Alcoholic Liver Diseases via Nrf2 and NF-KB Signaling Pathways. *Food Funct.* **2021**, *12*, 4591–4605. [CrossRef] [PubMed]
- 151. Arumugam, S.; Srinivasan, P.; Manikandaselvi, S.; Thinagarbabu, R. Protective effect and antioxidant role *of Achyranthus aspera*, L. against ethanol-induced oxidative stress in rats. *Int. J. Pharm. Pharm. Sci.* **2012**, *4* (Suppl. 3), 280–284.
- Sun, Q.; Zhong, W.; Zhang, W.; Zhou, Z. Defect of Mitochondrial Respiratory Chain Is a Mechanism of ROS Overproduction in a Rat Model of Alcoholic Liver Disease: Role of Zinc Deficiency. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2016, 310, 205–214. [CrossRef]
- 153. Tahir, M.; Rehman, M.U.; Lateef, A.; Khan, R.; Khan, A.Q.; Qamar, W.; Ali, F.; O'Hamiza, O.; Sultana, S. Diosmin Protects against Ethanol-Induced Hepatic Injury via Alleviation of Inflammation and Regulation of TNF-α and NF-KB Activation. *Alcohol* 2013, 47, 131–139. [CrossRef] [PubMed]
- 154. Tan, P.; Liang, H.; Nie, J.; Diao, Y.; He, Q.; Hou, B.; Zhao, T.; Huang, H.; Li, Y.; Gao, X.; et al. Establishment of an Alcoholic Fatty Liver Disease Model in Mice. *Am. J. Drug Alcohol Abuse* **2017**, *43*, 61–68. [CrossRef] [PubMed]
- 155. Tang, Y.; Gao, C.; Xing, M.; Li, Y.; Zhu, L.; Wang, D.; Yang, X.; Liu, L.; Yao, P. Quercetin Prevents Ethanol-Induced Dyslipidemia and Mitochondrial Oxidative Damage. *Food Chem. Toxicol.* **2012**, *50*, 1194–1200. [CrossRef] [PubMed]
- 156. Tang, C.C.; Lin, W.L.; Lee, Y.J.; Tang, Y.C.; Wang, C.J. Polyphenol-Rich Extract of Nelumbo Nucifera Leaves Inhibits Alcohol-Induced Steatohepatitis via Reducing Hepatic Lipid Accumulation and Anti-Inflammation in C57BL/6J Mice. *Food Funct.* 2014, 5, 678–687. [CrossRef] [PubMed]
- 157. Tang, Y.; Li, Y.; Yu, H.; Gao, C.; Liu, L.; Xing, M.; Yao, P. Quercetin Attenuates Chronic Ethanol Hepatotoxicity: Implication of "Free" Iron Uptake and Release. *Food Chem. Toxicol.* **2014**, 67, 131–138. [CrossRef] [PubMed]
- 158. Tang, X.; Wei, R.; Deng, A.; Lei, T. Protective Effects of Ethanolic Extracts from Artichoke, an Edible Herbal Medicine, against Acute Alcohol-Induced Liver Injury in Mice. *Nutrients* **2017**, *9*, 1000. [CrossRef] [PubMed]
- 159. Tao, Z.; Zhang, L.; Wu, T.; Fang, X.; Zhao, L. Echinacoside Ameliorates Alcohol-Induced Oxidative Stress and Hepatic Steatosis by Affecting SREBP1c/FASN Pathway via PPARα. *Food Chem. Toxicol.* 2021, 148, 111956. [CrossRef] [PubMed]
- Valansa, A.; Tietcheu Galani, B.R.; Djamen Chuisseu, P.D.; Tontsa Tsamo, A.; Ayissi Owona, V.B.; Yanou Njintang, N. Natural Limonoids Protect Mice from Alcohol-Induced Liver Injury. J. Basic Clin. Physiol. Pharmacol. 2020, 31, 20190271. [CrossRef] [PubMed]
- 161. Varghese, J.; James, J.V.; Sagi, S.; Chakraborty, S.; Sukumaran, A.; Ramakrishna, B.; Jacob, M. Decreased Hepatic Iron in Response to Alcohol May Contribute to Alcohol-Induced Suppression of Hepcidin. *Brit. J. Nutr.* **2016**, *115*, 1978–1986. [CrossRef] [PubMed]
- 162. Velvizhi, S.; Nagalashmi, T.; Essa, M.M.; Dakshayani, K.B.; Subramanian, P. Effects of alpha-ketoglutarate on lipid peroxidation and antioxidant status during chronic ethanol administration in Wistar rats. *Pol. J. Pharmacol.* **2002**, *54*, 231–236. [PubMed]
- Wang, C.; Li, X.; Wang, H.; Xie, Q.; Xu, Y. Notch1-Nuclear Factor KB Involves in Oxidative Stress-Induced Alcoholic Steatohepatitis. *Alcohol Alcohol.* 2014, 49, 10–16. [CrossRef] [PubMed]
- Wang, Z.; Su, B.; Fan, S.; Fei, H.; Zhao, W. Protective Effect of Oligomeric Proanthocyanidins against Alcohol-Induced Liver Steatosis and Injury in Mice. *Biochem. Biophys. Res. Commun.* 2015, 458, 757–762. [CrossRef] [PubMed]
- 165. Wang, H.; Zhang, Y.; Bai, R.; Wang, M.; Du, S. Baicalin Attenuates Alcoholic Liver Injury through Modulation of Hepatic Oxidative Stress, Inflammation and Sonic Hedgehog Pathway in Rats. *Cell. Physiol. Biochem.* **2016**, *39*, 1129–1140. [CrossRef] [PubMed]
- 166. Wang, X.; Liu, M.; Zhang, C.; Li, S.; Yang, Q.; Zhang, J.; Gong, Z.; Han, J.; Jia, L. Antioxidant Activity and Protective Effects of Enzyme-Extracted Oudemansiella Radiata Polysaccharides on Alcohol-Induced Liver Injury. *Molecules* 2018, 23, 481. [CrossRef] [PubMed]

- 167. Wang, G.; Fu, Y.; Li, J.; Li, Y.; Zhao, Q.; Hu, A.; Xu, C.; Shao, D.; Chen, W. Aqueous Extract of *Polygonatum sibiricum* Ameliorates Ethanol-Induced Mice Liver Injury via Regulation of the Nrf2/ARE Pathway. J. Food Biochem. 2021, 45, e13537. [CrossRef] [PubMed]
- 168. Wang, X.; Chang, X.; Zhan, H.; Zhang, Q.; Li, C.; Gao, Q.; Yang, M.; Luo, Z.; Li, S.; Sun, Y. Curcumin and Baicalin Ameliorate Ethanol-Induced Liver Oxidative Damage via the Nrf2/HO-1 Pathway. J. Food Biochem. 2020, 44, e13425. [CrossRef] [PubMed]
- 169. Wang, Z.D.; Zhang, Y.; Dai, Y.D.; Ren, K.; Han, C.; Wang, H.X.; Yi, S.Q. Tamarix Chinensis Lour Inhibits Chronic Ethanol-Induced Liver Injury in Mice. *World J. Gastroenterol.* **2020**, *26*, 1286–1297. [CrossRef]
- Wang, W.; Zhong, G.Z.; Long, K.B.; Liu, Y.; Liu, Y.Q.; Xu, A.L. Silencing MiR-181b-5p Upregulates PIAS1 to Repress Oxidative Stress and Inflammatory Response in Rats with Alcoholic Fatty Liver Disease through Inhibiting PRMT1. *Int. Immunopharmacol.* 2021, 101, 108151. [CrossRef] [PubMed]
- 171. Wang, X.; Yu, H.; Xing, R.; Li, P. Hepatoprotective Effect of Oyster Peptide on Alcohol-Induced Liver Disease in Mice. *Int. J. Mol. Sci.* **2022**, *23*, 8081. [CrossRef]
- 172. Wang, X.; Wang, Y.; Liu, Y.; Cong, P.; Xu, J.; Xue, C. Hepatoprotective Effects of Sea Cucumber Ether-Phospholipids against Alcohol-Induced Lipid Metabolic Dysregulation and Oxidative Stress in Mice. *Food Funct.* 2022, 13, 2791–2804. [CrossRef] [PubMed]
- 173. Wang, R.; Mu, J. Arbutin Attenuates Ethanol-Induced Acute Hepatic Injury by the Modulation of Oxidative Stress and Nrf-2/HO-1 Signaling Pathway. J. Biochem. Mol. Toxicol. 2021, 35, e22872. [CrossRef] [PubMed]
- 174. Wei, J.; Huang, Q.; Huang, R.; Chen, Y.; Lv, S.; Wei, L.; Liang, C.; Liang, S.; Zhuo, L.; Lin, X. Asiatic Acid from Potentilla Chinensis Attenuate Ethanol-Induced Hepatic Injury via Suppression of Oxidative Stress and Kupffer Cell Activation. *Biol. Pharm. Bull.* 2013, *36*, 1980–1989. [CrossRef] [PubMed]
- 175. Wu, X.; Wang, Y.; Jia, R.; Fang, F.; Liu, Y.; Cui, W. Computational and Biological Investigation of the Soybean Lecithin-Gallic Acid Complex for Ameliorating Alcoholic Liver Disease in Mice with Iron Overload. *Food Funct.* **2019**, *10*, 5203–5214. [CrossRef]
- 176. Wu, C.; Liu, J.; Tang, Y.; Li, Y.; Yan, Q.; Jiang, Z. Hepatoprotective Potential of Partially Hydrolyzed Guar Gum against Acute Alcohol-Induced Liver Injury in Vitro and Vivo. *Nutrients* **2019**, *11*, 963. [CrossRef] [PubMed]
- 177. Xia, T.; Zhang, J.; Yao, J.; Zhang, B.; Duan, W.; Xia, M.; Song, J.; Zheng, Y.; Wang, M. Shanxi Aged Vinegar Prevents Alcoholic Liver Injury by Inhibiting CYP2E1 and NADPH Oxidase Activities. *J. Funct. Foods* **2018**, 47, 575–584. [CrossRef]
- 178. Xiao, J.; Wang, J.; Xing, F.; Han, T.; Jiao, R.; Liong, E.C.; Fung, M.L.; So, K.F.; Tipoe, G.L. Zeaxanthin Dipalmitate Therapeutically Improves Hepatic Functions in an Alcoholic Fatty Liver Disease Model through Modulating MAPK Pathway. *PLoS ONE* **2014**, *9*, e95214. [CrossRef]
- 179. Xiao, J.; Zhang, R.; Huang, F.; Liu, L.; Deng, Y.; Ma, Y.; Wei, Z.; Tang, X.; Zhang, Y.; Zhang, M. Lychee (*Litchi chinensis* Sonn.) Pulp Phenolic Extract Confers a Protective Activity against Alcoholic Liver Disease in Mice by Alleviating Mitochondrial Dysfunction. J. Agric. Food Chem. 2017, 65, 5000–5009. [CrossRef]
- 180. Xiao, J.; Wu, C.; He, Y.; Guo, M.; Peng, Z.; Liu, Y.; Liu, L.; Dong, L.; Guo, Z.; Zhang, R.; et al. Rice Bran Phenolic Extract Confers Protective Effects against Alcoholic Liver Disease in Mice by Alleviating Mitochondrial Dysfunction via the PGC-1α-TFAM Pathway Mediated by MicroRNA-494-3p. *J. Agric. Food Chem.* 2020, *68*, 12284–12294. [CrossRef]
- 181. Xu, J.J.; Li, H.D.; Wu, M.F.; Zhu, L.; Du, X.S.; Li, J.J.; Li, Z.; Meng, X.M.; Huang, C.; Li, J. 3-B-RUT, a Derivative of RUT, Protected against Alcohol-Induced Liver Injury by Attenuating Inflammation and Oxidative Stress. Int. Immunopharmacol. 2021, 95, 107471. [CrossRef]
- 182. Yalçinkaya, S.; Ünlüçerçi, Y.; Uysal, M. Methionine-Supplemented Diet Augments Hepatotoxicity and Prooxidant Status in Chronically Ethanol-Treated Rats. *Exp. Toxicol. Pathol.* **2007**, *58*, 455–459. [CrossRef] [PubMed]
- Yan, S.L.; Yin, M.C. Protective and Alleviative Effects from 4 Cysteine-Containing Compounds on Ethanol-Induced Acute Liver Injury through Suppression of Oxidation and Inflammation. J. Food Sci. 2007, 72, S511–S515. [CrossRef] [PubMed]
- 184. Yang, P.; Wang, Z.; Zhan, Y.; Wang, T.; Zhou, M.; Xia, L.; Yang, X.; Zhang, J. Endogenous A1 Adenosine Receptor Protects Mice from Acute Ethanol-Induced Hepatotoxicity. *Toxicology* **2013**, *309*, 100–106. [CrossRef] [PubMed]
- 185. Yang, C.; Liao, A.M.; Cui, Y.; Yu, G.; Hou, Y.; Pan, L.; Chen, W.; Zheng, S.; Li, X.; Ma, J.; et al. Wheat Embryo Globulin Protects against Acute Alcohol-Induced Liver Injury in Mice. *Food Chem. Toxicol.* **2021**, *153*, 112240. [CrossRef] [PubMed]
- 186. Yang, Y.; Zhou, Z.; Liu, Y.; Xu, X.; Xu, Y.; Zhou, W.; Chen, S.; Mao, J. Non-Alcoholic Components in Huangjiu as Potential Factors Regulating the Intestinal Barrier and Gut Microbiota in Mouse Model of Alcoholic Liver Injury. *Foods* 2022, 11, 1537. [CrossRef]
- 187. Yao, P.; Li, K.; Song, F.; Zhou, S.; Sun, X.; Zhang, X.; Nüssler, A.K.; Liu, L. Heme Oxygenase-1 Upregulated by Ginkgo Biloba Extract: Potential Protection against Ethanol-Induced Oxidative Liver Damage. *Food Chem. Toxicol.* 2007, 45, 1333–1342. [CrossRef] [PubMed]
- Yeh, W.J.; Tsai, C.C.; Ko, J.; Yang, H.Y. Hylocereus Polyrhizus Peel Extract Retards Alcoholic Liver Disease Progression by Modulating Oxidative Stress and Inflammatory Responses in C57Bl/6 Mice. *Nutrients* 2020, 12, 3884. [CrossRef] [PubMed]
- 189. Yoon, S.J.; Koh, E.J.; Kim, C.S.; Zee, O.P.; Kwak, J.H.; Jeong, W.J.; Kim, J.H.; Lee, S.M. Agrimonia Eupatoria Protects against Chronic Ethanol-Induced Liver Injury in Rats. *Food Chem. Toxicol.* **2012**, *50*, 2335–2341. [CrossRef] [PubMed]
- 190. You, Y.; Yoo, S.; Yoon, H.G.; Park, J.; Lee, Y.H.; Kim, S.; Oh, K.T.; Lee, J.; Cho, H.Y.; Jun, W. In Vitro and in Vivo Hepatoprotective Effects of the Aqueous Extract from Taraxacum Officinale (Dandelion) Root against Alcohol-Induced Oxidative Stress. *Food Chem. Toxicol.* 2010, 48, 1632–1637. [CrossRef] [PubMed]

- 191. You, Y.; Liu, Y.L.; Ai, Z.Y.; Wang, Y.S.; Liu, J.M.; Piao, C.H.; Wang, Y.H. Lactobacillus Fermentum KP-3-Fermented Ginseng Ameliorates Alcohol-Induced Liver Disease in C57BL/6N Mice through the AMPK and MAPK Pathways. *Food Funct.* 2020, *11*, 9801–9809. [CrossRef]
- 192. Yu, Y.; Tian, Z.Q.; Liang, L.; Yang, X.; Sheng, D.D.; Zeng, J.X.; Li, X.Y.; Shi, R.Y.; Han, Z.P.; Wei, L.X. Babao Dan Attenuates Acute Ethanol-Induced Liver Injury via Nrf2 Activation and Autophagy. *Cell Biosci.* **2019**, *9*, 80. [CrossRef] [PubMed]
- 193. Lu, R.; Yu, R.-J.; Yang, C.; Wang, Q.; Xuan, Y.; Wang, Z.; He, Z.; Xu, Y.; Kou, L.; Zhao, Y.-Z.; et al. Evaluation of the Hepatoprotective Effect of Naringenin Loaded Nanoparticles against Acetaminophen Overdose Toxicity. *Drug Deliv.* 2022, 29, 3256–3269. [CrossRef] [PubMed]
- 194. Yuan, R.; Tao, X.; Liang, S.; Pan, Y.; He, L.; Sun, J.; Wenbo, J.; Li, X.; Chen, J.; Wang, C. Protective Effect of Acidic Polysaccharide from Schisandra Chinensis on Acute Ethanol-Induced Liver Injury through Reducing CYP2E1-Dependent Oxidative Stress. *Biomed. Pharmacother.* 2018, 99, 537–542. [CrossRef] [PubMed]
- 195. Yuan, H.; Duan, S.; Guan, T.; Yuan, X.; Lin, J.; Hou, S.; Lai, X.; Huang, S.; Du, X.; Chen, S. Vitexin Protects against Ethanol-Induced Liver Injury through Sirt1/P53 Signaling Pathway. *Eur. J. Pharmacol.* **2020**, *873*, 173007. [CrossRef] [PubMed]
- Zahid, M.; Arif, M.; Rahman, M.A.; Mujahid, M. Hepatoprotective and Antioxidant Activities of Annona Squamosa Seed Extract against Alcohol-Induced Liver Injury in Sprague Dawley Rats. Drug Chem. Toxicol. 2020, 43, 588–594. [CrossRef] [PubMed]
- Zeng, T.; Zhang, C.L.; Song, F.Y.; Zhao, X.L.; Yu, L.H.; Zhu, Z.P.; Xie, K.Q. The Activation of HO-1/Nrf-2 Contributes to the Protective Effects of Diallyl Disulfide (DADS) against Ethanol-Induced Oxidative Stress. *Biochim. Biophys. Acta Gen. Subj.* 2013, 1830, 4848–4859. [CrossRef] [PubMed]
- 198. Zhang, J.; Xue, J.; Wang, H.; Zhang, Y.; Xie, M. Osthole Improves Alcohol-Induced Fatty Liver in Mice by Reduction of Hepatic Oxidative Stress. *Phytother. Res.* **2011**, *25*, 638–643. [CrossRef] [PubMed]
- 199. Zhang, P.; Ma, D.; Wang, Y.; Zhang, M.; Qiang, X.; Liao, M.; Liu, X.; Wu, H.; Zhang, Y. Berberine Protects Liver from Ethanol-Induced Oxidative Stress and Steatosis in Mice. *Food Chem. Toxicol.* **2014**, *74*, 225–232. [CrossRef] [PubMed]
- 200. Zhang, P.; Qiang, X.; Zhang, M.; Ma, D.; Zhao, Z.; Zhou, C.; Liu, X.; Li, R.; Chen, H.; Zhang, Y. Demethyleneberberine, a Natural Mitochondria-Targeted Antioxidant, Inhibits Mitochondrial Dysfunction, Oxidative Stress, and Steatosis in Alcoholic Liver Disease Mouse Model. J. Pharmacol. Exp. Ther. 2015, 352, 139–147. [CrossRef]
- 201. Zhang, L.; Meng, B.; Li, L.; Wang, Y.; Zhang, Y.; Fang, X.; Wang, D. Boletus aereus Protects against Acute Alcohol-Induced Liver Damage in the C57BL/6 Mouse via Regulating the Oxidative Stress-Mediated NF-KB Pathway. *Pharm. Biol.* 2020, 58, 905–914. [CrossRef] [PubMed]
- 202. Zhang, Y.; Zhao, S.; Fu, Y.; Yan, L.; Feng, Y.; Chen, Y.; Wu, Y.; Deng, Y.; Zhang, G.; Chen, Z.; et al. Computational Repositioning of Dimethyl Fumarate for Treating Alcoholic Liver Disease. *Cell Death Dis.* 2020, 11, 641. [CrossRef] [PubMed]
- Zhang, W.; Yang, J.; Liu, J.; Long, X.; Zhang, X.; Li, J.; Hou, C. Red Yeast Rice Prevents Chronic Alcohol-Induced Liver Disease by Attenuating Oxidative Stress and Inflammatory Response in Mice. J. Food Biochem. 2021, 45, e13672. [CrossRef] [PubMed]
- Zhao, J.; Chen, H.; Li, Y. Protective Effect of Bicyclol on Acute Alcohol-Induced Liver Injury in Mice. *Eur. J. Pharmacol.* 2008, 586, 322–331. [CrossRef] [PubMed]
- 205. Zhao, L.; Zhang, N.; Yang, D.; Yang, M.; Guo, X.; He, J.; Wu, W.; Ji, B.; Cheng, Q.; Zhou, F. Protective Effects of Five Structurally Diverse Flavonoid Subgroups against Chronic Alcohol-Induced Hepatic Damage in a Mouse Model. *Nutrients* 2018, 10, 1754. [CrossRef]
- 206. Zhao, L.; Mehmood, A.; Soliman, M.M.; Iftikhar, A.; Iftikhar, M.; Aboelenin, S.M.; Wang, C. Protective Effects of Ellagic Acid Against Alcoholic Liver Disease in Mice. *Front. Nutr.* **2021**, *8*, 744520. [CrossRef] [PubMed]
- 207. Zhao, H.; Liu, S.; Zhao, H.; Liu, Y.; Xue, M.; Zhang, H.; Qiu, X.; Sun, Z.; Liang, H. Protective Effects of Fucoidan against Ethanol-Induced Liver Injury through Maintaining Mitochondrial Function and Mitophagy Balance in Rats. *Food Funct.* 2021, 12, 3842–3854. [CrossRef] [PubMed]
- 208. Zheng, Y.; Cui, J.; Chen, A.H.; Zong, Z.M.; Wei, X.Y. Optimization of Ultrasonic-Microwave Assisted Extraction and Hepatoprotective Activities of Polysaccharides from *Trametes orientalis*. *Molecules* **2019**, *24*, 147. [CrossRef] [PubMed]
- Zheng, L.Y.; Zou, X.; Wang, Y.L.; Zou, M.; Ma, F.; Wang, N.; Li, J.W.; Wang, M.S.; Hung, H.Y.; Wang, Q. Betulinic Acid-Nucleoside Hybrid Prevents Acute Alcohol -Induced Liver Damage by Promoting Anti-Oxidative Stress and Autophagy. *Eur. J. Pharmacol.* 2022, 914, 174686. [CrossRef] [PubMed]
- Zhou, Z.; Sun, X.; Kang, Y.J. Metallothionein Protection against Alcoholic Liver Injury through Inhibition of Oxidative Stress. *Exp. Biol. Med.* 2002, 227, 214–222. [CrossRef]
- Zhou, J.; Zhang, J.; Wang, C.; Qu, S.; Zhu, Y.; Yang, Z.; Wang, L. Açaí (Euterpe Oleracea Mart.) Attenuates Alcohol-Inducedliver Injury in Rats by Alleviating Oxidative Stressand Inflammatory Response. *Exp. Ther. Med.* 2018, 15, 166–172. [PubMed]
- 212. Zhou, J.; Zhang, N.; Zhao, L.; Wu, W.; Zhang, L.; Zhou, F.; Li, J. Astragalus Polysaccharides and Saponins Alleviate Liver Injury and Regulate Gut Microbiota in Alcohol Liver Disease Mice. *Foods* **2021**, *10*, 2688. [CrossRef] [PubMed]
- 213. Zhou, J.; Zhang, N.; Zhao, L.; Soliman, M.M.; Wu, W.; Li, J.; Zhou, F.; Zhang, L. Protective Effects of Honey-Processed Astragalus on Liver Injury and Gut Microbiota in Mice Induced by Chronic Alcohol Intake. *J. Food Qual.* **2022**, 2022, 5333691. [CrossRef]
- 214. Zhu, S.; Ma, L.; Wu, Y.; Ye, X.; Zhang, T.; Zhang, Q.; Rasoul, L.M.; Liu, Y.; Guo, M.; Zhou, B.; et al. FGF21 Treatment Ameliorates Alcoholic Fatty Liver through Activation of AMPK-SIRT1 Pathway. *Acta Biochim. Biophys. Sin.* 2014, 46, 1041–1048. [CrossRef] [PubMed]

- 216. Xie, N.; Zhang, L.; Gao, W.; Huang, C.; Huber, P.E.; Zhou, X.; Li, C.; Shen, G.; Zou, B. NAD+ Metabolism: Pathophysiologic Mechanisms and Therapeutic Potential. *Signal Transduct. Target Ther.* **2020**, *5*, 227. [CrossRef] [PubMed]
- Bougarne, N.; Weyers, B.; Desmet, S.J.; Deckers, J.; Ray, D.W.; Staels, B.; De Bosscher, K. Molecular Actions of PPARα in Lipid Metabolism and Inflammation. *Endocr. Rev.* 2018, *39*, 760–802. [CrossRef]
- 218. Namachivayam, A.; Gopalakrishnan, A.V. A Review on Molecular Mechanism of Alcoholic Liver Disease. *Life Sci.* 2021, 274, 119328. [CrossRef] [PubMed]
- 219. Shen, Y.; Huang, H.; Wang, Y.; Yang, R.; Ke, X. Antioxidant Effects of Se-Glutathione Peroxidase in Alcoholic Liver Disease. J. *Trace Elem. Med. Biol.* 2022, 74, 127048. [CrossRef] [PubMed]
- Sun, J.; Fu, J.; Li, L.; Chen, C.; Wang, H.; Hou, Y.; Xu, Y.; Pi, J. Nrf2 in Alcoholic Liver Disease. *Toxicol. Appl. Pharmacol.* 2018, 357, 62–69. [CrossRef] [PubMed]
- Bae, T.; Hallis, S.P.; Kwak, M.-K. Hypoxia, Oxidative Stress, and the Interplay of HIFs and NRF2 Signaling in Cancer. *Exp. Mol. Med.* 2024, 56, 501–514. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.